"Clinical.Annotation.ID","Gene","Level.of.Evidence","Score","Phenotype.Category","Drug","Phenotype","POS","QUAL","INFO","REF","ALT","Annotation.Text"
"613978931","SCN1A","2B","15.25","Dosage","carbamazepine","Epilepsy","166053034","838.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.589;DB;DP=55;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.25;ReadPosRankSum=-1.080;SOR=0.850","C","T","Patients with the rs3812718 CT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CC genotype but a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of carbamazepine."
"613978937","SCN1A","3","2.25","Dosage","phenytoin","Epilepsy","166053034","838.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.589;DB;DP=55;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.25;ReadPosRankSum=-1.080;SOR=0.850","C","T","Patients with the CT genotype who are treated with phenytoin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of phenytoin."
"613979643","LTC4S","3","4.5","Toxicity","aspirin","Urticaria","179793637","825.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.407;DB;DP=60;ExcessHet=3.0103;FS=5.303;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.99;ReadPosRankSum=1.044;SOR=0.711","A","C","Patients with the rs730012 AC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for urticaria."
"637879952","MOB3B","3","2.75","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors","Arthritis, Rheumatoid","27490969","750.06","AC=2;AF=1.00;AN=2;DB;DP=22;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.09;SOR=0.874","A","G","Rheumatoid Arthritis patients with the AG genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response."
"637879957","PON1","3","2.25","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors","Arthritis, Rheumatoid","95301079","630.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.197;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.42;ReadPosRankSum=-0.043;SOR=0.551","A","C","Rheumatoid Arthritis patients with the AC genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC. Other genetic and clinical factors may also influence a patient's response."
"637879962","PON1","3","0","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors","Arthritis, Rheumatoid","95296508","1648.06","AC=2;AF=1.00;AN=2;DB;DP=52;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.96;SOR=0.773","A","G","Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response."
"637879972","MAFB","3","2.75","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors","Arthritis, Rheumatoid","40192165","1142.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.043;DB;DP=89;ExcessHet=3.0103;FS=4.112;MLEAC=1;MLEAF=0.500;MQ=59.94;MQRankSum=-0.919;QD=13.44;ReadPosRankSum=-0.322;SOR=1.146","G","T","Rheumatoid Arthritis patients with the genotype GT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response."
"637879992","MOB3B","3","2.75","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors","Arthritis, Rheumatoid","27489253","1442.06","AC=2;AF=1.00;AN=2;DB;DP=46;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.35;SOR=0.780","A","G","Rheumatoid Arthritis patients with the AG genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response."
"637880014","ABCB1","3","2.5","Toxicity","Platinum compounds;taxanes","Ovarian Neoplasms","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens."
"637880087","SLC22A2","3","1","Toxicity","cisplatin","Neoplasms","160249250","1311.06","AC=2;AF=1.00;AN=2;DB;DP=35;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.85;SOR=1.885","A","C","Patients with the AC genotype may have reduced but not non-existent risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the CC genotype however studies with other biomarkers showed conflicting results. Other genetic and clinical factors may also influence a patient's risk for toxicity."
"637880243","EGFR","3","0","Efficacy","erlotinib","Neoplasms","55019062","811.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.785;DB;DP=72;ExcessHet=3.0103;FS=0.907;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.27;ReadPosRankSum=-0.220;SOR=0.527","G","T","Patients with the GT genotype may be more sensitive to treatment with erlotinib compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity."
"637880250","EGFR","3","0","Efficacy","topoisomerase I inhibitors","Neoplasms","55019062","811.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.785;DB;DP=72;ExcessHet=3.0103;FS=0.907;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.27;ReadPosRankSum=-0.220;SOR=0.527","G","T","Cancer patients with genotype GT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response."
"637880258","EGFR","3","0","Efficacy","geldanamycin","Neoplasms","55019062","811.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.785;DB;DP=72;ExcessHet=3.0103;FS=0.907;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.27;ReadPosRankSum=-0.220;SOR=0.527","G","T","Patients with the genotype GT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response."
"637880263","EGFR","3","0","Efficacy","Alkylating Agents","Neoplasms","55019062","811.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.785;DB;DP=72;ExcessHet=3.0103;FS=0.907;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.27;ReadPosRankSum=-0.220;SOR=0.527","G","T","Cancer cells with the GT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents."
"637880267","EGFR","3","4.5","Efficacy","gefitinib","Neoplasms","55019062","811.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.785;DB;DP=72;ExcessHet=3.0103;FS=0.907;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.27;ReadPosRankSum=-0.220;SOR=0.527","G","T","Patients with the GT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response."
"652519736","AGTR1","3","3","Efficacy","perindopril","Coronary Artery Disease","148741608","403.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.079;DB;DP=43;ExcessHet=3.0103;FS=2.887;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.91;ReadPosRankSum=0.759;SOR=1.226","C","T","Patients with the CT genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response."
"655384529","DTNBP1","3","2.5","Efficacy","clozapine","Schizophrenia","15572843","428.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.862;DB;DP=26;ExcessHet=3.0103;FS=1.810;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=17.15;ReadPosRankSum=-1.062;SOR=0.317","C","T","Patients with the CT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine."
"655384534","SOD2","3","2.5","Efficacy","cyclophosphamide","Breast Neoplasms","159692840","164.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.741;DB;DP=29;ExcessHet=3.0103;FS=1.708;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=5.68;ReadPosRankSum=1.488;SOR=0.273","A","G","Patients with the AG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype or may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide."
"655384539","ABCB1","3","3","Efficacy","cyclosporine","Colitis, Ulcerative","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine."
"655384546","ABCB1","3","2.75","Dosage","cyclosporine","Kidney Transplantation;Myasthenia Gravis","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype, and therefore may require an adjusted dose of the drug. Patients with the AG genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine."
"655384558","NRP2","3","2.5","Other","daunorubicin","Drug Toxicity","205787576","304.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.585;DB;DP=21;ExcessHet=3.0103;FS=1.848;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.23;ReadPosRankSum=1.103;SOR=1.180","C","G","Patients with the CG genotype may have reduced response to daunorubicin compared to patients with the GG genotype or may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment."
"655384578","CYP3A4","3","3.5","Toxicity;Metabolism/PK","docetaxel","Neoplasms","99784473","2096.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.27;SOR=0.859","C","T","Patients with the CT genotype may have increased clearance of docetaxel as compared to patients with the TT genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Patients with the CT genotype may have an increased risk of an infusion-related reaction as compared to patients with the TT genotype. These patients may experience a decreased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel."
"655384602","RGS4","3","1.75","Efficacy","risperidone","Schizophrenia","163063901","428.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.397;DB;DP=50;ExcessHet=3.0103;FS=5.959;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.75;ReadPosRankSum=0.914;SOR=0.809","C","T","Patients with the CT genotype may have decreased chance of response to risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of response to risperidone."
"655384607","RGS4","3","5","Efficacy","antipsychotics;olanzapine;perphenazine;quetiapine;ziprasidone","Schizophrenia","163063901","428.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.397;DB;DP=50;ExcessHet=3.0103;FS=5.959;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.75;ReadPosRankSum=0.914;SOR=0.809","C","T","Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics."
"655384621","KIF6","2B","8.5","Efficacy","pravastatin","Coronary Disease;Myocardial Infarction","39357302","533.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.343;DB;DP=62;ExcessHet=3.0103;FS=5.194;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.75;ReadPosRankSum=-0.499;SOR=0.773","A","G","Patients with the rs20455 AG genotype may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pravastatin treatment."
"655384767","NPPA","3","2","Efficacy","amlodipine;chlorthalidone","Cardiovascular Diseases;Coronary Disease;Stroke","11846011","806.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.350;DB;DP=56;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.40;ReadPosRankSum=0.767;SOR=0.789","A","G","Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone."
"655384794","BDKRB2","4","-1.25","Toxicity","Ace Inhibitors, Plain","Cough","96204802","539.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.491;DB;DP=39;ExcessHet=3.0103;FS=4.536;MLEAC=1;MLEAF=0.500;MQ=59.85;MQRankSum=-0.896;QD=14.20;ReadPosRankSum=-1.318;SOR=0.634","C","T","The current evidence base suggests that there is no significant association between the rs1799722 CT genotype and ACE inhibitor-induced cough. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for cough."
"655384817","EDN1","3","2.75","Toxicity","muraglitazar","Diabetes Mellitus;Edema;Hyperlipidemias","12296022","1742.06","AC=2;AF=1.00;AN=2;BaseQRankSum=-1.376;DB;DP=63;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;MQRankSum=0.000;QD=30.04;ReadPosRankSum=0.807;SOR=0.301","G","T","No conclusive results were found for patients with the GT genotype. But patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment."
"655384846","ABCB1","3","1.75","Toxicity","nortriptyline","Depression;Depressive Disorder;Depressive Disorder, Major;Hypotension","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment."
"655384850","ABCB1","3","1","Metabolism/PK","lansoprazole;tacrolimus","Gastroesophageal Reflux;Transplantation","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance."
"655384854","CYP3A4","3","1","Other","indinavir","HIV Infections","99784473","2096.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.27;SOR=0.859","C","T","Patients with the CT genotype and HIV infection may have increased metabolism of indinavir compared to patients with the CC genotype. Other genetic and clinical factors may also influence indinavir metabolism."
"655384862","HTR1A","3","2.5","Efficacy","fluvoxamine;milnacipran;paroxetine","Depressive Disorder, Major","63965502","581.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.733;DB;DP=54;ExcessHet=3.0103;FS=10.950;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.97;ReadPosRankSum=-1.225;SOR=2.219","C","T","Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
"655384886","CELF4","3","0","Toxicity","iloperidone","Acquired Long QT Syndrome (aLQTS)","37348676","1312.06","AC=2;AF=1.00;AN=2;DB;DP=47;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.16;SOR=1.038","C","T","Patients with the CT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
"655384894","NOS1AP","3","0","Toxicity","verapamil","Acquired Long QT Syndrome (aLQTS)","162060898","494.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.987;DB;DP=52;ExcessHet=3.0103;FS=1.098;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.70;ReadPosRankSum=-0.335;SOR=0.990","C","G","While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype, it was not shown conclusively if heterzygous (GC) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk."
"655384938","LTC4S","3","2.25","Efficacy","montelukast","Asthma","179793637","825.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.407;DB;DP=60;ExcessHet=3.0103;FS=5.303;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.99;ReadPosRankSum=1.044;SOR=0.711","A","C","Patients with the AC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment."
"655384954","HTR2C","3","1.25","Toxicity","risperidone","Schizophrenia;Weight gain","114731326","916.06","AC=2;AF=1.00;AN=2;DB;DP=27;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.93;SOR=1.781","C","G","Patients with two X-chromosomes, the CG genotype and schizophrenia, treated with risperidone, may have a decreased likelihood of antipsychotic-induced weight as compared to patients the genotype CC. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain. This gene is on the X chromosome therefore some individuals may have only one allele."
"655384962","DRD3","3","1.75","Efficacy","olanzapine","Schizophrenia","114171968","372.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.437;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.31;ReadPosRankSum=0.000;SOR=0.693","C","T","Patients with the CT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine."
"655384966","HTR2C","3","3.25","Toxicity","olanzapine","Schizophrenia;Weight gain","114584109","1583.06","AC=2;AF=1.00;AN=2;DB;DP=53;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.66;SOR=1.157","C","G","Patients with two X-chromosomes, the CG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine. This gene is on the X chromosome therefore some individuals may have only one allele."
"655384975","RGS4","3","2","Efficacy","olanzapine;perphenazine","Schizophrenia","163070705","564.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.166;DB;DP=36;ExcessHet=3.0103;FS=1.297;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.68;ReadPosRankSum=0.617;SOR=0.473","G","T","Patients with the GT genotype and schizophrenia may be less likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine."
"655384979","RGS4","3","0","Efficacy","risperidone","Schizophrenia","163070705","564.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.166;DB;DP=36;ExcessHet=3.0103;FS=1.297;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.68;ReadPosRankSum=0.617;SOR=0.473","G","T","Patients with the GT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response."
"655385037","DRD3","3","1.5","Efficacy","pramipexole","Parkinson Disease","114171968","372.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.437;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.31;ReadPosRankSum=0.000;SOR=0.693","C","T","Patients with the CT genotype may have lower response rate to pramipexole in Chinese patients with Parkinson's disease than TT allele carriers. Other genetic and clinical factors may also influence a patient's response."
"655385077","GRM3","3","2","Efficacy","risperidone","Schizophrenia","86696058","2109.06","AC=2;AF=1.00;AN=2;DB;DP=53;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=35.32;SOR=0.773","A","G","Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone."
"655385087","APOC3","3","2.5","Toxicity","ritonavir","HIV Infections;Hyperlipidemias","116829453","311.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.203;DB;DP=35;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.17;ReadPosRankSum=1.673;SOR=0.715","C","T","Patients with the CT genotype and HIV who are treated with ritonavir may have decreased severity of triglyceride elevation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels."
"655385097","LPIN1","3","2.75","Efficacy","rosiglitazone","Diabetes Mellitus, Type 2","11750302","1756.06","AC=2;AF=1.00;AN=2;DB;DP=53;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.43;SOR=0.900","C","G","Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone."
"655385120","CRHR2","4","-0.75","Efficacy","salbutamol;selective beta-2-adrenoreceptor agonists","Asthma","30689292","865.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.177;DB;DP=87;ExcessHet=3.0103;FS=0.845;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.43;ReadPosRankSum=1.610;SOR=0.845","A","T","Patients with the AT genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the TT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response."
"655385129","HMGCR","3","0","Other","simvastatin","Cardiovascular Diseases","75355259","1442.06","AC=2;AF=1.00;AN=2;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.54;SOR=0.836","A","G","The AG genotype may be associated with decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript as compared to AA genotype."
"655385159","ABCC4","3","0.5","Metabolism/PK","tenofovir","HIV Infections","95062722","929.06","AC=2;AF=1.00;AN=2;DB;DP=31;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.04;SOR=1.688","C","T","Patients with the rs1751034 CT genotype carriers may have decreased concentrations of tenofovir as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentations."
"655385404","LDLR","3","0.5","Efficacy","atenolol","Hypertension","11116926","1558.06","AC=2;AF=1.00;AN=2;DB;DP=56;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.85;SOR=0.693","C","T","Patients with the CT genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response."
"655385462","ABCB1","3","4.25","Efficacy;Toxicity","methotrexate","Arthritis, Rheumatoid","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the rs1045642 AG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased risk of drug toxicity as copmared to patients with the AA genotype but a decreased risk as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
"655385471","ARID5B","3","1.5","Other","methotrexate","Precursor Cell Lymphoblastic Leukemia-Lymphoma","61963818","1517.06","AC=2;AF=1.00;AN=2;DB;DP=46;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.98;SOR=0.874","C","T","Pediatric patients with the CT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation."
"655385483","DRD2","3","2.25","Toxicity","antipsychotics;clozapine;olanzapine","Schizophrenia","113425552","514.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.502;DB;DP=36;ExcessHet=3.0103;FS=3.225;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.70;ReadPosRankSum=0.762;SOR=0.233","A","G","Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects."
"655385674","HTR2C","3","6.875","Toxicity","clozapine","Metabolic Syndrome;Schizophrenia","114903581","882.06","AC=2;AF=1.00;AN=2;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.50;SOR=0.836","C","G","Patients with two X-chromosomes and the CG genotype who are treated with clozapine may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele."
"655385701","ABCB1","3","5.75","Efficacy;Toxicity","efavirenz;nelfinavir","HIV Infections","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the GA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity."
"655385705","BDNF","3","2.5","Efficacy","antidepressants;desipramine;fluoxetine","Depression;Depressive Disorder, Major","27700731","1335.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.718;DB;DP=98;ExcessHet=3.0103;FS=0.785;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.52;ReadPosRankSum=0.178;SOR=0.608","G","T","Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants."
"655385763","TCF7L2","3","1.5","Efficacy","repaglinide","Diabetes Mellitus, Type 2","113149972","618.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.451;DB;DP=63;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.98;ReadPosRankSum=-0.499;SOR=0.598","C","T","Patients with the CT genotype may have lower response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's repsonse."
"655385985","CYBA","3","5.25","Toxicity","doxorubicin;idarubicin","Neoplasms","88646828","597.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.735;DB;DP=50;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.72;ReadPosRankSum=0.878;SOR=0.859","A","G","Cancer patients with the AG genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
"655386075","ABCB1","3","2","Efficacy","cytarabine","Leukemia, Myeloid, Acute","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have increased response to cytarabine regimens as compared to patients with the GG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to cytarabine regimens."
"655386088","CBR1","3","3.5","Metabolism/PK","doxorubicin;doxorubicinol","Breast Neoplasms","36072675","761.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.157;DB;DP=58;ExcessHet=3.0103;FS=2.244;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.60;ReadPosRankSum=2.077;SOR=0.439","C","T","Patients with the CT genotype may have 1) decreased clearance of doxorubicin 2) increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with CC genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure."
"655386136","PPARD","3","2","Efficacy","docetaxel;thalidomide","Prostatic Neoplasms","35427233","602.06","AC=2;AF=1.00;AN=2;DB;DP=24;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=26.18;SOR=0.776","C","T","Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response."
"655386161","PPARD","3","2","Efficacy","docetaxel;thalidomide","Prostatic Neoplasms","35411001","1074.06","AC=2;AF=1.00;AN=2;DB;DP=34;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.55;SOR=1.352","C","T","Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response."
"655386166","PPARD","3","2","Efficacy","docetaxel;thalidomide","Prostatic Neoplasms","35402029","2262.06","AC=2;AF=1.00;AN=2;DB;DP=74;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.86;SOR=0.904","C","T","Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response."
"655386181","SULT1C4","3","2","Efficacy","docetaxel;thalidomide","Prostatic Neoplasms","108378352","478.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.227;DB;DP=40;ExcessHet=3.0103;FS=3.297;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.60;ReadPosRankSum=-0.015;SOR=0.261","C","G","Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response."
"655386244","ABCB1","3","6.25","Toxicity","nevirapine","HIV Infections;Toxic liver disease","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","While patients with the rs1045642 AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype, it is not clear what the association is between the AG genotype and risk of neravirapine hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment."
"655386612","XPC","3","0.75","Toxicity","cisplatin","Neoplasms;Osteosarcoma;Ototoxicity;Testicular Neoplasms","14145949","581.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.699;DB;DP=50;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.38;ReadPosRankSum=-1.033;SOR=0.784","G","T","Patients with the GT genotype may have an increased risk for ototoxicity with cisplatin treatment as compared to patients with the TT genotype. However, another study failed to find this association. Other genetic and clinical factors may also influence a patient's risk for ototoxicity when treated with cisplatin."
"655386639","ERCC1","3","3.25","Toxicity","carboplatin;cisplatin;oxaliplatin;platinum;Platinum compounds","Neoplasms","45420395","1040.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.802;DB;DP=78;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.69;ReadPosRankSum=0.427;SOR=0.595","A","G","Patients with the AG genotype may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy."
"655386801","GSTA1","3","1.75","Toxicity","cisplatin;cyclophosphamide","Anemia;Ovarian Neoplasms","52803889","103.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.182;DB;DP=25;ExcessHet=3.0103;FS=4.589;MLEAC=1;MLEAF=0.500;MQ=52.89;MQRankSum=-2.886;QD=4.71;ReadPosRankSum=-0.886;SOR=1.158","A","G","Patients with the AG genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens."
"655386856","SERPINE1","3","2","Efficacy","antidepressants;citalopram;fluoxetine","Depressive Disorder, Major","101126257","374.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.000;DB;DP=14;ExcessHet=3.0103;FS=3.358;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=26.76;ReadPosRankSum=-2.008;SOR=0.636","A","G","Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants."
"655386961","ADORA2A","3","1.25","Toxicity","methotrexate","Arthritis, Rheumatoid","24429543","622.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.223;DB;DP=39;ExcessHet=3.0103;FS=9.940;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.83;ReadPosRankSum=1.504;SOR=1.259","C","T","Patients with the rs2298383 CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate."
"655386990","CYP2B6","3","3","Toxicity","cyclophosphamide","Transplantation","41009358","170.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.434;DB;DP=43;ExcessHet=3.0103;FS=3.968;MLEAC=1;MLEAF=0.500;MQ=48.66;MQRankSum=-4.633;QD=4.27;ReadPosRankSum=-3.157;SOR=1.819","A","G","Patients with the AG genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis."
"655386995","CYP3A4","3","2.25","Toxicity","cyclophosphamide","Breast Neoplasms","99784473","2096.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.27;SOR=0.859","C","T","Premenopausal patients with the CT genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure."
"655387004","ABCC4","3","7.75","Toxicity","cyclophosphamide","Breast Neoplasms;Drug Toxicity","95061461","1706.06","AC=2;AF=1.00;AN=2;BaseQRankSum=-0.035;DB;DP=56;ExcessHet=3.0103;FS=3.819;MLEAC=2;MLEAF=1.00;MQ=60.00;MQRankSum=0.000;QD=32.19;ReadPosRankSum=1.572;SOR=0.861","G","T","Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment."
"655387014","NOS3","3","3","Efficacy","cyclophosphamide;doxorubicin;fluorouracil;methotrexate","Breast Neoplasms","150992991","857.06","AC=2;AF=1.00;AN=2;DB;DP=27;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.96;SOR=1.445","C","T","Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival."
"655387023","CDA","3","7","Toxicity","cytarabine","Leukemia;Lymphoma","20589208","559.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.531;DB;DP=56;ExcessHet=3.0103;FS=5.726;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.18;ReadPosRankSum=-0.198;SOR=0.557","A","C","Patients with the AC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity."
"655387027","CDA","3","6.5","Efficacy","cytarabine","Leukemia, Myeloid, Acute;Neoplasms","20588679","730.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.723;DB;DP=51;ExcessHet=3.0103;FS=4.179;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.22;ReadPosRankSum=-1.207;SOR=1.258","C","T","Patients with the genotype CT who are treated with cytarabine may have increased toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine."
"655387221","DRD3","3","1.5","Efficacy","risperidone","Autistic Disorder","114171968","372.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.437;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.31;ReadPosRankSum=0.000;SOR=0.693","C","T","Patients with the CT genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patient's response."
"655387229","ABCB1","3","1.5","Efficacy","risperidone","Autistic Disorder","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response."
"655387237","HTR2A","3","1.5","Efficacy","risperidone","Autistic Disorder","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","Patients with the CT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
"655387825","FPGS","3","3.25","Efficacy","methotrexate","Arthritis, Rheumatoid","127800446","256.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.539;DB;DP=23;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.16;ReadPosRankSum=0.443;SOR=0.627","C","T","Patients with the TC genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate."
"655388022","ABCB1","3","1.75","Other","prednisone;tacrolimus","Organ Transplantation;Transplantation","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Pediatric patients with the AG genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation."
"699642190","TPH2","3","3","Efficacy","antidepressants;mirtazapine;venlafaxine","Depressive Disorder, Major","71958055","545.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.084;DB;DP=68;ExcessHet=3.0103;FS=2.046;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.14;ReadPosRankSum=0.577;SOR=0.830","C","T","Patients with the CT genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants."
"827831021","CDA","3","4.5","Toxicity","cytarabine","Leukemia, Myeloid","20588679","730.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.723;DB;DP=51;ExcessHet=3.0103;FS=4.179;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.22;ReadPosRankSum=-1.207;SOR=1.258","C","T","Patients with the CT genotype and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk of death as compared to patients with the CC genotype or may have an increased survival time and a decreased risk for death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine."
"827831123","EGFR","3","2.25","Toxicity","erlotinib","Neoplasms","55019062","811.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.785;DB;DP=72;ExcessHet=3.0103;FS=0.907;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.27;ReadPosRankSum=-0.220;SOR=0.527","G","T","Patients with the GT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib."
"827843617","DPYD","1A","255.75","Toxicity","fluorouracil","Neoplasms","97450058","503.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.590;DB;DP=30;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.79;ReadPosRankSum=2.793;SOR=1.085","C","T","The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
"827847744","GALNT14","3","7.25","Efficacy","cisplatin;fluorouracil;mitoxantrone","Carcinoma, Hepatocellular;Liver Neoplasms","31024648","515.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.143;DB;DP=54;ExcessHet=3.0103;FS=1.079;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.73;ReadPosRankSum=-0.199;SOR=1.007","G","T","Patients with the rs9679162 GT genotype and Liver Neoplasms may decreased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy."
"827848548","ABCC4","3","2.75","Toxicity","cyclophosphamide;doxorubicin;fluorouracil","Breast Neoplasms;Neoplasms","95061461","1706.06","AC=2;AF=1.00;AN=2;BaseQRankSum=-0.035;DB;DP=56;ExcessHet=3.0103;FS=3.819;MLEAC=2;MLEAF=1.00;MQ=60.00;MQRankSum=0.000;QD=32.19;ReadPosRankSum=1.572;SOR=0.861","G","T","Patients with the rs9561778 GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs."
"827848740","ESR1","3","2","Efficacy","leflunomide","Arthritis, Rheumatoid","151842246","860.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.177;DB;DP=53;ExcessHet=3.0103;FS=2.477;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.55;ReadPosRankSum=0.075;SOR=0.343","A","G","Patients with the AG genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693."
"827862764","IFNL3;IFNL4","1A","350.5","Efficacy","peginterferon alfa-2a;peginterferon alfa-2b;ribavirin","Hepatitis C","39248147","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.448;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=58.43;MQRankSum=-1.834;QD=13.47;ReadPosRankSum=-0.076;SOR=0.693","C","T","Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CC genotype, but an increased response as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alpha and ribavirin."
"827864159","GRK4","3","1.75","Efficacy","metoprolol","Hypertension;Kidney Diseases;Nephrosclerosis","3004316","606.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.109;DB;DP=54;ExcessHet=3.0103;FS=2.455;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.89;ReadPosRankSum=-0.218;SOR=1.230","C","T","In male patients with the rs1024323 CT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype TT, or better response compared to those with rs1024323 genotype CC, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CC and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment."
"827923032","CYP2B6","1A","229.0625","Metabolism/PK","efavirenz","HIV Infections","41006936","384.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.804;DB;DP=34;ExcessHet=3.0103;FS=1.394;MLEAC=1;MLEAF=0.500;MQ=59.51;MQRankSum=1.002;QD=11.31;ReadPosRankSum=1.503;SOR=0.374","G","T","Patients with the rs3745274 GT genotype and HIV infection may have increased plasma concentrations and decreased clearance of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between rs3745274 and efavirenz and does not include evidence about clinical outcomes."
"827923042","CYP2B6","1A","109.25","Toxicity","efavirenz","HIV Infections","41006936","384.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.804;DB;DP=34;ExcessHet=3.0103;FS=1.394;MLEAC=1;MLEAF=0.500;MQ=59.51;MQRankSum=1.002;QD=11.31;ReadPosRankSum=1.503;SOR=0.374","G","T","Patients with the rs3745274 GT genotype may have an increased risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of efavirenz toxicity."
"981188379","CDA","3","1","Toxicity","gemcitabine","Carcinoma, Non-Small-Cell Lung;Mesothelioma;Pancreatic Neoplasms","20589208","559.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.531;DB;DP=56;ExcessHet=3.0103;FS=5.726;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.18;ReadPosRankSum=-0.198;SOR=0.557","A","C","Patients with the AC genotype who are treated with gemcitabine may have a decreased risk of toxicity when compared to patients with the AA genotype. Other genetic and clinical factors may also influence the risk of adverse events in cancer patients administered gemcitabine."
"981201408","IMPDH1","3","2.25","Efficacy","mycophenolate mofetil","Kidney Transplantation;Organ Transplantation","128400645","315.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.260;DB;DP=29;ExcessHet=3.0103;FS=1.549;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.27;ReadPosRankSum=1.361;SOR=0.328","C","T","Patients with the CT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events."
"981201424","IMPDH1","3","0.75","Toxicity","mycophenolate mofetil","Leukopenia","128400645","315.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.260;DB;DP=29;ExcessHet=3.0103;FS=1.549;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.27;ReadPosRankSum=1.361;SOR=0.328","C","T","Patients with the CT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events."
"981201443","NOS3","3","3.25","Efficacy","Antihypertensives;Antihypertensives And Diuretics In Combination;diuretics","Hypertension","150992991","857.06","AC=2;AF=1.00;AN=2;DB;DP=27;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.96;SOR=1.445","C","T","Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives."
"981201788","CYP3A;CYP3A4","3","0.75","Other","efavirenz","HIV Infections","99784473","2096.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.27;SOR=0.859","C","T","Patients with the CT genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism."
"981201895","ABCB1","4","-5.75","Efficacy","antiepileptics","Epilepsies, Partial;Epilepsy;Epilepsy, Generalized","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics."
"981201981","DPYD","1A","93.25","Toxicity","fluorouracil","Neoplasms","97883329","451.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.571;DB;DP=50;ExcessHet=3.0103;FS=4.029;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.22;ReadPosRankSum=0.462;SOR=1.292","A","G","Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
"981202294","CYP2B6","2A","24.625","Metabolism/PK","nevirapine","HIV Infections","41006936","384.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.804;DB;DP=34;ExcessHet=3.0103;FS=1.394;MLEAC=1;MLEAF=0.500;MQ=59.51;MQRankSum=1.002;QD=11.31;ReadPosRankSum=1.503;SOR=0.374","G","T","Patients with the rs3745274 GT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug. This annotation only covers the pharmacokinetic relationship between rs3745274 and nevirapine and does not include evidence about clinical outcomes."
"981202334","CYP2B6","3","2.5","Toxicity","cyclophosphamide","Hepatic Veno-Occlusive Disease;Transplantation","41006936","384.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.804;DB;DP=34;ExcessHet=3.0103;FS=1.394;MLEAC=1;MLEAF=0.500;MQ=59.51;MQRankSum=1.002;QD=11.31;ReadPosRankSum=1.503;SOR=0.374","G","T","Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver."
"981202356","CYP2B6","3","2","Dosage","cyclophosphamide;doxorubicin","Breast Neoplasms","41006936","384.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.804;DB;DP=34;ExcessHet=3.0103;FS=1.394;MLEAC=1;MLEAF=0.500;MQ=59.51;MQRankSum=1.002;QD=11.31;ReadPosRankSum=1.503;SOR=0.374","G","T","Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements."
"981202393","MTRR","3","1.75","Toxicity","methotrexate","Drug Toxicity;Lymphoma;Osteosarcoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma","7870860","1568.06","AC=2;AF=1.00;AN=2;DB;DP=49;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.09;SOR=0.693","A","G","Patients with the rs1801394 AG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate."
"981202598","EGF","3","3.75","Efficacy","cetuximab","Colorectal Neoplasms;Rectal Neoplasms","109912954","286.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.942;DB;DP=23;ExcessHet=3.0103;FS=1.707;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.03;ReadPosRankSum=2.081;SOR=1.179","A","G","Patients with the rs4444903 AG genotype may have a poorer response to cetuximab as compared to patients with the GG genotype or may have a better response as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment."
"981203545","DRD2","3","0.75","Dosage","methadone","Heroin Dependence","113412755","2030.06","AC=2;AF=1.00;AN=2;DB;DP=71;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=59.92;QD=30.30;SOR=0.784","A","G","Patients with the rs6275 AG genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype or may require an increased dose of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
"981203578","DRD3","3","1.25","Efficacy","clozapine","Schizophrenia","114171968","372.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.437;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.31;ReadPosRankSum=0.000;SOR=0.693","C","T","Patients with the CT genotype and Schizophrenia who are treated with clozapine may have a poorer response to treatment as compared to patients with the TT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment."
"981204107","PTGS2","3","1.75","Efficacy","aspirin","Coronary Artery Disease","186681189","760.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.313;DB;DP=60;ExcessHet=3.0103;FS=2.226;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.34;ReadPosRankSum=1.099;SOR=0.784","C","G","Patients with the CG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin."
"981204116","ABCB1","3","0.5","Efficacy","tacrolimus","Colitis, Ulcerative;Kidney Transplantation","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with AC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus."
"981204137","ABCB1","4","-3.75","Efficacy","antiepileptics","Epilepsy","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics."
"981204258","ABCB1","4","-1.25","Toxicity","paclitaxel","Drug Toxicity;Neoplasms;Neutropenia;Peripheral Nervous System Diseases","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel."
"981204272","ABCB1","4","-1","Efficacy","paclitaxel","Breast Neoplasms;Neoplasms","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel."
"981204286","ABCB1","3","0.25","Metabolism/PK","cyclosporine","Transplantation","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with genotype AG may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine."
"981204306","ABCB1","3","0","Efficacy","phenytoin","Epilepsy","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with epilepsy and the AG genotype may have increased likelihood of drug resistance when treated with phenytoin as compared to patients with the AA genotype. However, other studies have failed to find this association. Other genetic or clinical factors may influence a patient's response to phenytoin."
"981204345","ABCB1","4","-6.75","Efficacy","carbamazepine","Epilepsy","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine."
"981204361","ABCB1","3","0.75","Efficacy;Toxicity;Metabolism/PK","clopidogrel","Acute coronary syndrome;Myocardial Infarction","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","People with AG genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel."
"981204403","ABCB1","4","-0.5","Efficacy","cisplatin;fluorouracil","Esophageal Neoplasms","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have a decreased risk of lymph node metastases and an increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil."
"981204414","ABCB1","4","-1.25","Toxicity","fluorouracil","Colorectal Neoplasms","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with AG genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil."
"981204433","ABCB1","3","2","Efficacy","dexamethasone;doxorubicin;vincristine","Multiple Myeloma","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine."
"981204466","ABCB1","3","0.25","Toxicity","capecitabine","Neoplasms","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine."
"981204995","ERCC2","4","-0.75","Efficacy;Toxicity","Platinum compounds","Neoplasms","45364001","527.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.383;DB;DP=30;ExcessHet=3.0103;FS=4.499;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=17.59;ReadPosRankSum=-1.027;SOR=0.170","C","T","Patients with the CT genotype and cancer who are treated with platinum-based chemotherapy may have longer survival times as compared to patients with the CC genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy."
"981237930","ERCC1","3","1.25","Toxicity","cisplatin;cyclophosphamide","Ovarian Neoplasms","45420395","1040.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.802;DB;DP=78;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.69;ReadPosRankSum=0.427;SOR=0.595","A","G","Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment."
"981238041","ABCB1","3","2.5","Efficacy","dexamethasone;doxorubicin;vincristine","Multiple Myeloma","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy."
"981238057","ABCB1","3","1.25","Other","doxorubicin","Breast Neoplasms","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin."
"981238092","ABCB1","3","2","Dosage;Efficacy","antiepileptics;carbamazepine","Epilepsy","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine."
"981238288","ABCB1","4","-0.25","Efficacy","efavirenz","HIV Infections","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz."
"981419540","COQ2","3","2.25","Toxicity","atorvastatin;hmg coa reductase inhibitors;rosuvastatin","Muscular Diseases","83269878","283.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.020;DB;DP=35;ExcessHet=3.0103;FS=6.479;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.34;ReadPosRankSum=-0.776;SOR=2.080","A","G","Patients with the AG genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin."
"981419550","RYR2","3","0","Toxicity","cerivastatin","Rhabdomyolysis","237826822","1501.06","AC=2;AF=1.00;AN=2;DB;DP=60;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=25.88;SOR=1.085","A","G","Patients with the AG genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity."
"981478113","NOS1AP","3","5","Toxicity","amiodarone","Long QT Syndrome","162267300","628.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.789;DB;DP=54;ExcessHet=3.0103;FS=3.855;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.86;ReadPosRankSum=0.410;SOR=0.317","C","T","Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation."
"981478131","NOS1AP","3","3","Toxicity","amiodarone","Long QT Syndrome","162274222","792.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.314;DB;DP=75;ExcessHet=3.0103;FS=7.955;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.71;ReadPosRankSum=1.338;SOR=1.018","C","T","Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation."
"982009415","KCNH2","3","2.75","Efficacy","calcium channel blockers;nitrendipine","Essential hypertension","150951110","127.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.103;DB;DP=19;ExcessHet=3.0103;FS=4.752;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=7.09;ReadPosRankSum=0.000;SOR=1.479","A","G","Patients with the AG genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AG genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments."
"982030757","FDPS","3","1.75","Toxicity","zoledronate","Neoplasms;Osteonecrosis","155309691","136.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.087;DB;DP=19;ExcessHet=3.0103;FS=12.700;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=7.59;ReadPosRankSum=-0.705;SOR=3.912","T","G","Patients with genotype TG may have increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's chance of response."
"982030854","COMT","3","2.25","Efficacy","risperidone","Schizophrenia","19932836","344.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.055;DB;DP=36;ExcessHet=3.0103;FS=2.958;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.85;ReadPosRankSum=1.368;SOR=0.557","C","G","Patients with the rs9606186 CG genotype and Schizophrenia may be less likely to respond when treated with risperidone as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may influence response to risperidone."
"982030916","GAL","3","3","Efficacy","antidepressants;benzodiazepine derivatives;mirtazapine;Selective serotonin reuptake inhibitors","Depressive Disorder, Major","68682735","1230.06","AC=2;AF=1.00;AN=2;DB;DP=39;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.24;SOR=0.984","C","T","Female patients with the CT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants."
"982030990","MAP3K5","3","1.5","Efficacy","hydroxyurea","Thalassemia","136784262","2392.06","AC=2;AF=1.00;AN=2;DB;DP=83;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=59.93;QD=30.67;SOR=0.744","C","T","Patients with the CT genotype and Thalassemia may be less likely to respond to hydroxyurea treatment as compared to genotype CC or TT. Other genetic and clinical factors may also influence a patient's response to treatment."
"982031034","P2RY12","3","2.75","Efficacy","clopidogrel","Coronary Artery Disease","151338810","1881.06","AC=2;AF=1.00;AN=2;DB;DP=58;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.00;SOR=1.140","A","C","Patients with the AC genotype and treated with clopidogrel may have 1) an average aggregation 2) decreased, but not absent, risk of non-response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
"982031045","NOS3","3","2","Toxicity","aspirin;Beta Blocking Agents;clopidogrel;hmg coa reductase inhibitors","Coronary Artery Disease","150999023","443.06","AC=2;AF=1.00;AN=2;DB;DP=16;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=27.69;SOR=1.244","T","G","Male patients with the TG genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis."
"982031308","DRD1","3","0","Efficacy","lithium","Bipolar Disorder","175443147","659.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.479;DB;DP=66;ExcessHet=3.0103;FS=2.125;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.31;ReadPosRankSum=1.470;SOR=0.436","C","T","Patients with the CT genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment."
"982031346","OR52J2P;OR52J3","3","2.5","Efficacy","lithium","Bipolar Disorder","5040311","183.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.075;DB;DP=19;ExcessHet=3.0103;FS=1.820;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.67;ReadPosRankSum=-1.406;SOR=0.330","A","G","Patients with the AG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium."
"982031956","IL4R","3","3","Efficacy","pitrakinra","Asthma","27364466","1805.06","AC=2;AF=1.00;AN=2;DB;DP=58;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.23;SOR=1.009","A","G","Patients with the AG genotype and Asthma may be less likely to respond when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pitrakinra."
"982032512","NTRK2","3","0","Dosage","methadone","Heroin Dependence;Opioid-Related Disorders","85017403","754.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.352;DB;DP=63;ExcessHet=3.0103;FS=3.468;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.17;ReadPosRankSum=2.175;SOR=1.174","C","T","Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment."
"982032672","NGF","3","0.75","Dosage","methadone","Heroin Dependence;Opioid-Related Disorders","115295088","1613.06","AC=2;AF=1.00;AN=2;DB;DP=58;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.30;SOR=0.960","A","G","Patients with the AG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment."
"982032727","NR1D1;THRA","3","0.25","Efficacy","lithium","Bipolar Disorder","40098239","249.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.248;DB;DP=18;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.87;ReadPosRankSum=-0.445;SOR=0.765","C","T","Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium."
"982032743","ABCB1","3","1.25","Toxicity","clomipramine;lithium;nefazodone;paroxetine;venlafaxine","Depression","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine."
"982032763","TPH1","3","0","Efficacy","lithium","Bipolar Disorder","18026269","493.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.208;DB;DP=48;ExcessHet=3.0103;FS=2.488;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.50;ReadPosRankSum=-0.309;SOR=0.856","G","T","Patients with the GT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium."
"982034831","ABCB1","3","2.5","Efficacy","oxaliplatin","Colorectal Neoplasms","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and colorectal cancer may have a longer period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment."
"982034869","ABCB1","3","6","Efficacy","oxaliplatin","Colorectal Neoplasms","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment."
"982036604","ABCB1","3","0","Efficacy","cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine","Osteosarcoma","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response."
"982037378","ITGA2","3","1","Efficacy","aspirin;clopidogrel","Coronary Artery Disease;Coronary Disease;Myocardial Infarction","53051539","1385.06","AC=2;AF=1.00;AN=2;DB;DP=39;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.98;SOR=1.949","C","T","Patients with the CT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel."
"982037753","LEPR","3","1.75","Efficacy","simvastatin","Hyperlipidemias","65592830","1550.06","AC=2;AF=1.00;AN=2;DB;DP=61;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.25;SOR=1.402","A","G","Patients with the AG genotype and hypercholesterolemia may have a better response to treatment with increased reductions in total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment."
"982037796","LEPR","3","2.25","Efficacy","simvastatin","Coronary Disease","65592830","1550.06","AC=2;AF=1.00;AN=2;DB;DP=61;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.25;SOR=1.402","A","G","Patients with the AG genotype and coronary heart disease may have a reduced response to treatment with smaller increases in HDL-C levels when treated with simvastatin as compared to patients with the GG genotype or may have a better response to treatment with higher increases in HDL-C levels when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment."
"982040619","ABCB1","3","2.5","Efficacy","cyclosporine;mycophenolate mofetil","Kidney Transplantation","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
"982042110","WNT5B","3","2","Other","fluorouracil","Colonic Neoplasms","1647476","884.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.626;DB;DP=61;ExcessHet=3.0103;FS=5.228;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.99;ReadPosRankSum=1.208;SOR=1.402","C","A","Colon cancer patients with CA genotype may have longer time to tumor recurrence when treated 5-fluorouracil compared to patients with CC genotypes. Other genetic and clinical factors may also influence the tumor recurrence time."
"982043234","AKR1C3","3","3","Efficacy","docetaxel;doxorubicin","Breast Neoplasms","5099115","1414.06","AC=2;AF=1.00;AN=2;DB;DP=45;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.89;SOR=0.739","C","G","Patients with breast cancer and the rs1937840 CG genotype may have a decreased response to treatment with docetaxel and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin."
"982045674","CDK4","3","2","Other","somatropin recombinant","Turner Syndrome","57750882","803.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.533;DB;DP=59;ExcessHet=3.0103;FS=7.450;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.61;ReadPosRankSum=2.671;SOR=1.293","C","T","Patient with CT + TT genotypes may have increased IGF-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy."
"982047849","DRD3","3","2.75","Efficacy","paroxetine","Depressive Disorder, Major","114171968","372.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.437;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.31;ReadPosRankSum=0.000;SOR=0.693","C","T","Patients with the CT genotype and major depressive disorder may have a better response when treated with paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine."
"1043858632","TPH1","4","-1","Efficacy","antidepressants;citalopram;escitalopram;fluoxetine;paroxetine","Depressive Disorder, Major","18026269","493.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.208;DB;DP=48;ExcessHet=3.0103;FS=2.488;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.50;ReadPosRankSum=-0.309;SOR=0.856","G","T","Patients with the GT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment."
"1043858651","PPARG","3","5.5","Toxicity","aspirin","Asthma","12434058","824.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.838;DB;DP=66;ExcessHet=3.0103;FS=0.973;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.30;ReadPosRankSum=-0.451;SOR=0.484","C","T","Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity."
"1043858656","IL4","3","1.75","Toxicity","aspirin","Asthma","132673462","558.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.867;DB;DP=60;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.80;ReadPosRankSum=0.857;SOR=0.569","C","T","Patients with the CT genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
"1043858680","FCER1G","3","4.5","Toxicity","aspirin","Asthma","161215085","538.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.287;DB;DP=32;ExcessHet=3.0103;FS=3.256;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.83;ReadPosRankSum=-0.755;SOR=1.609","A","G","Patients with the AG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity."
"1043858872","ZNF423","3","0","Efficacy","raloxifene;tamoxifen","Breast Neoplasms","49796293","636.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.246;DB;DP=51;ExcessHet=3.0103;FS=1.157;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.55;ReadPosRankSum=0.460;SOR=0.592","A","G","Patients with the AG genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy."
"1043859020","AGT","3","1.75","Efficacy","atenolol","Hypertension","230714126","519.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.076;DB;DP=32;ExcessHet=3.0103;FS=2.991;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.24;ReadPosRankSum=-1.590;SOR=1.048","C","T","Patients with the CT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure."
"1043873013","ALDH1A2","3","0","Efficacy","Bisphosphonates","Osteonecrosis","58014595","598.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.657;DB;DP=49;ExcessHet=3.0103;FS=13.462;MLEAC=1;MLEAF=0.500;MQ=59.88;MQRankSum=0.887;QD=12.47;ReadPosRankSum=-1.329;SOR=1.617","A","G","Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates."
"1043880082","UGT1A8","3","3.5","Toxicity","cyclosporine;mycophenolate mofetil;sirolimus;tacrolimus","Kidney Transplantation","233618225","499.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.384;DB;DP=31;ExcessHet=3.0103;FS=8.272;MLEAC=1;MLEAF=0.500;MQ=54.64;MQRankSum=-3.786;QD=16.12;ReadPosRankSum=0.257;SOR=0.346","C","G","Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea."
"1043880426","SCAP","3","1.75","Efficacy","simvastatin","Hypercholesterolemia","47418189","2527.06","AC=2;AF=1.00;AN=2;DB;DP=92;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.05;SOR=1.090","C","T","Patients with the CT genotype and Hypercholesterolemia may have a better response to simvastatin treatment as compared to patients with the the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment."
"1043880447","BDKRB2","3","3.25","Toxicity","Ace Inhibitors, Plain","Cough","96209596","2810.06","AC=2;AF=1.00;AN=2;BaseQRankSum=-1.215;DB;DP=100;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;MQRankSum=0.000;QD=28.38;ReadPosRankSum=-0.543;SOR=0.240","A","G","Patients with the AG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough."
"1043880608","SLCO1B1","3","4.25","Efficacy","atorvastatin","Hypercholesterolemia","21176804","361.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.460;DB;DP=33;ExcessHet=3.0103;FS=3.093;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.30;ReadPosRankSum=-1.572;SOR=1.314","A","G","Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have less reduction in LDL as compared to patients with the GG genotype. However, one study found no association with LDL levels. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
"1043880900","SLCO1B1","3","0.5","Toxicity","hmg coa reductase inhibitors","Coronary Artery Disease;Diabetes Mellitus;Hypercholesterolemia","21176804","361.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.460;DB;DP=33;ExcessHet=3.0103;FS=3.093;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.30;ReadPosRankSum=-1.572;SOR=1.314","A","G","Patients with the AG genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and an increased risk of adverse events in response to treatment as compared to patients with the GG genotype, but a lower creatine kinase levels and lower risk of intolerance as compared to the AA genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment."
"1127092670","UST","3","0","Efficacy","nortriptyline","Depressive Disorder, Major","149008131","1447.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.16;SOR=0.737","A","G","Patients with the AG genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline."
"1139265477","ABCB1","3","0.25","Efficacy","atorvastatin","Coronary Artery Disease","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype who are treated with atorvastatin may have a better response to treatment (as measured by an increased reduction in LDL-cholesterol or total cholesterol) as compared to patients with the GG genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
"1140655380","ABCB1","3","1","Toxicity","atorvastatin","Coronary Artery Disease;Myalgia unspecified","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype, or may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia."
"1143176298","ABCB1","3","1","Toxicity","simvastatin","Hypercholesterolemia;Myalgia unspecified","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype or may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia."
"1145231686","ABCB1","3","2.375","Efficacy","pravastatin","Acute coronary syndrome;Hyperlipoproteinemia Type II","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the rs2032582 AC genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment."
"1146391450","FKBP5","3","2.75","Efficacy","corticosteroids","Crohn Disease","35702206","808.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.400;DB;DP=68;ExcessHet=3.0103;FS=4.729;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.25;ReadPosRankSum=-1.791;SOR=1.044","A","G","Patients with the AG genotype and Crohn Disease who are treated with corticosteroids may have an increased likelihood of responsiveness as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids."
"1148995043","ABCB1","3","5","Efficacy","atorvastatin","Hypercholesterolemia","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the rs2032582 AC genotype who are treated with atorvastatin may have a decreased response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype or may have an increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment."
"1150414901","ABCB1","3","5.25","Efficacy","simvastatin","Hypercholesterolemia","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment."
"1152661500","ABCB1","3","1","Toxicity","simvastatin","Hypercholesterolemia;Myalgia unspecified","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions."
"1153928101","NQO2","3","1","Efficacy","cyclophosphamide;doxorubicin","Breast Neoplasms","3010156","234.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.424;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=5.10;ReadPosRankSum=-0.414;SOR=0.504","C","T","Patients with the CT genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have worse prognosis (overall survival and progression-free survival) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis."
"1183490994","PDE4D","3","2.5","Efficacy","diuretics","Nephrosclerosis","60440946","1488.06","AC=2;AF=1.00;AN=2;DB;DP=51;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.18;SOR=1.094","A","T","Patients with the AT genotype and Nephrosclerosis may have a higher baseline mean arterial blood pressure when treated with diuretics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics."
"1183491035","MTRR","3","2.5","Efficacy","folic acid;vitamin b-complex, plain","Migraine with Aura","7870860","1568.06","AC=2;AF=1.00;AN=2;DB;DP=49;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.09;SOR=0.693","A","G","Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have decreased severity of pain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain."
"1183491262","SLC6A4","3","2.25","Efficacy","ondansetron","Alcoholism","30197993","2417.06","AC=2;AF=1.00;AN=2;DB;DP=74;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.66;SOR=0.693","A","C","Patients with the AC genotype who are treated with ondansetron may have decreased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron."
"1183491333","CYBA","3","2.25","Other","simvastatin","Hypercholesterolemia","88646828","597.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.735;DB;DP=50;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.72;ReadPosRankSum=0.878;SOR=0.859","A","G","Patients with the AG genotype and Hypercholesterolemia may benefit more from simvastatin treatment due to an increased reduction in DNA damage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment."
"1183491380","ABCB1","3","1.75","Efficacy","fluvastatin","Hypercholesterolemia","87544351","156.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.601;DB;DP=10;ExcessHet=3.0103;FS=10.792;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=17.40;ReadPosRankSum=-1.242;SOR=3.901","A","T","Patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment."
"1183491403","ADAMTS1","3","4","Efficacy","pravastatin","Coronary Disease;Myocardial Infarction","26844276","1370.06","AC=2;AF=1.00;AN=2;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.14;SOR=1.508","C","G","Patients with the CG genotype may benefit less from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment."
"1183491446","KIF6","3","4","Efficacy","atorvastatin","Coronary Disease;Hypercholesterolemia;Myocardial Infarction","39357302","533.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.343;DB;DP=62;ExcessHet=3.0103;FS=5.194;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.75;ReadPosRankSum=-0.499;SOR=0.773","A","G","Patients with the rs20455 AG genotype may have increased response to atorvastatin treatment as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin."
"1183492030","GABRA1","3","4.5","Efficacy","carbamazepine;phenytoin;valproic acid","Epilepsy","161895883","714.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.364;DB;DP=67;ExcessHet=3.0103;FS=0.938;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.17;ReadPosRankSum=1.947;SOR=0.843","G","A","Patients with the GA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance."
"1183492235","ABCA1","3","2.25","Efficacy","pravastatin","Coronary Disease","104858586","1921.06","AC=2;AF=1.00;AN=2;DB;DP=60;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.56;SOR=1.123","C","T","Patients with the CT genotype and Coronary Disease who are treated with pravastatin may have a better response (increased HDL-cholesterol) as compared to patients with the CC genotype or may have a reduced response (lower increases in HDL-cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment."
"1183532599","SCARB1","3","2.75","Efficacy","atorvastatin","Hypercholesterolemia","124800202","1560.06","AC=2;AF=1.00;AN=2;BaseQRankSum=0.687;DB;DP=57;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;MQRankSum=0.000;QD=27.37;ReadPosRankSum=-0.109;SOR=0.884","A","G","Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
"1183533592","HMGCR","3","5.5","Other","hmg coa reductase inhibitors","Colonic Neoplasms","75352778","1433.06","AC=2;AF=1.00;AN=2;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.33;SOR=0.836","A","T","Patients with the AT genotype may have a higher reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype or may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment."
"1183533961","CYP3A4","4","-1.75","Efficacy","amlodipine","Hypertension","99784473","2096.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.27;SOR=0.859","C","T","Women with the CT genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CC genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine."
"1183533966","TBXT","3","3","Efficacy","flunisolide","Asthma","166165782","3090.06","AC=2;AF=1.00;AN=2;DB;DP=98;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.53;SOR=1.109","C","T","Patients with the CT genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide."
"1183533981","GABRA1","3","2.75","Efficacy","carbamazepine","Epilepsy","161897892","54.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.488;DB;DP=31;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=1.95;ReadPosRankSum=-0.541;SOR=0.582","A","G","Patients with the AG genotype and epilepsy may have increased retention rates when treated with carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine."
"1183554425","CASP7","3","0.5","Efficacy","docetaxel;gemcitabine;paclitaxel;Platinum compounds;vinorelbine","Carcinoma, Non-Small-Cell Lung","113679810","3699.06","AC=2;AF=1.00;AN=2;DB;DP=122;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.17;SOR=0.782","C","T","Patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time."
"1183564259","EDN1","3","0.75","Efficacy","atenolol;irbesartan","Essential hypertension","12296022","1742.06","AC=2;AF=1.00;AN=2;BaseQRankSum=-1.376;DB;DP=63;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;MQRankSum=0.000;QD=30.04;ReadPosRankSum=0.807;SOR=0.301","G","T","Men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan."
"1183590959","SRP19","3","2.5","Efficacy","citalopram;fluoxetine;paroxetine;sertraline","Depressive Disorder, Major","112865397","104.14","AC=2;AF=1.00;AN=2;DB;DP=4;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=26.04;SOR=0.693","A","G","Patients with the AG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline."
"1183603764","HTR2C","3","2.25","Toxicity","olanzapine","Weight gain","114733932","1694.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=26.88;SOR=0.823","A","C","Patients with two X-chromosomes, the AC genotype, and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the AA genotype, or decreased weight gain when treated with olanzapine as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain. This gene is on the X chromosome therefore some individuals may have only one allele."
"1183607013","KCNQ1","3","2","Efficacy","repaglinide","Diabetes Mellitus, Type 2","2835964","308.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-3.094;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=56.38;MQRankSum=0.897;QD=11.43;ReadPosRankSum=0.100;SOR=0.675","A","C","Patients with the AC genotype an type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide."
"1183607901","ABCA1","3","4.5","Efficacy","fenofibrate","Hypertriglyceridemia","104858586","1921.06","AC=2;AF=1.00;AN=2;DB;DP=60;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.56;SOR=1.123","C","T","Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate."
"1183612432","CASP7","3","5.5","Efficacy","docetaxel;gemcitabine;paclitaxel;Platinum compounds;vinorelbine","Carcinoma, Non-Small-Cell Lung","113729393","741.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.331;DB;DP=65;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.96;ReadPosRankSum=1.773;SOR=0.616","C","G","Patients with the CG genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time."
"1183614504","F12","3","3.5","Efficacy","Enzymes","Stroke","177409531","2257.06","AC=2;AF=1.00;AN=2;DB;DP=74;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.35;SOR=1.073","A","G","Patients with the AG genotype who have had a stroke may have a decreased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of in-hospital death."
"1183614591","SCN1A","4","-2.5","Efficacy","carbamazepine;oxcarbazepine","Epilepsy","166036278","77.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.612;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=1.94;ReadPosRankSum=-0.553;SOR=0.984","C","T","Patients with the CT genotype and epilepsy who are treated with carbamazepine may have a decreased likelihood of a good response as compared to patients with the TT genotype, although most studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment."
"1183614600","CYP11B2","3","2.5","Efficacy","candesartan","Hypertension","142918184","990.06","AC=2;AF=1.00;AN=2;DB;DP=33;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.00;SOR=0.826","A","G","Patients with the AG genotype and hypertension may be less likely to respond to treatment with candesartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to candesartan."
"1183614605","CYP11B2","3","1.5","Efficacy","benazepril;imidapril","Essential hypertension","142918184","990.06","AC=2;AF=1.00;AN=2;DB;DP=33;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.00;SOR=0.826","A","G","Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response."
"1183614624","SCN1A","3","4.75","Efficacy","carbamazepine","Epilepsy","166053034","838.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.589;DB;DP=55;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.25;ReadPosRankSum=-1.080;SOR=0.850","C","T","Patients with the CT genotype and epilepsy who are treated with carbamazepine may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine."
"1183614701","REEP5","3","3","Efficacy","citalopram;fluoxetine;paroxetine;sertraline","Depressive Disorder, Major","112900600","471.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.082;DB;DP=63;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.13;ReadPosRankSum=0.289;SOR=0.593","A","G","Patients with the AG genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline."
"1183614711","ZNF804A","3","2","Efficacy","antipsychotics","Schizophrenia","184913701","600.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.271;DB;DP=44;ExcessHet=3.0103;FS=2.649;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.97;ReadPosRankSum=0.197;SOR=0.803","A","C","Patients with the AC genotype and schizophrenia may have a better response when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antipsychotics."
"1183614761","ABCB1","3","2.25","Toxicity","sirolimus","Kidney Transplantation","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels."
"1183614840","ABCB1","3","4.5","Toxicity","sirolimus","Kidney Transplantation","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels."
"1183614881","IL4R","3","3","Efficacy","pitrakinra","Asthma","27364896","1763.06","AC=2;AF=1.00;AN=2;DB;DP=61;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.65;SOR=0.767","A","G","Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pitrakinra."
"1183614891","HTR1A","3","3","Efficacy","amisulpride;antipsychotics;olanzapine;quetiapine;risperidone","Schizophrenia","63965502","581.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.733;DB;DP=54;ExcessHet=3.0103;FS=10.950;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.97;ReadPosRankSum=-1.225;SOR=2.219","C","T","Patients with the CT genotype and schizophrenia may have a poorer response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antipsychotics."
"1183615135","HTR2C","3","2.25","Toxicity","olanzapine","Mental Disorders","114903581","882.06","AC=2;AF=1.00;AN=2;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.50;SOR=0.836","C","G","Women with the CG genotype and mental disorders (excluding schizophrenia) may have greater weight gain when treated with olanzapine as compared to women with the CC genotype, or smaller weight gain when treated with olanzapine as compared to women with the GG genotype. Other genetic and clinical factors may also influence weight gain."
"1183615150","AGT","3","3.5","Efficacy","benazepril","Hypertension","230702585","804.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.660;DB;DP=101;ExcessHet=3.0103;FS=2.769;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.13;ReadPosRankSum=0.058;SOR=1.083","G","T","Patients with the GT genotype and hypertension may have smaller decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence change in systolic and diastrolic blood pressure."
"1183615268","ERCC1","3","0.75","Toxicity","fluorouracil;leucovorin;oxaliplatin","Colonic Neoplasms","45420395","1040.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.802;DB;DP=78;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.69;ReadPosRankSum=0.427;SOR=0.595","A","G","Patients with the AG genotype and colon cancer may have a decreased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia."
"1183615273","ERCC1","3","1.5","Efficacy","fluorouracil;leucovorin;oxaliplatin","Colorectal Neoplasms","45420395","1040.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.802;DB;DP=78;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.69;ReadPosRankSum=0.427;SOR=0.595","A","G","Patients with the AG genotype and colorectal cancer may have decreased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time."
"1183615573","AGT","3","1.875","Efficacy","irbesartan","Hypertension;Hypertrophy, Left Ventricular","230710048","373.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.101;DB;DP=21;ExcessHet=3.0103;FS=1.885;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=18.68;ReadPosRankSum=-0.502;SOR=1.445","A","G","Patients with the rs699 AG genotype may have an increased response to irbesartan as compared to patients with the AA genotype, but a decreased response as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan."
"1183615582","AGT","3","0.25","Efficacy","atenolol","Hypertension;Hypertrophy, Left Ventricular","230710048","373.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.101;DB;DP=21;ExcessHet=3.0103;FS=1.885;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=18.68;ReadPosRankSum=-0.502;SOR=1.445","A","G","Patients with the rs699 AG genotype may have an increased response to atenolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atenolol."
"1183617724","FKBP5","3","4.5","Efficacy","antidepressants;Selective serotonin reuptake inhibitors","Depressive Disorder;Mood Disorders","35702206","808.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.400;DB;DP=68;ExcessHet=3.0103;FS=4.729;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.25;ReadPosRankSum=-1.791;SOR=1.044","A","G","Patients with the AG genotype may have a better response to antidepressants as compared to patients with the GG genotype or may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment."
"1183624306","DRD3","3","2","Efficacy","duloxetine","Anxiety Disorders","114172195","378.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.833;DB;DP=24;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=17.21;ReadPosRankSum=0.171;SOR=0.976","C","T","Patients with the CT genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine."
"1183631536","OPRM1","3","2.5","Toxicity","carboplatin;docetaxel;paclitaxel","Ovarian Neoplasms","154136358","1535.06","AC=2;AF=1.00;AN=2;DB;DP=56;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.52;SOR=0.941","G","T","Patients with the GT genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity."
"1183631564","HRH4","3","1.25","Efficacy","risperidone","Schizophrenia","24464436","1919.06","AC=2;AF=1.00;AN=2;DB;DP=67;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.95;SOR=0.976","G","T","Patients with the GT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone."
"1183632145","WNK1","3","2.5","Efficacy","hydrochlorothiazide","Hypertension","879392","386.06","AC=2;AF=1.00;AN=2;DB;DP=14;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=27.58;SOR=0.976","C","T","Patients with the CT genotype may have increased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide."
"1183632190","ABCB1","3","1.75","Efficacy","anthracyclines and related substances;taxanes","Breast Neoplasms","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes."
"1183632195","ABCB1","3","4.5","Efficacy","ondansetron","Postoperative Nausea and Vomiting;Vomiting","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the rs1045642 AG genotype may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to ondansetron."
"1183632200","ABCB1","3","4.5","Efficacy","ondansetron","Postoperative Nausea and Vomiting;Vomiting","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the rs2032582 AC genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron."
"1183679780","CSRNP3","3","0","Toxicity","Bisphosphonates","Osteonecrosis","165551001","423.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.413;DB;DP=21;ExcessHet=3.0103;FS=1.808;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=20.17;ReadPosRankSum=0.703;SOR=0.375","A","G","Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates."
"1183680511","C8orf34","3","0","Toxicity","irinotecan","Carcinoma, Non-Small-Cell Lung","68476982","1319.06","AC=2;AF=1.00;AN=2;DB;DP=41;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.98;SOR=0.793","C","G","Patients with the CG genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity."
"1183680531","SLC30A8","3","1.5","Efficacy","repaglinide","Diabetes Mellitus, Type 2","117172544","452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.704;DB;DP=43;ExcessHet=3.0103;FS=5.870;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.91;ReadPosRankSum=0.284;SOR=2.066","C","T","Patients with the CT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide."
"1183680546","IFNL3;IFNL4","1A","213.25","Efficacy","boceprevir;peginterferon alfa-2a;peginterferon alfa-2b;ribavirin","Hepatitis C, Chronic","39248147","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.448;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=58.43;MQRankSum=-1.834;QD=13.47;ReadPosRankSum=-0.076;SOR=0.693","C","T","Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy."
"1183680555","PLCD3","3","3","Efficacy","diltiazem","Hypertension","45130754","90.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.405;DB;DP=10;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.33;ReadPosRankSum=-0.545;SOR=0.693","A","T","Patients with the AT genotype may have increased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem."
"1183680570","OASL","3","2.25","Efficacy","peginterferon alfa-2b;ribavirin","Hepatitis C","121020597","859.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.773;DB;DP=53;ExcessHet=3.0103;FS=6.534;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=17.91;ReadPosRankSum=-0.248;SOR=1.798","C","T","Patients with the CT genotype may have decreased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons."
"1183680656","POR","4","-0.5","Toxicity","tacrolimus","Kidney Transplantation","75985688","1716.06","AC=2;AF=1.00;AN=2;DB;DP=52;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.00;SOR=1.358","C","T","Patients with the CT (POR *1/*28) genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation as compared to patients with the CC (*1/*1) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus."
"1183684144","CYP2E1","3","2.75","Toxicity","cytarabine;fludarabine;gemtuzumab ozogamicin;idarubicin","Leukemia, Myeloid, Acute","133527063","2153.06","AC=2;AF=1.00;AN=2;DB;DP=70;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.20;SOR=1.131","A","T","Patients with the AT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype and an increased likelihood of toxic liver disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
"1183684172","ABCB1","3","5.25","Efficacy","cytarabine;daunorubicin;dexrazoxane;idarubicin","Leukemia, Myeloid, Acute","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment."
"1183689987","CYP3A4","3","2.25","Other","sirolimus","Kidney Transplantation","99784473","2096.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.27;SOR=0.859","C","T","Transplant recipients with the CT (CYP3A4 *1B/*1) genotype may require an increased dose of sirolimus as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements."
"1183690892","ABCB1","3","2.25","Efficacy","highly active antiretroviral therapy (haart)","HIV Infections","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the rs1045642 AG genotype and HIV may have an increased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART."
"1183693433","XDH","3","1.75","Toxicity","didanosine","HIV Infections","31356103","1040.06","AC=2;AF=1.00;AN=2;DB;DP=35;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.72;SOR=0.869","A","C","Patients with the AC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension."
"1183693438","XDH","3","1.75","Toxicity","didanosine","HIV Infections","31365695","891.06","AC=2;AF=1.00;AN=2;DB;DP=24;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=36.94;SOR=1.270","A","C","Patients with the AC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension."
"1183697540","SLCO1B1","3","2.5","Efficacy","irinotecan","Colorectal Neoplasms","21176804","361.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.460;DB;DP=33;ExcessHet=3.0103;FS=3.093;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.30;ReadPosRankSum=-1.572;SOR=1.314","A","G","Patients with the AG genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment."
"1183697557","CDA","3","3","Toxicity","capecitabine","Neoplasms","20589038","851.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.079;DB;DP=80;ExcessHet=3.0103;FS=7.794;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.21;ReadPosRankSum=-0.474;SOR=0.476","A","G","Cancer patients with the AG genotype may have an increased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration."
"1183697570","ABCB1","3","2","Efficacy","tamoxifen","Breast Neoplasms","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Women with the AG genotype and breast cancer may have an increased chance of disease recurrence when treated with tamoxifen as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence breast cancer recurrence."
"1183697592","SLCO1B1","3","2.25","Metabolism/PK","methotrexate","Precursor Cell Lymphoblastic Leukemia-Lymphoma","21176804","361.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.460;DB;DP=33;ExcessHet=3.0103;FS=3.093;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.30;ReadPosRankSum=-1.572;SOR=1.314","A","G","Patients with the rs2306283 AG genotype may have increased exposure to methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2306283 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure."
"1183698831","IL6","3","1.5","Efficacy","fenofibrate","Cardiovascular Diseases","22727026","1341.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.80;SOR=0.829","C","G","Patients with the CG genotype who have a high risk of cardiovascular disease may have a better anti-inflammatory response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate."
"1183699226","AKT1","3","2","Efficacy","carboplatin;cisplatin","Carcinoma, Non-Small-Cell Lung","104797271","1028.06","AC=2;AF=1.00;AN=2;DB;DP=33;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.15;SOR=0.880","A","G","Patients with the AG genotype who are treated with carboplatin or cisplatin may have increased risk of progression of disease as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin."
"1183700243","RRM2B","3","1.75","Efficacy","cladribine;cytarabine","Leukemia, Myeloid, Acute","102187808","525.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.095;DB;DP=70;ExcessHet=3.0103;FS=3.435;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=7.73;ReadPosRankSum=0.006;SOR=1.109","A","G","Patients with the AG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to first remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment."
"1183700248","RRM1","3","1.75","Efficacy","cladribine;cytarabine","Leukemia, Myeloid, Acute","4082830","1509.06","AC=2;AF=1.00;AN=2;DB;DP=42;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=27.13;SOR=2.419","A","C","Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to the first course of remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment."
"1183700258","RRM1","3","2.25","Efficacy","cladribine;cytarabine","Leukemia, Myeloid, Acute","4138534","910.06","AC=2;AF=1.00;AN=2;DB;DP=30;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.71;SOR=0.765","A","T","Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer event-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment."
"1183700517","NOS2","3","0.75","Toxicity","isoniazid;rifampin","Toxic liver disease;Tuberculosis","27777485","955.06","AC=2;AF=1.00;AN=2;DB;DP=27;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=35.07;SOR=1.022","T","C","Patients with the TC genotype may have decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin."
"1183702975","CYP2B6","3","2.75","Dosage","methadone","Heroin Dependence;Opioid-Related Disorders","41006936","384.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.804;DB;DP=34;ExcessHet=3.0103;FS=1.394;MLEAC=1;MLEAF=0.500;MQ=59.51;MQRankSum=1.002;QD=11.31;ReadPosRankSum=1.503;SOR=0.374","G","T","Patients with the rs3745274 GT genotype may have increased methadone dose requirements as compared to patients with the TT genotype but decreased dose requirements as compared to the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence dose of methadone."
"1183702981","CYP2B6","3","1","Dosage","methadone","Heroin Dependence","41009358","170.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.434;DB;DP=43;ExcessHet=3.0103;FS=3.968;MLEAC=1;MLEAF=0.500;MQ=48.66;MQRankSum=-4.633;QD=4.27;ReadPosRankSum=-3.157;SOR=1.819","A","G","Patients with the rs2279343 AG genotype may have increased methadone dose requirements as compared to patients with the GG genotype but decreased dose requirements as compared to the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
"1183703000","VEGFA","3","2","Efficacy","cyclophosphamide","Prostatic Neoplasms","43770613","1380.06","AC=2;AF=1.00;AN=2;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.37;SOR=0.784","C","G","Patients with the CG genotype and prostate cancer may have longer progression-free survival time when treated with cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of progression-free survival."
"1183703760","HAS3","3","3.5","Toxicity","anthracyclines and related substances","Cardiomyopathies","69109674","1017.06","AC=2;AF=1.00;AN=2;DB;DP=34;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.78;SOR=0.693","A","G","Patients with genotype AG may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines."
"1183704243","SLC31A1","3","2.25","Efficacy","carboplatin;cisplatin","Carcinoma, Non-Small-Cell Lung","113240184","725.06","AC=2;AF=1.00;AN=2;DB;DP=23;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.96;SOR=1.329","A","G","Patients with the AG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin."
"1183704358","SLC22A16","3","4.25","Efficacy;Toxicity","cyclophosphamide;doxorubicin;fluorouracil","Breast Neoplasms","110456759","1064.06","AC=2;AF=1.00;AN=2;DB;DP=33;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.24;SOR=0.752","A","G","Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil."
"1183704390","EPB41","3","3.25","Efficacy","bupropion;nicotine","Tobacco Use Disorder","29084738","174.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.523;DB;DP=25;ExcessHet=3.0103;FS=1.935;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=7.28;ReadPosRankSum=0.367;SOR=1.238","A","G","Patients with the AG genotype may have increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to bupropion or nicotine."
"1183704404","CD84","3","2","Efficacy","etanercept","Arthritis, Rheumatoid;Psoriasis","160546518","677.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.248;DB;DP=60;ExcessHet=3.0103;FS=0.982;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.68;ReadPosRankSum=-0.540;SOR=0.846","A","G","Patients with the AG genotype may have increased response to etanercept in people with Arthritis, Rheumatoid or Psoriasis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to etanercept."
"1183704409","HTR2A","3","0","Efficacy","antipsychotics","tardive dyskinesia","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","Patients with the CT genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics."
"1183863785","CYP19A1","3","3","Toxicity","exemestane","Breast Neoplasms","51339082","587.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.662;DB;DP=50;ExcessHet=3.0103;FS=1.087;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.99;ReadPosRankSum=-0.566;SOR=0.528","C","T","Patients with the CT genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane."
"1183888969","IFNL3;IFNL4","1A","219","Efficacy","peginterferon alfa-2a;peginterferon alfa-2b;ribavirin;telaprevir","Hepatitis C, Chronic","39248147","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.448;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=58.43;MQRankSum=-1.834;QD=13.47;ReadPosRankSum=-0.076;SOR=0.693","C","T","Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy."
"1184134170","DCK","3","2.5","Toxicity","gemcitabine","Pancreatic Neoplasms","71028147","308.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.046;DB;DP=54;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=6.05;ReadPosRankSum=1.818;SOR=0.650","C","T","Patients with CT genotype and pancreatic cancer who are treated with gemcitabine may have an decreased risk of neutropenia compared to patients with the TT genotype, and increased risk of neutropenia compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine."
"1184134274","ABCB1","3","2.5","Efficacy","morphine","Pain","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have decreased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence response to morphine."
"1184233161","NR3C2","3","2.75","Efficacy","enalapril","Hypertension","148436323","1823.06","AC=2;AF=1.00;AN=2;DB;DP=52;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=26.79;SOR=1.270","C","T","Patients with the CT genotype and hypertension may have a lower reduction in diastolic blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril."
"1184233504","COMT","3","2","Other","opioids","Pain","19962712","616.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.046;DB;DP=49;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.85;ReadPosRankSum=0.320;SOR=0.693","C","T","Patients with the CT genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management."
"1184233711","ABCB1","3","0.5","Other","efavirenz","HIV Infections","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and HIV infection who are treated with efavirenz may have increased clearance of efavirenz as compared to patients with the GG genotype and may have reduced clearance of efavirenz as compared to patients with the AA genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics."
"1184348774","LIG3","3","1.875","Toxicity","cisplatin;cyclophosphamide","Ovarian Neoplasms","35004556","749.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.616;DB;DP=65;ExcessHet=3.0103;FS=1.027;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.71;ReadPosRankSum=1.375;SOR=0.957","C","T","Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 3-4 neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy."
"1184472721","SLC29A1","3","0","Efficacy","gemcitabine","Neoplasms","44233216","489.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.707;DB;DP=47;ExcessHet=3.0103;FS=1.119;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.42;ReadPosRankSum=-0.723;SOR=0.507","A","G","Patients with cancer and the AG genotype may have increased response to gemcitabine as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine."
"1184472746","ESR1","3","2.75","Toxicity","anastrozole;letrozole","Neoplasms","151842246","860.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.177;DB;DP=53;ExcessHet=3.0103;FS=2.477;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.55;ReadPosRankSum=0.075;SOR=0.343","A","G","Patients with cancer and the AG genotype may experience increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the GG genotype, or decreased as compared to the AA genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain."
"1184472751","CDA","3","2.5","Other","gemcitabine","Neoplasms","20618562","819.06","AC=2;AF=1.00;AN=2;DB;DP=25;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.13;SOR=1.270","C","T","Patients with cancer and the CT genotype may have increased metabolism of gemcitabine as compared to patients with the TT genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine."
"1184514458","GRM3","3","2.5","Other","heroin","Heroin Dependence","86683758","1700.06","AC=2;AF=1.00;AN=2;DB;DP=55;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.48;SOR=1.022","A","G","Patients with the AG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype and an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence."
"1184514469","GRM3","3","2.5","Other","heroin","Heroin Dependence","86696058","2109.06","AC=2;AF=1.00;AN=2;DB;DP=53;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=35.32;SOR=0.773","A","G","Patients with the AG genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype and a decreased risk of Heroin Dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence."
"1184661194","CYP4F2","2A","11.75","Dosage","acenocoumarol","Atrial Fibrillation","15879621","853.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.514;DB;DP=70;ExcessHet=3.0103;FS=0.907;MLEAC=1;MLEAF=0.500;MQ=59.96;MQRankSum=1.059;QD=12.55;ReadPosRankSum=0.362;SOR=0.576","C","T","Patients with the rs2108622 CT genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the TT genotype or may require a higher dose as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence required acenocoumarol dose."
"1184747857","MYLIP","3","2.5","Efficacy","atorvastatin","Hypercholesterolemia","16145094","591.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.396;DB;DP=32;ExcessHet=3.0103;FS=1.470;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=18.49;ReadPosRankSum=-0.877;SOR=0.368","A","G","Patients with the AG genotype and hypercholesterolemia who are treated with atorvastatin may have decreased LDL-C responses and are less likely to achieve LDL-C levels of less than 130mg/dl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin."
"1184749208","ABCB1","3","2.75","Efficacy","vincristine","Precursor Cell Lymphoblastic Leukemia-Lymphoma","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a decreased likelihood of event-free survival as compared to patients with the GG genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment."
"1184986491","PPARA","3","1.5","Other","tacrolimus","Organ Transplantation","46202410","636.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.141;DB;DP=65;ExcessHet=3.0103;FS=12.041;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.98;ReadPosRankSum=-0.527;SOR=1.175","A","G","Patients with the AG genotype and organ transplantation administered tacrolimus may have increased metabolism of tacrolimus as compared to patients with the GG genotype and decreased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus."
"1184986567","TLR4","3","2.25","Other","tacrolimus","Organ Transplantation","117710486","194.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.093;DB;DP=31;ExcessHet=3.0103;FS=1.657;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=6.28;ReadPosRankSum=0.283;SOR=0.307","C","T","Organ transplant patients with the CT genotype who are administered tacrolimus may have decreased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CC genotype. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients."
"1184986763","ABCB1","3","4.75","Other","opioids","Opioid-Related Disorders","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA or GG genotypes. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids."
"1184986770","GAL","3","2.25","Other","opioids","Opioid-Related Disorders","68682735","1230.06","AC=2;AF=1.00;AN=2;DB;DP=39;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.24;SOR=0.984","C","T","Patients with the CT genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids."
"1184987030","GALNT2","3","2","Other","atenolol","Hypertension","230159169","2211.06","AC=2;AF=1.00;AN=2;DB;DP=73;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.52;SOR=1.022","C","T","Patients with the CT genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT genotype. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension."
"1184998947","ABCB1","3","0","Other","morphine","Pain","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype who are treated with morphine may have lower levels of morphine-3-glucuronide formation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine."
"1184998975","ABCC3","3","3.75","Other","morphine","Pain","50634726","1182.06","AC=2;AF=1.00;AN=2;DB;DP=45;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.14;SOR=0.693","C","T","Patients with the CT genotype may have decreased metabolism of morphine as compared to patients with the CC genotype, but increased metabolism of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine."
"1185000522","ABCB1","4","-7.375","Other","atazanavir;ritonavir","HIV Infections","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in most studies. There is no evidence that the AG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV."
"1185003571","FCGR2A","3","4.75","Efficacy","trastuzumab","Breast Neoplasms","161509955","2796.06","AC=2;AF=1.00;AN=2;DB;DP=103;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=27.96;SOR=1.007","A","G","Patients with the AG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab."
"1296599132","ABCB1","3","4.75","Toxicity","methotrexate","Burkitt Lymphoma;Drug Toxicity;Lymphoma, T-Cell;Precursor Cell Lymphoblastic Leukemia-Lymphoma","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the rs1045642 AG genotype and cancer who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or a decreased risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities."
"1444607318","NR1I2","3","3.875","Metabolism/PK","risperidone","Psychotic Disorders","119806650","1306.06","AC=2;AF=1.00;AN=2;DB;DP=45;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.68;SOR=1.364","A","G","No information available."
"1444607373","E2F7","3","2","Toxicity","tamoxifen","Breast Neoplasms","77042368","1383.06","AC=2;AF=1.00;AN=2;DB;DP=49;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.43;SOR=0.823","C","T","Women with the CT genotype and breast cancer may have decreased lumbar bone loss when treated with tamoxifen as compared to women with the CC genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen."
"1444607408","ABCB1","3","2.5","Efficacy","imatinib","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and chronic myeloid leukemia may have a decreased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the GG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response."
"1444607716","ABCB1","3","2","Metabolism/PK","ritonavir","HIV Infections","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype who are treated with ritonavir may have a increased intracellular/plasma trough concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir."
"1444607730","TBC1D1","3","2","Toxicity","clozapine;olanzapine","Schizophrenia","38137403","727.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.568;DB;DP=74;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.25;ReadPosRankSum=-0.408;SOR=0.619","C","T","Patients with the CT genotype and schizophrenia may experience less of a weight gain when treated with clozapine or olanzapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine."
"1444607768","HTR2A","4","-2.25","Toxicity","fluvoxamine","Depressive Disorder, Major","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","Patients with the CT genotype who are treated with fluvoxamine may have an increased risk of gastrointestinal side effects as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine."
"1444607803","ABCB1","3","3.5","Other","olanzapine","Psychotic Disorders","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and Psychotic Disorders who are treated with olanzapine may have decreased social and clinical needs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to olanzapine."
"1444607966","DAPK1","3","0","Toxicity","gemcitabine","Neoplasms","87620879","868.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-3.266;DB;DP=72;ExcessHet=3.0103;FS=3.468;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.79;ReadPosRankSum=0.508;SOR=0.782","A","C","Patients with the AC genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the CC genotype and decreased risk of leukopenia as compared to patients with the AA. Other genetic and clinical factors may also influence a patient's risk of leukopenia."
"1444607979","RRM1","3","1.25","Efficacy","gemcitabine;Platinum compounds","Mesothelioma","4138699","1332.06","AC=2;AF=1.00;AN=2;DB;DP=45;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.27;SOR=0.693","C","A","Patients with the CA genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have a decreased overall survival probability as compared to patients with the AA genotype and increased overall survival probability as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's survival probability."
"1444608027","BDNF","3","1.25","Efficacy","citalopram","Depressive Disorder, Major","27655494","715.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.833;DB;DP=64;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.13;ReadPosRankSum=0.114;SOR=0.680","C","T","Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram."
"1444608040","BDNF","4","-0.5","Efficacy","citalopram","Depressive Disorder, Major","27678578","1388.06","AC=2;AF=1.00;AN=2;DB;DP=45;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.85;SOR=0.737","C","T","Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype, or a poorer response when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to citalopram."
"1444608053","GSTA1","3","1.5","Efficacy","doxorubicin","Sarcoma","52803889","103.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.182;DB;DP=25;ExcessHet=3.0103;FS=4.589;MLEAC=1;MLEAF=0.500;MQ=52.89;MQRankSum=-2.886;QD=4.71;ReadPosRankSum=-0.886;SOR=1.158","A","G","Patients with the AG genotype and soft tissue sarcoma may have a shorter progression-free survival time when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time."
"1444608132","VEGFA","3","5","Efficacy","bevacizumab;pegaptanib;ranibizumab","Choroidal Neovascularization","43770613","1380.06","AC=2;AF=1.00;AN=2;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.37;SOR=0.784","C","G","Patients with the CG genotype and choroidal neovascularization may have a better response to anti-VEGF treatment, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment."
"1444608189","ENOSF1","3","2.5","Toxicity","capecitabine","Neoplasms","683607","1178.06","AC=2;AF=1.00;AN=2;DB;DP=41;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.84;SOR=0.746","C","T","Patients with the CT genotype and cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype, or a decreased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
"1444608238","DRD1","3","4.5","Toxicity","dextroamphetamine;methylphenidate","Attention Deficit Disorder with Hyperactivity","175443147","659.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.479;DB;DP=66;ExcessHet=3.0103;FS=2.125;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.31;ReadPosRankSum=1.470;SOR=0.436","C","T","Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine."
"1444608377","IL11","3","1.5","Efficacy","escitalopram","Depression","55368504","651.06","AC=2;AF=1.00;AN=2;DB;DP=23;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.55;SOR=1.721","C","T","Patients with the CT genotype and depression may respond better to treatment with escitalopram, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to escitalopram."
"1444608396","EGFR","3","3","Efficacy","fluorouracil","Stomach Neoplasms","55201223","1858.06","AC=2;AF=1.00;AN=2;DB;DP=58;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.18;SOR=1.101","C","T","Patients with the CT genotype and gastric cancer may have a better response when treated with fluorouracil, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fluorouracil."
"1444608441","DRD3","3","1.75","Efficacy","methylphenidate","Autism Spectrum Disorder","114171968","372.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.437;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.31;ReadPosRankSum=0.000;SOR=0.693","C","T","Patients with the CT genotype and autism spectrum disorders may have a poorer tolerance for methylphenidate treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment."
"1444665946","AREG","3","4.5","Efficacy","cetuximab;irinotecan;panitumumab","Colorectal Neoplasms","74556244","811.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.386;DB;DP=65;ExcessHet=3.0103;FS=0.962;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.88;ReadPosRankSum=0.626;SOR=0.523","A","G","Patients with the AG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment as compared to patients with the AA genotype, but a longer overall survival time as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
"1444665984","EGFR","3","2.25","Efficacy","cetuximab;irinotecan;panitumumab","Colorectal Neoplasms","55019062","811.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.785;DB;DP=72;ExcessHet=3.0103;FS=0.907;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.27;ReadPosRankSum=-0.220;SOR=0.527","G","T","Patients with the GT genotype and colorectal cancer may have a longer overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment."
"1444666376","AGT","3","2.5","Efficacy","benazepril;imidapril","Hypertension","230714126","519.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.076;DB;DP=32;ExcessHet=3.0103;FS=2.991;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.24;ReadPosRankSum=-1.590;SOR=1.048","C","T","Patients with the CT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril."
"1444666589","ERCC3","3","2.25","Efficacy","Platinum compounds","Carcinoma, Non-Small-Cell Lung","127260487","611.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.491;DB;DP=47;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.01;ReadPosRankSum=-2.364;SOR=0.616","A","G","Patients with the AG genotype and non-small-cell lung cancer may have a decreased response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype, and an increased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy."
"1444666629","ERCC2","3","4.5","Toxicity","Platinum compounds","Carcinoma, Non-Small-Cell Lung","45364001","527.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.383;DB;DP=30;ExcessHet=3.0103;FS=4.499;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=17.59;ReadPosRankSum=-1.027;SOR=0.170","C","T","Patients with the CT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis."
"1444666667","CXXC4","3","3","Efficacy","Platinum compounds","Carcinoma, Non-Small-Cell Lung","104472204","397.06","AC=2;AF=1.00;AN=2;DB;DP=15;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.36;SOR=2.985","A","G","Patients with the AG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy."
"1444666705","MTR","3","2.75","Toxicity","methotrexate","Agranulocytosis","236865264","1059.06","AC=2;AF=1.00;AN=2;BaseQRankSum=1.256;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;MQRankSum=0.000;QD=29.42;ReadPosRankSum=1.003;SOR=0.941","G","T","Patients with the GT genotype and acute lymphoblastic leukemia may have a decreased risk of granulocytopenia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of agranulocytosis."
"1444666770","DHFR","3","2.5","Toxicity","pemetrexed","Carcinoma, Non-Small-Cell Lung;Mesothelioma","80654962","1698.06","AC=2;AF=1.00;AN=2;DB;DP=51;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=59.87;QD=34.65;SOR=1.473","A","G","Patients with the AG genotype and lung cancer may have an increased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity."
"1444666855","ABCB1","3","2.25","Toxicity","risperidone","Schizophrenia","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and schizophrenia may have a longer QTc interval when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone."
"1444667461","SLC30A9","3","3","Toxicity","aspirin","aspirin-induced asthma","42001654","1259.06","AC=2;AF=1.00;AN=2;DB;DP=42;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.71;SOR=2.247","A","G","Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma."
"1444667661","CAPN10","3","3","Efficacy","metformin","Diabetes Mellitus","240592062","486.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.766;DB;DP=51;ExcessHet=3.0103;FS=6.054;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.35;ReadPosRankSum=-0.331;SOR=0.555","A","G","Patients with the AG genotype and diabetes mellitus may have a decreased response when treated with metformin as compared to patients with the AA genotypes and an increased response to metformin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to metformin."
"1444667912","SOD2","3","1.5","Toxicity","valproic acid","Epilepsy","159692840","164.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.741;DB;DP=29;ExcessHet=3.0103;FS=1.708;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=5.68;ReadPosRankSum=1.488;SOR=0.273","A","G","Patients with genotype AG and epilepsy may have a decreased risk of drug toxicity when taking valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid."
"1444672826","ABCB1","4","-2.25","Efficacy","pantoprazole","Helicobacter Infections","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and eradication of Helicobacter infection when treated with pantoprazole. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of response to pantoprazole."
"1444672993","ABCB1","4","-11.875","Dosage;Metabolism/PK","tacrolimus","Transplantation","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus."
"1444673046","HRH3","3","0.25","Efficacy","risperidone","Schizophrenia","62216348","2360.06","AC=2;AF=1.00;AN=2;DB;DP=70;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.71;SOR=1.445","C","T","Patients with the CT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. However, another study found no association between this variant and response to riperidone in patients with schizophrenia. Other genetic and clinical factors may also influence response to risperidone."
"1444673053","HRH3","3","3","Efficacy","risperidone","Schizophrenia","62216366","959.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.531;DB;DP=79;ExcessHet=3.0103;FS=2.020;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.97;ReadPosRankSum=-1.647;SOR=1.022","C","T","Patients with the CT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone."
"1444673072","TNFRSF10A","3","4.75","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors","Arthritis","23201811","2018.06","AC=2;AF=1.00;AN=2;DB;DP=64;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.20;SOR=1.421","C","G","Patients with the CG genotype and rheumatoid or psoriatic arthritis may have a poorer response when treated with anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies."
"1444673084","SLC22A5","3","2.75","Efficacy","imatinib","Gastrointestinal Stromal Tumors","132369766","2426.06","AC=2;AF=1.00;AN=2;DB;DP=74;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.17;SOR=0.904","C","G","Patients with the CG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment."
"1444673142","CR1","3","2.75","Efficacy","eculizumab","paroxysmal nocturnal hemoglobinuria","207580276","835.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.392;DB;DP=63;ExcessHet=3.0103;FS=5.516;MLEAC=1;MLEAF=0.500;MQ=58.31;MQRankSum=-0.819;QD=13.48;ReadPosRankSum=-0.809;SOR=0.230","A","G","Patients with the AG genotype and paroxysmal nocturnal hemoglobinuria may have a poorer response to treatment with eculizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to eculizumab."
"1444673149","FCGR2A","4","-0.75","Efficacy","adalimumab;etanercept;infliximab","Psoriasis","161509955","2796.06","AC=2;AF=1.00;AN=2;DB;DP=103;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=27.96;SOR=1.007","A","G","Patients with the AG genotype and psoriasis may have a lower psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
"1444673163","POR","3","2.75","Metabolism/PK","cyclosporine","Kidney Transplantation","75985688","1716.06","AC=2;AF=1.00;AN=2;DB;DP=52;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.00;SOR=1.358","C","T","Patients with the CT genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1/*3 or *3/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have increased trough concentrations of cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations."
"1444679942","OPRD1","3","1.5","Efficacy","buprenorphine","Opioid-Related Disorders","28848434","285.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.591;DB;DP=33;ExcessHet=3.0103;FS=3.506;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.93;ReadPosRankSum=-1.059;SOR=1.609","A","C","Patients with the AC genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the CC genotype, or a better response as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine."
"1444680101","OPRD1","4","-0.75","Efficacy","buprenorphine","Opioid-Related Disorders","28848861","717.06","AC=2;AF=1.00;AN=2;DB;DP=27;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=26.56;SOR=0.765","A","G","Patients with the AG genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the GG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine."
"1444686789","CYP2B6","3","6.5","Efficacy;Toxicity","imatinib","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","41006936","384.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.804;DB;DP=34;ExcessHet=3.0103;FS=1.394;MLEAC=1;MLEAF=0.500;MQ=59.51;MQRankSum=1.002;QD=11.31;ReadPosRankSum=1.503;SOR=0.374","G","T","Patients with the GT genotype and chronic myeloid leukemia may have a 1) a better response to treatment with imatinib as compared to patients with the TT genotype, 2) a decreased risk of developing cytogenetic resistance to imatinib as compared to patients with the GG or TT genotype, and 3) a decreased risk for side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib."
"1444686983","CD14","3","2.25","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors","Colitis, Ulcerative","140633331","1227.06","AC=2;AF=1.00;AN=2;DB;DP=40;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.16;SOR=0.746","A","G","Patients with the AG genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
"1444687039","TNFRSF1A","3","3.5","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors","Crohn Disease;Inflammatory Bowel Diseases","6342424","1855.06","AC=2;AF=1.00;AN=2;DB;DP=59;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.44;SOR=1.034","A","C","Patients with the AC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
"1444694504","KCNQ1","3","2","Toxicity","tacrolimus","Kidney Transplantation","2835964","308.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-3.094;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=56.38;MQRankSum=0.897;QD=11.43;ReadPosRankSum=0.100;SOR=0.675","A","C","Patients with the AC genotype who are undergoing kidney transplantation may have a decreased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the CC genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation."
"1444694511","ABCB1","4","-7.375","Dosage;Metabolism/PK","tacrolimus","Kidney Transplantation;liver transplantation","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus."
"1444694588","ABCB1","4","-11.125","Dosage;Metabolism/PK","tacrolimus","Organ Transplantation","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype who are undergoing organ transplantation, or who have other diseases, may have increased clearance of tacrolimus as compared to patients with the AA genotype, and decreased dose requirements of tacrolimus as compared to patients with the GG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus."
"1444694602","ABCB1","3","0.5","Efficacy","tacrolimus","Colitis, Ulcerative","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and ulcerative colitis may have a poorer chance at achieving remission when treated with tacrolimus as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission."
"1444694609","ABCB1","4","-6.5","Toxicity","tacrolimus","Kidney Transplantation","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype who are undergoing kidney transplantation and are treated with tacrolimus may have an increased risk of experiencing transplant rejection as compared to patients with the AA or GG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection."
"1444694616","ABCB1","3","1.5","Toxicity","tacrolimus","Kidney Transplantation","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype who are undergoing kidney transplantation may have an increased risk of hypokalemia when treated with tacrolimus as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk of hypokalemia."
"1444700362","NTRK2","3","3.5","Efficacy","clozapine","Schizophrenia","84777667","920.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.811;DB;DP=73;ExcessHet=3.0103;FS=1.962;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.97;ReadPosRankSum=1.058;SOR=0.699","C","T","Patients with the CT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine."
"1444700423","SLC22A2","3","1","Toxicity","cisplatin","Ototoxicity","160249250","1311.06","AC=2;AF=1.00;AN=2;DB;DP=35;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.85;SOR=1.885","A","C","Patients with the AC genotype may have increased risk of cisplatin-induced ototoxicity as compared to patients with AA genotype. However, other studies have failed to find an association. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin."
"1444700639","PTGIR","3","1.5","Toxicity","aspirin","Asthma","46620526","744.06","AC=2;AF=1.00;AN=2;DB;DP=23;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.35;SOR=1.426","A","G","Patients with the AG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin."
"1444700667","HTR1B","3","2.5","Toxicity","escitalopram","Anxiety Disorders","77463665","401.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.043;DB;DP=41;ExcessHet=3.0103;FS=1.293;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.57;ReadPosRankSum=-3.200;SOR=0.446","A","C","Patients with the AC genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to escitalopram."
"1444700675","HTR2A","3","0.75","Toxicity","escitalopram","Anxiety Disorders;Depressive Disorder, Major","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","Patients with the CT genotype who are treated with escitalopram may have increased risk of adverse cognitive effects and sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to escitalopram."
"1444700767","IL6R","3","4.5","Efficacy","tocilizumab","Arthritis, Rheumatoid","154408627","755.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.104;DB;DP=76;ExcessHet=3.0103;FS=4.626;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.64;ReadPosRankSum=-0.801;SOR=0.330","A","G","Patients with the AG genotype and rheumatoid arthritis who are treated with tocilizumab may have increased response to tocilizumab as compared to patients with the AA genotype. However, a different study found a decreased response to tocilizumab for patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab."
"1444701007","BDKRB2","3","3","Toxicity","enalapril;imidapril;lisinopril","Cough;Essential hypertension","96204802","539.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.491;DB;DP=39;ExcessHet=3.0103;FS=4.536;MLEAC=1;MLEAF=0.500;MQ=59.85;MQRankSum=-0.896;QD=14.20;ReadPosRankSum=-1.318;SOR=0.634","C","T","Patients with the CT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril."
"1444701017","KCNT2","3","0","Toxicity","Bisphosphonates","Osteonecrosis","196185768","966.06","AC=2;AF=1.00;AN=2;DB;DP=33;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.27;SOR=1.022","C","T","Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates."
"1444701024","NOS3","3","2.25","Efficacy","sildenafil","Erectile Dysfunction","150992991","857.06","AC=2;AF=1.00;AN=2;DB;DP=27;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.96;SOR=1.445","C","T","Patients with the CT genotype may have increased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to sildenafil."
"1444702822","ABCB1","3","2.5","Efficacy","phenobarbital","Epilepsy","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with genotype AG may have increased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to phenobarbital."
"1444703171","IL6","3","2","Efficacy","adalimumab;etanercept;infliximab","Arthritis, Rheumatoid","22727026","1341.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.80;SOR=0.829","C","G","Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab."
"1444703178","IL6","3","2.25","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors","Psoriasis","22727026","1341.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.80;SOR=0.829","C","G","Patients with the CG genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have decreased response as compared to patients with CC genotype or may have increased response as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors."
"1444703230","ABCB1","3","0","Efficacy","fluoxetine","Depressive Disorder","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AA genotype and Depressive Disorder may have increased response to fluoxetine as compared to patients with the CC genotype or may have decreased response to fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine."
"1444703258","DRD2","3","0","Efficacy","Selective serotonin reuptake inhibitors","Depressive Disorder, Major","113451074","1391.06","AC=2;AF=1.00;AN=2;DB;DP=47;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.62;SOR=0.784","C","T","Patients with the CT genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have early decrease in the percentage of HAMD scores as compared to patients with the TT genotype or may have late decrease in the percentage of HAMD scores as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors."
"1444703273","ABCC4","3","4.5","Metabolism/PK","tenofovir","HIV Infections","95021537","1770.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.842;DB;DP=95;ExcessHet=3.0103;FS=0.838;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=19.04;ReadPosRankSum=-0.231;SOR=0.892","A","C","Patients with the rs3742106 AC genotype may have increased plasma concentrations of tenofovir in people with HIV as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations."
"1444703339","PTGER2","3","1","Toxicity","aspirin","Asthma","52313933","929.06","AC=2;AF=1.00;AN=2;DB;DP=29;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.04;SOR=1.071","C","G","Patients with the GG genotype and asthma who are treated with aspirin may have decreased risk of aspirin-intolerant asthma as compared to patients with the CC genotype or may have increased risk of aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
"1444703346","CYP4F2","3","3.5","Other","aspirin;clopidogrel","Acute coronary syndrome","15879621","853.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.514;DB;DP=70;ExcessHet=3.0103;FS=0.907;MLEAC=1;MLEAF=0.500;MQ=59.96;MQRankSum=1.059;QD=12.55;ReadPosRankSum=0.362;SOR=0.576","C","T","Patients with the CT genotype and acute coronary syndrome may have increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CC or TT genotype and and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel."
"1444703487","PTGER3","3","1.5","Toxicity","aspirin","Asthma","71049286","346.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.648;DB;DP=32;ExcessHet=3.0103;FS=1.406;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.83;ReadPosRankSum=1.305;SOR=0.585","A","T","Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin-intolerant asthma as compared to patients with the TT genotype or may have decreased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
"1444703495","ACE","3","2.25","Toxicity","aspirin","Asthma","63476980","601.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.944;DB;DP=39;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.83;ReadPosRankSum=-0.088;SOR=0.892","C","T","Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
"1444703529","EIF2AK4","3","0","Efficacy","olanzapine;quetiapine;risperidone;ziprasidone","Schizophrenia","40003758","1427.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.73;SOR=0.866","C","T","Patients with the CT genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone."
"1444703537","EIF2AK4","3","0","Efficacy","haloperidol","Schizophrenia","40003758","1427.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.73;SOR=0.866","C","T","Patients with the CT genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol."
"1444703777","ITPA","3","3","Toxicity","peginterferon alfa-2a;ribavirin","Hepatitis C","3271278","934.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.330;DB;DP=60;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.11;ReadPosRankSum=-0.450;SOR=0.811","A","C","Patients with the AC genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have decreased, but not absent, risk of anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin."
"1444704012","NR1H3","3","2.25","Toxicity","verapamil","Coronary Artery Disease;Hypertension","47260473","760.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.465;DB;DP=58;ExcessHet=3.0103;FS=2.296;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.11;ReadPosRankSum=0.506;SOR=0.385","C","T","Patients with the CT genotype and hypertension and coronary artery disease who are treated with verapamil may have increased risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the CC genotype or may have decreased, but not absent, risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to verapamil."
"1444704025","CYP2B6","3","2.5","Metabolism/PK","nicotine","Tobacco Use Disorder","41009358","170.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.434;DB;DP=43;ExcessHet=3.0103;FS=3.968;MLEAC=1;MLEAF=0.500;MQ=48.66;MQRankSum=-4.633;QD=4.27;ReadPosRankSum=-3.157;SOR=1.819","A","G","Patients with the AG genotype may have increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect nicotine metabolism."
"1444704081","TPH2","3","0","Efficacy","citalopram","Depressive Disorder","71938143","421.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.342;DB;DP=37;ExcessHet=3.0103;FS=2.862;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.40;ReadPosRankSum=0.900;SOR=0.539","G","T","Patients with the GT genotype and depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram."
"1444704328","TNFRSF1B","3","5.5","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors","Arthritis, Rheumatoid","12207235","1704.06","AC=2;AF=1.00;AN=2;DB;DP=52;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.77;SOR=0.693","C","T","Patients with the CT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors."
"1444704784","GRK4","3","0","Toxicity","atenolol;verapamil","Coronary Artery Disease;Hypertension","3004316","606.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.109;DB;DP=54;ExcessHet=3.0103;FS=2.455;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.89;ReadPosRankSum=-0.218;SOR=1.230","C","T","Patients with the CT genotype and hypertension and coronory artery disease may have decreased, but not absent, risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil."
"1444704810","ARRB2","3","1.5","Other","methamphetamine","Substance-Related Disorders","4719343","402.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.451;DB;DP=32;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.58;ReadPosRankSum=-0.170;SOR=0.892","C","T","Patients with the TT genotype may have increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to CC genotype or may have decreased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine."
"1444704833","ABCB1","3","2.75","Dosage","opioids","Pain;Pain, Postoperative","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have decreased opioid dose requirements as compared to patients with the GG genotype, but increased opioid dose requirements as compared to patients with the AA genotype. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements."
"1444704869","CHRNA4","3","2.75","Other","nicotine","Tobacco Use Disorder","63349752","1272.06","AC=2;AF=1.00;AN=2;DB;DP=40;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.62;SOR=1.387","C","T","Male patients with the CT genotype may have increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the TT genotype or may have decreased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine."
"1444704881","ABCB1","3","2","Toxicity","methylprednisolone;prednisolone","Kidney Transplantation","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone."
"1444704914","ABCB1","3","2","Metabolism/PK","etoposide","Precursor Cell Lymphoblastic Leukemia-Lymphoma","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have decreased metabolism of etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide."
"1444704928","GPR83","3","0","Efficacy","hydrochlorothiazide","Essential hypertension","94398973","422.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.170;DB;DP=45;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.61;ReadPosRankSum=2.071;SOR=0.700","A","G","Patients with the AG genotype may have decreased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide."
"1444704936","GPR83","3","0","Efficacy","candesartan","Essential hypertension","94398973","422.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.170;DB;DP=45;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.61;ReadPosRankSum=2.071;SOR=0.700","A","G","Patients with the AG genotype may have increased response to candesartan in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to candesartan."
"1444705158","AGTR1","3","0","Toxicity","Ace Inhibitors, Plain","Hypertension","148741608","403.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.079;DB;DP=43;ExcessHet=3.0103;FS=2.887;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.91;ReadPosRankSum=0.759;SOR=1.226","C","T","Patients with the CT genotype and Hypertension may have decreased, but not absent, risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain."
"1444706124","SLCO1B1","3","0","Metabolism/PK","methotrexate","Precursor Cell Lymphoblastic Leukemia-Lymphoma","21219410","413.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.327;DB;DP=33;ExcessHet=3.0103;FS=1.410;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.53;ReadPosRankSum=1.094;SOR=1.193","A","G","Pediatric patients with ALL and the AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate."
"1444706810","SLC1A1","3","0","Efficacy","Selective serotonin reuptake inhibitors","Obsessive-Compulsive Disorder","4582082","853.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.231;DB;DP=68;ExcessHet=3.0103;FS=6.617;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.93;ReadPosRankSum=0.732;SOR=0.936","C","T","Patients with the CT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors."
"1444706890","DRD2","3","3.25","Toxicity","clozapine;olanzapine;risperidone","Schizophrenia","113436043","1491.06","AC=2;AF=1.00;AN=2;DB;DP=54;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.82;SOR=0.773","C","T","Patients with the CT genotype and Schizophrenia may have decreased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone."
"1444843613","IFNL3","3","6.5","Efficacy","peginterferon alfa-2a;peginterferon alfa-2b;ribavirin","Hepatitis C, Chronic","39241143","500.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.651;DB;DP=59;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.94;ReadPosRankSum=1.092;SOR=0.606","A","G","Patients with the AG genotype may have decreased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN/RBV) in people with chronic Hepatitis C as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy."
"1444876859","IFNL3;IFNL4","3","2","Efficacy","deleobuvir;faldaprevir","Hepatitis C, Chronic","39248147","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.448;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=58.43;MQRankSum=-1.834;QD=13.47;ReadPosRankSum=-0.076;SOR=0.693","C","T","Patients with the CT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir."
"1444930642","IFNL3;IFNL4","3","5.75","Efficacy","ledipasvir;sofosbuvir","Hepatitis C, Chronic","39248147","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.448;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=58.43;MQRankSum=-1.834;QD=13.47;ReadPosRankSum=-0.076;SOR=0.693","C","T","Patients with Hepatitis C and the rs12979860 CT genotype may have a decreased response to ledipasvir and sofosbuvir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir."
"1444930850","IFNL3;IFNL4","3","2","Efficacy","peginterferon alfa-2a;peginterferon alfa-2b;ribavirin;simeprevir","Hepatitis C, Chronic","39248147","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.448;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=58.43;MQRankSum=-1.834;QD=13.47;ReadPosRankSum=-0.076;SOR=0.693","C","T","Patients with CT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy."
"1444930908","IFNL3;IFNL4","3","0","Efficacy","daclatasvir;peginterferon alfa-2a;peginterferon alfa-2b;ribavirin","Hepatitis C, Chronic","39248147","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.448;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=58.43;MQRankSum=-1.834;QD=13.47;ReadPosRankSum=-0.076;SOR=0.693","C","T","Patients with genotype CT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy."
"1445400792","FDPS","3","4.25","Efficacy","atorvastatin;Bisphosphonates","Coronary Disease;Osteoporosis","155313038","589.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.386;DB;DP=44;ExcessHet=3.0103;FS=6.638;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.71;ReadPosRankSum=1.066;SOR=1.555","A","G","Patients with the AG genotype may have a decrease in bone density when treated with atorvastatin, as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response."
"1445400992","MDM4","3","2.5","Efficacy","docetaxel;epirubicin","Breast Neoplasms","204547449","749.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.468;DB;DP=45;ExcessHet=3.0103;FS=2.561;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.66;ReadPosRankSum=1.171;SOR=0.521","A","G","Patients with the AG genotype and breast cancer may have a poorer response when treated with docetaxel and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment."
"1445401125","ERCC1","3","1.75","Efficacy","capecitabine;radiotherapy","Rectal Neoplasms","45420395","1040.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.802;DB;DP=78;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.69;ReadPosRankSum=0.427;SOR=0.595","A","G","Patients with the AG genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy."
"1445401156","RGS5","3","2","Efficacy","bevacizumab;fluorouracil;irinotecan;leucovorin","Colorectal Neoplasms","163143470","441.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.853;DB;DP=42;ExcessHet=3.0103;FS=1.281;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.62;ReadPosRankSum=0.366;SOR=0.392","G","T","Patients with the GT genotype and colorectal cancer may have a poorer response when treated with FOLFIRI and bevacizumab as compared to patients with the TT genotype. However, this result only applied to tumors occurring in the right colon. Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab."
"1445401193","MVK","3","3.25","Efficacy","alendronate","Bone Diseases","109604543","992.06","AC=2;AF=1.00;AN=2;DB;DP=41;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=26.11;SOR=0.798","A","G","Patients with the AG genotype and osteoporosis or osteopenia may have a poorer response when treated with alendronate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to alendronate."
"1445401205","ABCB1","3","2.5","Efficacy","imatinib","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib."
"1445401325","ATG16L1","3","2.75","Efficacy","adalimumab","Crohn Disease","233250193","592.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.206;DB;DP=52;ExcessHet=3.0103;FS=1.096;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.85;ReadPosRankSum=-0.583;SOR=0.446","C","T","Patients with the CT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab."
"1445401389","LEPR","3","2.5","Toxicity","valproic acid","Epilepsy","65592830","1550.06","AC=2;AF=1.00;AN=2;DB;DP=61;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.25;SOR=1.402","A","G","Patients with the AG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain."
"1445401406","ABCB1","3","5.25","Toxicity","sunitinib","Carcinoma, Renal Cell","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and renal cell carcinoma may have a lower risk for adverse effects when treated with sunitinib as compared to patients with the GG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities."
"1445401427","SLC28A2","3","2.5","Toxicity","peginterferon alfa-2b;protease inhibitors;ribavirin","Hepatitis C","45253280","738.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.750;DB;DP=85;ExcessHet=3.0103;FS=4.394;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.79;ReadPosRankSum=-0.232;SOR=1.242","C","T","Patients with the CT genotype and hepatitis C may have a decreased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for anemia."
"1445401439","CYP2C9","3","1.25","Metabolism/PK","phenytoin","Epilepsy","94988738","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.995;DB;DP=36;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.16;ReadPosRankSum=-0.469;SOR=0.813","A","T","Patients with the AT genotype and epilepsy may have increased dose-adjusted trough concentrations of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin."
"1445401804","SOD2","3","2","Toxicity","paclitaxel","Breast Neoplasms","159692840","164.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.741;DB;DP=29;ExcessHet=3.0103;FS=1.708;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=5.68;ReadPosRankSum=1.488;SOR=0.273","A","G","Patients with the AG genotype and breast cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for neuropathy."
"1445401853","ERCC1","3","1.75","Toxicity","docetaxel","Breast Neoplasms","45420395","1040.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.802;DB;DP=78;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.69;ReadPosRankSum=0.427;SOR=0.595","A","G","Patients with the AG genotype and breast cancer may have a decreased risk for mucositis when treated with docetaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for mucositis."
"1445401915","ABCB1","4","-1.5","Dosage;Metabolism/PK","carbamazepine","Epilepsy","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine and may need an increased dose as compared to patients with the AA or GG genotypes. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence concentrations of carbamazepine."
"1445401952","POR","3","2.5","Efficacy","atorvastatin","familial hypercholesterolemia","75985688","1716.06","AC=2;AF=1.00;AN=2;DB;DP=52;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.00;SOR=1.358","C","T","Patients with the CT genotype (POR *1/*28) and familial hypercholesterolemia may have a lower decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CC genotype (*1/*1). Other genetic and clinical factors may also influence response to atorvastatin."
"1445402033","ABCB1","3","1.25","Efficacy","cytarabine","Leukemia, Myeloid, Acute","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine."
"1445402163","HSD11B1","3","1.75","Metabolism/PK","tacrolimus","Kidney Transplantation","209685108","780.06","AC=2;AF=1.00;AN=2;DB;DP=29;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=27.86;SOR=0.693","A","G","Patients with the AG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
"1445402175","HSD11B1","3","2.25","Metabolism/PK","tacrolimus","Kidney Transplantation","209697571","759.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.474;DB;DP=55;ExcessHet=3.0103;FS=5.672;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.33;ReadPosRankSum=-0.656;SOR=0.741","A","T","Patients with the AT genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
"1445402182","HSD11B1","3","1.75","Metabolism/PK","tacrolimus","Kidney Transplantation","209701909","1179.06","AC=2;AF=1.00;AN=2;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.87;SOR=0.859","A","G","Patients with the AG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
"1445556297","CYP2B6","3","4","Efficacy","bupropion","Tobacco Use Disorder","41016810","200.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.795;DB;DP=21;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=53.74;MQRankSum=-2.850;QD=10.03;ReadPosRankSum=-0.715;SOR=0.693","C","T","Patients with the CT genotype who are smokers may have a better chance of smoking cessation when treated with bupropion as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation."
"1445594359","FBXL17","3","0","Efficacy","hydrochlorothiazide","Essential hypertension","108251082","1005.06","AC=2;AF=1.00;AN=2;DB;DP=37;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.72;SOR=1.002","A","G","Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension."
"1445594491","FBXL17","3","0","Efficacy","hydrochlorothiazide","Essential hypertension","108253257","1105.05","AC=2;AF=1.00;AN=2;DB;DP=30;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=25.26;SOR=0.765","A","T","Patients with the AT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with TT genotypes and a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension."
"1445594556","CSMD1","3","0","Efficacy","hydrochlorothiazide","Essential hypertension","3045498","557.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.747;DB;DP=58;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.61;ReadPosRankSum=0.342;SOR=0.606","A","G","Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with GG genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension."
"1445619585","ANKFN1","3","0","Efficacy","hydrochlorothiazide","Essential hypertension","56355850","1424.06","AC=2;AF=1.00;AN=2;DB;DP=47;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.12;SOR=0.941","A","G","Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension."
"1446897184","IL1B","3","3","Toxicity","antipsychotics","Schizophrenia","112844982","693.06","AC=2;AF=1.00;AN=2;DB;DP=24;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.13;SOR=0.963","A","G","Patients with the AG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics."
"1446897383","CYP19A1","3","5.75","Efficacy","tamoxifen","Breast Neoplasms;Menopause","51210647","646.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.339;DB;DP=43;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.04;ReadPosRankSum=0.768;SOR=0.754","A","C","Post-menopausal women with the AC genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to tamoxifen."
"1446897675","ABCB1","3","3.75","Toxicity","sunitinib","Carcinoma, Renal Cell","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with renal cell carcinoma and the AG genotype who are treated with sunitinib may have an increased risk of neutropenia, leukopenia as compared to patients with the AA genotypes and a decreased risk of diarrhea as compared to patients with the GG genotype, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib."
"1446897696","ABCB1","3","5","Toxicity","sunitinib","Carcinoma, Renal Cell;Neutropenia","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with renal cell carcinoma and the AC genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib."
"1446897710","ABCB1","3","5","Efficacy","sunitinib","Carcinoma, Renal Cell","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with renal cell carcinoma and the AC genotype may have an increased overall survival as compared to the AA or AT genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma."
"1446898324","CYP2B6","3","0.25","Efficacy","bupropion","Tobacco Use Disorder","41009358","170.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.434;DB;DP=43;ExcessHet=3.0103;FS=3.968;MLEAC=1;MLEAF=0.500;MQ=48.66;MQRankSum=-4.633;QD=4.27;ReadPosRankSum=-3.157;SOR=1.819","A","G","Individuals with tobacco use disorder and the AG genotype may have a decreased response to bupropion as compared to individuals with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder."
"1446899905","ATP7B","3","3","Toxicity","carboplatin;taxanes","Ovarian Neoplasms","51941218","436.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.358;DB;DP=36;ExcessHet=3.0103;FS=1.363;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.23;ReadPosRankSum=1.485;SOR=0.465","A","G","Women with ovarian cancer and the AG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
"1446906328","NR1I2","3","1.25","Metabolism/PK","carbamazepine","Epilepsy","119805244","524.06","AC=2;AF=1.00;AN=2;DB;DP=15;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=59.62;QD=33.76;SOR=3.912","G","T","Patients with the GT genotype may have increased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype GG. Other genetic and clinical factors may also influence metabolism of carbamazepine."
"1446906350","FSHR","3","1.375","Efficacy","follitropin beta;thyrotropin alfa;urofollitropin","Infertility, Female;Ovarian hyperstimulation syndrome","48962782","184.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.051;DB;DP=29;ExcessHet=3.0103;FS=1.708;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=6.37;ReadPosRankSum=1.002;SOR=1.179","C","T","Patients with the CT genotype may have good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation."
"1446906439","ABCB1","3","1.75","Toxicity","capecitabine","Colorectal Neoplasms;hand-foot syndrome","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with genotype AC may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to capecitabine."
"1446908594","ABCG1","3","3.25","Toxicity","fluorouracil;irinotecan;leucovorin","Colorectal Neoplasms","42232943","779.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.851;DB;DP=64;ExcessHet=3.0103;FS=2.139;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.78;ReadPosRankSum=-0.678;SOR=0.434","C","T","Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia."
"1447680068","CYP19A1","3","1.5","Other","letrozole","Breast Neoplasms;Menopause","51210647","646.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.339;DB;DP=43;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.04;ReadPosRankSum=0.768;SOR=0.754","A","C","Post-menopausal women with the AC genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the CC genotype and increased plasma concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
"1447681876","CYP19A1","3","1.5","Other","letrozole","Breast Neoplasms;Menopause","51243825","863.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.150;DB;DP=67;ExcessHet=3.0103;FS=0.950;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.09;ReadPosRankSum=0.160;SOR=0.954","C","T","Post-menopausal women with the CT genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of triglycerides as compared to women with TT genotypes and increased levels as compared to women with the CC genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
"1447682300","CYP19A1","3","1.25","Other","hmg coa reductase inhibitors;letrozole","Breast Neoplasms;Menopause","51255741","790.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.698;DB;DP=62;ExcessHet=3.0103;FS=3.617;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.75;ReadPosRankSum=-0.227;SOR=1.283","C","G","Post-menopausal women with breast cancer and the CG genotype may have increased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CC genotypes and decreased concentrations as compared to women with the GG genotype. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer."
"1447813539","ABCC4","3","2.25","Toxicity","tenofovir","HIV Infections","95020696","1001.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.634;DB;DP=78;ExcessHet=3.0103;FS=5.965;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.36;ReadPosRankSum=0.401;SOR=0.299","A","G","Individuals with the AG genotype and HIV may have a decreased risk of developing Kidney disease when treated with tenofovir as compared to those with the GG genotype and an increased risk as compared to those with the AA genotype. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir."
"1447814178","VEGFA","3","2.75","Toxicity","sorafenib","Carcinoma, Renal Cell;hand-foot syndrome","43770613","1380.06","AC=2;AF=1.00;AN=2;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.37;SOR=0.784","C","G","Patients with the CG genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib."
"1447814185","ABCB1","3","2.25","Toxicity","sorafenib","Carcinoma, Renal Cell;Hypertension","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib."
"1447814385","ADCY9","3","3","Efficacy;Toxicity","dalcetrapib","Acute coronary syndrome","4015582","890.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.081;DB;DP=67;ExcessHet=3.0103;FS=0.924;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.29;ReadPosRankSum=1.143;SOR=0.644","A","G","Patients with the AG genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the GG genotype, but increased risk compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo."
"1447943591","ABCB1","3","1.75","Efficacy","agomelatine","Depressive Disorder","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and depressive disorder may have a decreased response to agomelatine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to agomelatine."
"1447943597","ABCB1","3","0.5","Efficacy","venlafaxine","Depressive Disorder;Narcolepsy","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with genotype AG and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AG genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine."
"1447943608","ABCB1","3","1.75","Efficacy","Selective serotonin reuptake inhibitors","Depressive Disorder","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and depressive disorder may have decreased response to serotonin reuptake inhibitors compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors."
"1447943700","ABCB1","3","2","Efficacy","modafinil","Narcolepsy","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with genotype AG and narcolepsy may have increased response to modafinil compared to patients with genotypes AA or GG. Other clinical and genetic factors may affect a patient's response to modafinil."
"1447943739","ABCB1","4","-0.625","Metabolism/PK","efavirenz","HIV Infections","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with AG genotype and HIV may have increased concentrations of efavirenz in plasma compared to patients with AA genotype. However, this association was not significant and has not been found in other studies. Other clinical and genetic factors may affect efavirenz concentrations."
"1447943753","ABCB1","3","2","Efficacy","modafinil","Narcolepsy","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with AG genotype and narcolepsy may have increased response to modafinil compared to patients with AA or GG genotype. Other clinical and genetic factors may affect response to modafinil."
"1447943760","NRG1","3","1.625","Efficacy","antipsychotics","Schizophrenia","32535292","1045.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.588;DB;DP=79;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.32;ReadPosRankSum=-0.410;SOR=0.796","A","G","Patients with AG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AA genotype. Other clinical and genetic factors may affect response to antipsychotics."
"1447943772","ZMAT4","3","0","Efficacy","atenolol","Hypertension","40544855","2148.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.55;SOR=0.754","C","T","Patients with genotype CT and hypertension have increased response to atenolol compared to patients with the TT genotype. Other clinical and genetic factors may affect patient response to atenolol."
"1447944755","DRD2","3","2","Efficacy","amisulpride","Schizophrenia","113425564","512.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.291;DB;DP=37;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.24;ReadPosRankSum=0.777;SOR=0.874","C","T","Patients with the CT genotype and schizophrenia may have a decreased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to amisulpride."
"1447944806","ST13","3","1.5","Efficacy","corticosteroids","Asthma","40831082","658.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.159;DB;DP=64;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.45;ReadPosRankSum=0.311;SOR=0.665","C","G","Patients with the CG genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics."
"1447944813","ST13","3","1.5","Efficacy","corticosteroids","Asthma","40835049","683.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.615;DB;DP=56;ExcessHet=3.0103;FS=2.239;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.66;ReadPosRankSum=0.104;SOR=0.893","A","G","Patients with the AG genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics."
"1447945985","NRXN1","3","1.75","Efficacy","antipsychotics","Schizophrenia","51015132","1389.06","AC=2;AF=1.00;AN=2;DB;DP=41;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.73;SOR=0.902","A","G","Patients with the AG genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment."
"1447945999","HMGCR","3","5.5","Efficacy","atorvastatin","Hypercholesterolemia","75319196","1206.06","AC=2;AF=1.00;AN=2;DB;DP=40;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.15;SOR=0.793","C","T","Patients with the CT genotype and hypercholesterolemia who are treated with atorvastatin may have an increased drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
"1447946011","ARMS2","3","4.25","Efficacy","bevacizumab","Macular Degeneration","122454932","386.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.287;DB;DP=48;ExcessHet=3.0103;FS=1.425;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.99;ReadPosRankSum=-0.027;SOR=1.123","G","T","Patients with the GT genotype and age-related macular degeneration who are treated with bevacizumab may have better improvement in visual acuity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment."
"1447949305","ABCB1","3","0.5","Toxicity","tacrolimus","Kidney Transplantation","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients who receive a kidney with the AG genotype may have decreased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the GG genotype, and increased eGFR as compared to patients with the AA genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR."
"1447949632","VDR","3","2.5","Efficacy","selective beta-2-adrenoreceptor agonists","Asthma","47863543","443.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.616;DB;DP=51;ExcessHet=3.0103;FS=4.041;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.05;ReadPosRankSum=1.598;SOR=0.674","C","T","Patients with CT genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists."
"1447952921","HNF4A","3","1.5","Metabolism/PK","efavirenz","HIV Infections","44351775","424.06","AC=2;AF=1.00;AN=2;DB;DP=13;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.62;SOR=1.609","C","G","Patients with the CG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz."
"1447953123","HOTAIR","3","2.75","Efficacy","Platinum compounds","Lung Neoplasms","53963768","820.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.860;DB;DP=88;ExcessHet=3.0103;FS=2.924;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.54;ReadPosRankSum=-0.089;SOR=0.543","C","G","Patients with the CG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds."
"1447953250","ABCB1","3","2","Efficacy","modafinil","Narcolepsy","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype and narcolepsy may have an increased response to modafinil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to modafinil."
"1447953277","ESR1","3","2.5","Toxicity","exemestane","Breast Neoplasms","152103343","990.06","AC=2;AF=1.00;AN=2;DB;DP=31;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.00;SOR=1.143","A","G","Patients with the AG genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane."
"1447953328","CTNNB1","3","4","Efficacy;Toxicity","cyclophosphamide;dexamethasone;lenalidomide;thalidomide","Multiple Myeloma","41237949","835.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.713;DB;DP=67;ExcessHet=3.0103;FS=3.800;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.06;ReadPosRankSum=0.256;SOR=0.340","A","G","Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide."
"1447959508","SOD2","3","3","Toxicity","asparaginase","Precursor Cell Lymphoblastic Leukemia-Lymphoma","159692840","164.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.741;DB;DP=29;ExcessHet=3.0103;FS=1.708;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=5.68;ReadPosRankSum=1.488;SOR=0.273","A","G","Patients with the AG genotype and acute lymphoblastic leukemia (ALL) may have a decreased risk for hepatotoxicity when treated with asparaginase as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity."
"1447959700","ZNF697","3","2.5","Efficacy","interferon beta-1a;interferon beta-1b","Multiple Sclerosis","119594822","135.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.400;DB;DP=19;ExcessHet=3.0103;FS=4.560;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=7.98;ReadPosRankSum=-0.539;SOR=0.595","A","G","Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype, or a decreased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
"1447959717","FHIT","3","2.5","Efficacy","interferon beta-1a;interferon beta-1b","Multiple Sclerosis","60113241","1140.06","AC=2;AF=1.00;AN=2;DB;DP=37;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.81;SOR=1.121","C","T","Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype, or a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
"1447959731","GAPVD1","3","2.5","Efficacy","interferon beta-1a;interferon beta-1b","Multiple Sclerosis","125274966","1006.06","AC=2;AF=1.00;AN=2;DB;DP=34;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.49;SOR=1.542","C","T","Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype, or a decreased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
"1447959738","GAPVD1","3","2.5","Efficacy","interferon beta-1a;interferon beta-1b","Multiple Sclerosis","125366503","1746.06","AC=2;AF=1.00;AN=2;DB;DP=59;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.63;SOR=1.047","A","G","Patients with the AG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the GG genotype, or an increased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
"1447960211","ABCB1","3","0","Efficacy","Platinum compounds","Carcinoma, Non-Small-Cell Lung","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and non-small-cell lung cancer may have a poorer response to platinum-based chemotherapy as compared to patients with the GG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy."
"1447960225","ADRA1A","3","2.75","Efficacy","nifedipine","Hypertension","26770511","735.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.146;DB;DP=50;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.65;ReadPosRankSum=-0.108;SOR=0.765","A","G","Patients with the AG genotype and hypertension may have a greater reduction in systolic blood pressure when treated with nifedipine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine."
"1447960335","SLC28A2","3","2.25","Efficacy","gemcitabine","Carcinoma, Non-Small-Cell Lung","45253280","738.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.750;DB;DP=85;ExcessHet=3.0103;FS=4.394;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.79;ReadPosRankSum=-0.232;SOR=1.242","C","T","Patients with the CT genotype and non-small-cell lung cancer may have a longer median survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival."
"1447960379","ACSS2","3","3","Efficacy","carboplatin;cisplatin;docetaxel;gemcitabine;paclitaxel","Carcinoma, Non-Small-Cell Lung","34927985","225.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.270;DB;DP=29;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.68;ReadPosRankSum=0.223;SOR=0.919","A","T","Patients with the AT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
"1447960484","NOS3","3","2","Efficacy","enalapril","Hypertension","150992991","857.06","AC=2;AF=1.00;AN=2;DB;DP=27;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.96;SOR=1.445","C","T","Patients with the CT genotype and hypertension may have a greater reduction in blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril."
"1447960663","AGT","3","2","Efficacy","quinapril","Coronary Artery Disease","230710048","373.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.101;DB;DP=21;ExcessHet=3.0103;FS=1.885;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=18.68;ReadPosRankSum=-0.502;SOR=1.445","A","G","Patients with the AG genotype and coronary artery disease may have a poorer response when treated with quinapril as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to quinapril."
"1447960795","POLR3G","3","3.25","Toxicity","nevirapine","HIV Infections","90485154","740.06","AC=2;AF=1.00;AN=2;DB;DP=25;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.84;SOR=1.051","C","T","Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash."
"1447960874","ABCB1","3","1","Metabolism/PK","tipifarnib","Neoplasms","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib."
"1447961028","NAT2","3","7.25","Toxicity","Drugs For Treatment Of Tuberculosis","Tuberculosis","18400484","650.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.345;DB;DP=53;ExcessHet=3.0103;FS=4.006;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.28;ReadPosRankSum=-0.099;SOR=0.283","C","T","Patients with the CT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity."
"1447961057","CMPK1","3","2.5","Efficacy","gemcitabine","Neoplasms","47377105","665.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.109;DB;DP=65;ExcessHet=3.0103;FS=2.107;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.40;ReadPosRankSum=0.945;SOR=0.541","C","T","Patients with the CT genotype and cancer may have shorter overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times."
"1447961166","EGFR","3","4.5","Efficacy","gefitinib","Carcinoma, Non-Small-Cell Lung","55201223","1858.06","AC=2;AF=1.00;AN=2;DB;DP=58;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.18;SOR=1.101","C","T","Patients with the CT genotype and non-small-cell lung cancer may have a poorer response to treatment with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to gefitinib."
"1447961178","EGFR","3","2.25","Toxicity","cetuximab;irinotecan;leucovorin;tegafur","Colorectal Neoplasms","55019087","2687.06","AC=2;AF=1.00;AN=2;DB;DP=72;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.78;SOR=0.779","A","C","Patients with the AC genotype and colorectal cancer may have a decreased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence drug toxicity."
"1447961194","CYP2B6","3","1.75","Metabolism/PK","efavirenz","HIV Infections","41012868","416.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.354;DB;DP=34;ExcessHet=3.0103;FS=1.664;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.37;ReadPosRankSum=-1.071;SOR=0.317","C","T","Patients with the CT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz."
"1447961322","DAOA","3","2.75","Toxicity","methamphetamine","Psychotic Disorders","105516850","521.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.712;DB;DP=41;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.04;ReadPosRankSum=0.014;SOR=0.874","C","T","Patients with the CT genotype who use methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis."
"1447961337","HTR1A","3","3","Toxicity","methamphetamine","Substance-Related Disorders","63960164","1034.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.309;DB;DP=66;ExcessHet=3.0103;FS=1.003;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=17.24;ReadPosRankSum=-1.484;SOR=0.809","A","G","Patients with the AC genotype who take methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis."
"1447962843","ABCB1","3","4","Efficacy","simvastatin","Hypercholesterolemia","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels."
"1447962855","ABCB1","3","2","Toxicity","simvastatin","Hypercholesterolemia","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia."
"1447963004","ABCB1","3","1","Metabolism/PK","cyclosporine;dicloxacillin","Cystic Fibrosis","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin."
"1447963070","CHRNB4","3","0","Toxicity","nicotine","Tobacco Use Disorder","88821613","286.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.078;DB;DP=35;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.43;ReadPosRankSum=-0.781;SOR=0.741","C","T","Patients with the CT genotype who smoke tobacco may have a lower body mass index as compared to patients with the TT genotype, or a greater body mass index as compared to patients with the CC genotype. Other genetic and clinical factors may also influence body mass index."
"1447963432","AGT","3","2.5","Efficacy","Ace Inhibitors, Plain","Hypertension","230710048","373.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.101;DB;DP=21;ExcessHet=3.0103;FS=1.885;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=18.68;ReadPosRankSum=-0.502;SOR=1.445","A","G","Patients with the AG genotype and hypertension may have an increased risk of stroke when treated with ACE inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of stroke."
"1447963681","ARRB2","3","1.5","Toxicity","methamphetamine","Substance-Related Disorders","4723059","1235.06","AC=2;AF=1.00;AN=2;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.48;SOR=0.941","A","C","Patients with the AC genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the CC genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction."
"1447963701","CYP3A4","3","2","Toxicity","tamoxifen","Breast Neoplasms","99784473","2096.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.27;SOR=0.859","C","T","Patients with the CT genotype and breast cancer may have an increased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer."
"1447963979","ABCB1","4","-6.5","Efficacy","antiepileptics","Epilepsy","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics."
"1447963991","ABCB1","3","3.5","Efficacy","antiepileptics","Epilepsy","87591570","738.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.406;DB;DP=48;ExcessHet=3.0103;FS=4.181;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.39;ReadPosRankSum=-0.281;SOR=0.283","A","G","Male patients with the AG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or an increased risk for resistance as compared to patients with the AA genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics."
"1447964002","PPARG","3","1.25","Toxicity","olanzapine","Schizophrenia","12351626","589.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.073;DB;DP=45;ExcessHet=3.0103;FS=1.184;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.40;ReadPosRankSum=-0.965;SOR=1.061","C","G","Patients with the CG genotype and schizophrenia may have greater weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain."
"1447964025","ABCB1","3","0.75","Toxicity","Drugs For Treatment Of Tuberculosis;isoniazid","Tuberculosis","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatotoxicity."
"1447964041","NAT2","3","3","Toxicity","ethambutol;isoniazid;pyrazinamide;rifampin","Toxic liver disease;Tuberculosis","18400285","735.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.877;DB;DP=56;ExcessHet=3.0103;FS=8.058;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.62;ReadPosRankSum=-0.470;SOR=1.907","C","T","Patients with the rs1041983 CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity."
"1447964331","IGFBP3","3","3","Efficacy","fluorouracil","Stomach Neoplasms","45921476","1421.06","AC=2;AF=1.00;AN=2;DB;DP=49;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.00;SOR=0.909","G","T","Patients with the GT genotype and stomach cancer may have a better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome."
"1447964542","ABCB1","3","2.25","Toxicity","capecitabine","Colorectal Neoplasms","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome."
"1447979493","VEGFA","3","4.5","Efficacy","sorafenib","Carcinoma, Hepatocellular","43770613","1380.06","AC=2;AF=1.00;AN=2;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.37;SOR=0.784","C","G","Patients with the CG genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib."
"1447979507","NOS3","3","5.75","Efficacy","sorafenib","Carcinoma, Hepatocellular","150992991","857.06","AC=2;AF=1.00;AN=2;DB;DP=27;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.96;SOR=1.445","C","T","Patients with the CT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib."
"1447980904","ABCB1","3","2","Toxicity","Antivirals for treatment of HIV infections, combinations;Drugs For Treatment Of Tuberculosis","HIV Infections;Tuberculosis","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity."
"1447980911","CYP2B6","3","2","Toxicity","Antivirals for treatment of HIV infections, combinations;Drugs For Treatment Of Tuberculosis","HIV Infections;Tuberculosis","41006936","384.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.804;DB;DP=34;ExcessHet=3.0103;FS=1.394;MLEAC=1;MLEAF=0.500;MQ=59.51;MQRankSum=1.002;QD=11.31;ReadPosRankSum=1.503;SOR=0.374","G","T","Patients with the GT genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the TT genotype, and an increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity."
"1447981372","CDA","3","1","Metabolism/PK","difluorodeoxyuridine","Neoplasms","20601791","352.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.165;DB;DP=36;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.08;ReadPosRankSum=1.227;SOR=0.829","C","T","Patients with the CT genotype and cancer may have decreased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine."
"1447981465","TENT4A","3","0","Efficacy","gemcitabine","Pancreatic Neoplasms","6720954","417.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.108;DB;DP=27;ExcessHet=3.0103;FS=3.628;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.71;ReadPosRankSum=-0.436;SOR=1.034","A","G","Patients with the AG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer."
"1447982723","TOLLIP","3","1.75","Efficacy","acetylcysteine","Pulmonary Fibrosis","1288726","398.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.187;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.30;ReadPosRankSum=-0.042;SOR=0.743","C","T","Patients with the CT genotype and pulmonary fibrosis may have decreased response to N-acetylcysteine compared to patients with the TT genotype. Other genetic and clinical factors may affect response to N-acetylcysteine."
"1447983057","EIF3A","3","2.75","Toxicity","Platinum compounds","Carcinoma, Non-Small-Cell Lung","118856049","333.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.722;DB;DP=42;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.55;ReadPosRankSum=1.671;SOR=0.741","C","T","Patients with the CT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
"1447983064","EIF3A","3","2.75","Toxicity","Platinum compounds","Carcinoma, Non-Small-Cell Lung","118856097","471.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.324;DB;DP=52;ExcessHet=3.0103;FS=2.512;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.63;ReadPosRankSum=0.675;SOR=0.783","A","G","Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
"1447983071","EIF3A","3","3.25","Toxicity","Platinum compounds","Carcinoma, Non-Small-Cell Lung","118856240","243.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.130;DB;DP=35;ExcessHet=3.0103;FS=1.524;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=6.96;ReadPosRankSum=-0.165;SOR=1.270","A","G","Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
"1447983078","EIF3A","3","3.25","Toxicity","Platinum compounds","Carcinoma, Non-Small-Cell Lung","118867050","763.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.881;DB;DP=53;ExcessHet=3.0103;FS=1.150;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.25;ReadPosRankSum=-2.101;SOR=0.504","A","G","Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
"1447983818","ABCB1","3","2.5","Dosage","antipsychotics","Schizophrenia","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the GG genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics."
"1447984146","ABCB1","3","2.5","Dosage","antipsychotics","Schizophrenia","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics."
"1447987030","NR1I3","3","1","Metabolism/PK","efavirenz","HIV Infections","161234427","1867.06","AC=2;AF=1.00;AN=2;DB;DP=59;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.69;SOR=1.179","A","G","Patients with the AG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz."
"1447987045","NR1I2","3","1","Metabolism/PK","carbamazepine","Epilepsy","119781188","257.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.434;DB;DP=45;ExcessHet=3.0103;FS=1.223;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=5.99;ReadPosRankSum=-0.536;SOR=0.709","C","T","Patients with the CT genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the TT genotype, or decreased clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of carbamazepine."
"1447987059","NR1I2","3","1.25","Metabolism/PK","carbamazepine","Epilepsy","119806650","1306.06","AC=2;AF=1.00;AN=2;DB;DP=45;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.68;SOR=1.364","A","G","Patients with the AG genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the GG genotype, or increased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine."
"1447987094","ABCB1","4","-2","Metabolism/PK","carbamazepine","Epilepsy","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","African American and white patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine."
"1447987101","CYP3A4","3","1.25","Metabolism/PK","carbamazepine","Epilepsy","99784473","2096.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.27;SOR=0.859","C","T","Patients with the CT genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine."
"1447987124","RYR2","3","0.5","Toxicity","atorvastatin;simvastatin","Cardiovascular Diseases","237826822","1501.06","AC=2;AF=1.00;AN=2;DB;DP=60;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=25.88;SOR=1.085","A","G","Patients with the AG genotype and cardiovascular disease who are taking a statin may have an increased likelihood of statin-associated myopathy and myalgia as compared with patients with the GG genotypes and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients with cardiovascular disease who are taking atorvastatin or simvastatin, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins."
"1447987227","ERICH3","3","2.5","Efficacy","citalopram;escitalopram","Depressive Disorder","74572544","339.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.863;DB;DP=30;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.71;ReadPosRankSum=0.554;SOR=0.743","A","C","Patients with depressive disorder and the AC genotype may have improved response to citalopram or escitalopram as compared to patients with the CC genotypes and worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder."
"1447987264","VAC14","3","0","Toxicity","docetaxel","Prostatic Neoplasms","70741552","430.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.855;DB;DP=29;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=17.23;ReadPosRankSum=0.350;SOR=0.437","C","T","Patients with the CT genotype and prostate cancer who are treated with docetaxel may have a decreased risk of neuropathy as compared to patients with the TT genotypes and an increased risk of neuropathy as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel."
"1447990143","CYP2C9","3","6","Efficacy;Metabolism/PK","irbesartan","Essential hypertension","94981296","1456.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.484;DB;DP=106;ExcessHet=3.0103;FS=0.754;MLEAC=1;MLEAF=0.500;MQ=59.95;MQRankSum=-0.940;QD=14.86;ReadPosRankSum=0.864;SOR=0.600","A","C","Patients with the AC genotype and essential hypertension may have decreased metabolism or clearance of irbesartan as compared to patients with the AA genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension."
"1447990271","GRM3","3","2.5","Other","heroin","Heroin Dependence","86643624","737.06","AC=2;AF=1.00;AN=2;DB;DP=19;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.05;SOR=2.948","C","T","Patients with the CT genotype may have an decreased risk of addiction to heroin when using heroin as compared to patients with the CC genotype and an increased risk of heroin addiction as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin."
"1447990283","DROSHA","3","2.5","Toxicity","cyclophosphamide;cytarabine;daunorubicin;mercaptopurine;methotrexate;prednisone;vincristine","Precursor Cell Lymphoblastic Leukemia-Lymphoma","31433540","195.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.053;DB;DP=30;ExcessHet=3.0103;FS=3.853;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=6.75;ReadPosRankSum=2.102;SOR=1.781","C","T","Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy."
"1447990578","SLCO1B1","3","1.5","Metabolism/PK","mycophenolic acid","Kidney Transplantation","21176804","361.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.460;DB;DP=33;ExcessHet=3.0103;FS=3.093;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.30;ReadPosRankSum=-1.572;SOR=1.314","A","G","Kidney transplant patients with the AG genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants."
"1447990855","RBFOX1","3","1.75","Efficacy","antineoplastic agents","Breast Neoplasms","6820854","599.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.900;DB;DP=55;ExcessHet=3.0103;FS=1.072;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.76;ReadPosRankSum=-0.312;SOR=0.803","A","G","Women with the AG genotype and breast cancer who are treated with antineoplastic agents may be associated improved survival as compared to women with the GG genotypes and worse survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence survival rates in women with breast cancer."
"1448097711","CMPK1","3","2.5","Efficacy","cisplatin;gemcitabine","Carcinoma, Non-Small-Cell Lung","47335173","470.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.894;DB;DP=58;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.40;ReadPosRankSum=0.892;SOR=0.653","A","C","Patients with non-small cell lung cancer and the AC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer."
"1448098287","NR1I3","3","2","Toxicity","docetaxel","Anemia;Nasopharyngeal Neoplasms","161234748","950.06","AC=2;AF=1.00;AN=2;DB;DP=31;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.76;SOR=0.906","C","T","Patients with nasopharyngeal cancer and the CT genotype may have an increased severity of anemia when treated with docetaxel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel."
"1448098315","NR1I2","3","2","Toxicity","docetaxel","Anemia;Nasopharyngeal Neoplasms","119817734","536.06","AC=2;AF=1.00;AN=2;DB;DP=17;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.79;SOR=0.818","C","T","Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia who are treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel."
"1448098354","RXRA","3","1.5","Toxicity","docetaxel","Nasopharyngeal Neoplasms","134429310","643.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.613;DB;DP=46;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.97;ReadPosRankSum=0.547;SOR=0.595","A","G","Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel."
"1448099022","GSTA1","3","1.75","Metabolism/PK","busulfan","Transplantation","52803889","103.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.182;DB;DP=25;ExcessHet=3.0103;FS=4.589;MLEAC=1;MLEAF=0.500;MQ=52.89;MQRankSum=-2.886;QD=4.71;ReadPosRankSum=-0.886;SOR=1.158","A","G","Pediatric patients with the AG genotype who are undergoing hematopoietic stem cell transplantation may have decreased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence busulfan clearance."
"1448099112","BMP7","3","0","Toxicity","cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine","Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma","57126159","770.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.949;DB;DP=42;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=18.35;ReadPosRankSum=2.015;SOR=0.693","C","T","Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
"1448099149","ABCB1","3","1","Efficacy","tramadol","Fractures, Bone;Pain;Pain, Postoperative","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the rs2032582 AC genotype may be more likely to respond to tramadol treatment as compared to patients with the CC genotype, or less likely as compared to those with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol."
"1448099568","SLCO1B1","3","2.5","Efficacy","cytarabine;daunorubicin;etoposide;mitoxantrone","Leukemia, Myeloid, Acute","21178691","416.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.722;DB;DP=32;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.02;ReadPosRankSum=0.757;SOR=0.801","C","T","Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia."
"1448099574","SLCO1B1","3","2.5","Efficacy","cytarabine;daunorubicin;etoposide;mitoxantrone","Leukemia, Myeloid, Acute","21178691","416.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.722;DB;DP=32;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.02;ReadPosRankSum=0.757;SOR=0.801","C","T","Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia."
"1448099828","CXCL12","3","2.25","Efficacy","alemtuzumab;chlorambucil;cyclophosphamide;fludarabine;prednisone;rituximab;vincristine","Leukemia, Lymphocytic, Chronic, B-Cell","44372809","2155.06","AC=2;AF=1.00;AN=2;DB;DP=67;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.15;SOR=1.437","C","T","Patients with chronic lymphocytic leukemia (CLL) and the genotype CT may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment."
"1448100146","PON2","3","0","Efficacy","antidepressants","Depressive Disorder, Major","95432609","2016.06","AC=2;AF=1.00;AN=2;DB;DP=61;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.05;SOR=0.793","A","G","Patients with the AG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants."
"1448100201","DRD1","3","2.5","Other","nicotine","Tobacco Use Disorder","175443147","659.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.479;DB;DP=66;ExcessHet=3.0103;FS=2.125;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.31;ReadPosRankSum=1.470;SOR=0.436","C","T","Patients with the CT genotype may be at decreased risk for nicotine dependence as compared to patients with the TT genotype, or increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nicotine dependence."
"1448100257","IL6","3","2.25","Toxicity","peginterferon alfa-2b;ribavirin","Hepatitis C, Chronic","22727026","1341.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.80;SOR=0.829","C","G","Patients with the CG genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment."
"1448100514","ACY3","3","0","Efficacy","bisoprolol","Hypertension","67647583","647.06","AC=2;AF=1.00;AN=2;DB;DP=22;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.41;SOR=1.329","C","T","Men with the CT genotype and hypertension may have decreased response to bisoprolol compared to men with the TT genotype. Other factors may affect response to bisoprolol."
"1448100521","NPHS1","3","0","Efficacy","losartan","Hypertension","35851310","666.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.852;DB;DP=61;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.30;ReadPosRankSum=-0.053;SOR=0.638","C","T","Men with the CT genotype and hypertension may have reduced response to losartan compared to men with the TT genotype. Other factors may affect response to losartan."
"1448100712","ABCB1","3","2.5","Toxicity","codeine","Pain","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Breast-feeding infants whose mothers have the AG genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype, or at decreased risk as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants."
"1448100826","EPHA5","3","2","Toxicity","paclitaxel","Breast Neoplasms;Ovarian Neoplasms;Peripheral Nervous System Diseases","65332086","581.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.672;DB;DP=51;ExcessHet=3.0103;FS=5.967;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.63;ReadPosRankSum=0.679;SOR=0.401","C","T","Women with the CT genotype and breast or ovarian cancer may have an increased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CC genotype, and a decreased risk as compared to women with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for peripheral neuropathy."
"1448100861","PACSIN2","3","2","Toxicity","mercaptopurine;methotrexate","Precursor Cell Lymphoblastic Leukemia-Lymphoma","43001030","632.06","AC=2;AF=1.00;AN=2;DB;DP=24;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.73;SOR=1.085","C","T","Patients with the CT genotype and acute lymphoblastic leukemia may have a decreased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity."
"1448100942","ABCB1","3","0","Metabolism/PK","dabigatran","Atrial Fibrillation","87533733","670.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.962;DB;DP=64;ExcessHet=3.0103;FS=5.239;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.18;ReadPosRankSum=1.481;SOR=1.269","C","T","Patients with genotype CT and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the CC genotype. Other factors may affect dabigatran plasma concentrations."
"1448101059","SLC6A12","3","2.5","Toxicity","aspirin","Asthma","209959","1088.06","AC=2;AF=1.00;AN=2;DB;DP=41;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=27.90;SOR=1.096","A","G","Patients with the AG genotype may have a decreased risk for aspirin-intolerant asthma as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma."
"1448101102","PTGS2","3","2.5","Efficacy","aspirin","Prostatic Neoplasms","186682744","304.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.419;DB;DP=21;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.51;ReadPosRankSum=-0.282;SOR=0.527","G","T","Patients with the GT genotype may have an increased risk for developing prostate cancer when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin."
"1448101163","CHRNA5","3","2.25","Toxicity","nicotine;Opium alkaloids and derivatives","Pain;Tobacco Use Disorder","78595490","1980.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.46;SOR=0.787","A","G","Patients with the AG genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for nicotine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction."
"1448101202","SLC29A1","3","2","Efficacy","peginterferon alfa-2a;peginterferon alfa-2b;ribavirin","Hepatitis C, Chronic","44233216","489.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.707;DB;DP=47;ExcessHet=3.0103;FS=1.119;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.42;ReadPosRankSum=-0.723;SOR=0.507","A","G","Patients with the AG genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response."
"1448101278","CHRNA5","3","1.5","Toxicity","nicotine","Tobacco Use Disorder","78566058","1866.06","AC=2;AF=1.00;AN=2;DB;DP=59;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.93;SOR=1.487","C","G","Patients with the CG genotype may have an increased likelihood of smoking addiction as compared to patients with the GG genotype, or a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction."
"1448102294","GSTA1","3","1","Efficacy","cyclophosphamide;doxorubicin;prednisone;rituximab;vincristine","Lymphoma, Large B-Cell, Diffuse","52803889","103.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.182;DB;DP=25;ExcessHet=3.0103;FS=4.589;MLEAC=1;MLEAF=0.500;MQ=52.89;MQRankSum=-2.886;QD=4.71;ReadPosRankSum=-0.886;SOR=1.158","A","G","Patients with the AG genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time."
"1448102306","CYBA","3","4","Efficacy;Toxicity","doxorubicin;idarubicin","Neoplasms","88646828","597.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.735;DB;DP=50;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.72;ReadPosRankSum=0.878;SOR=0.859","A","G","Cancer patients with the AG genotype may have a longer overall and event-free survival time as compared to patients with the AA genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times."
"1448102324","IL18","3","2.5","Efficacy","interferons;ribavirin","Hepatitis C, Chronic","112164265","803.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.619;DB;DP=68;ExcessHet=3.0103;FS=0.935;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.82;ReadPosRankSum=-0.437;SOR=0.881","C","G","Patients with the CG genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the GG genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy."
"1448102407","DRD3","3","1.75","Toxicity","methamphetamine","HIV Infections","114171968","372.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.437;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.31;ReadPosRankSum=0.000;SOR=0.693","C","T","Patients with the CT genotype and HIV may have increased cognitive impairment when taking methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines."
"1448102439","IFNL3","2A","11.5","Efficacy","peginterferon alfa-2a;peginterferon alfa-2b;ribavirin","Hepatitis C;HIV Infections","39244283","340.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.894;DB;DP=27;ExcessHet=3.0103;FS=3.682;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.10;ReadPosRankSum=-3.105;SOR=1.561","A","G","Patients with the rs11881222 AG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment."
"1448102477","IFNL3","3","5","Efficacy","peginterferon alfa-2a;peginterferon alfa-2b;ribavirin","Hepatitis C, Chronic;HIV Infections","39245004","556.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.271;DB;DP=57;ExcessHet=3.0103;FS=1.039;MLEAC=1;MLEAF=0.500;MQ=54.71;MQRankSum=-2.939;QD=9.94;ReadPosRankSum=2.134;SOR=0.507","C","G","Patients with the CG genotype and chronic hepatitis C or HIV may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment."
"1448102543","CYP27B1","3","0.5","Efficacy","peginterferon alfa-2b;ribavirin","Hepatitis C, Chronic","57768302","334.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.940;DB;DP=48;ExcessHet=3.0103;FS=2.755;MLEAC=1;MLEAF=0.500;MQ=59.88;MQRankSum=0.720;QD=7.44;ReadPosRankSum=-0.945;SOR=0.853","G","T","Patients with the GT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment."
"1448102550","VDR","3","6","Efficacy","peginterferon alfa-2b;ribavirin","Hepatitis C, Chronic","47879112","1371.06","AC=2;AF=1.00;AN=2;DB;DP=45;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.28;SOR=2.419","A","G","Patients with the AG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment."
"1448103846","PTGS2","3","2.75","Efficacy","capecitabine;oxaliplatin","Colorectal Neoplasms","186673926","88.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.000;DB;DP=7;ExcessHet=3.0103;FS=3.310;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.77;ReadPosRankSum=0.431;SOR=0.105","A","G","Patients with the AG genotype and colorectal cancer may have shorter progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time."
"1448103928","NR1I2","3","3.5","Toxicity","flucloxacillin","Toxic liver disease","119781188","257.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.434;DB;DP=45;ExcessHet=3.0103;FS=1.223;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=5.99;ReadPosRankSum=-0.536;SOR=0.709","C","T","Patients with the CT genotype may have a decreased risk for flucloxacillin-induced liver injury as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury."
"1448103956","CHRNA5","3","1","Other","cocaine","Cocaine-Related Disorders","78566058","1866.06","AC=2;AF=1.00;AN=2;DB;DP=59;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.93;SOR=1.487","C","G","Patients with the CG genotype may have a decreased risk for cocaine addiction as compared to patients with the GG genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction."
"1448103963","IGF2BP2","3","1.5","Efficacy","repaglinide","Diabetes Mellitus, Type 2","185793899","225.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.622;DB;DP=22;ExcessHet=3.0103;FS=1.875;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.26;ReadPosRankSum=2.667;SOR=1.457","G","T","Patients with the GT genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide."
"1448103973","IGF2BP2","3","1.5","Efficacy","repaglinide","Diabetes Mellitus, Type 2","185811292","481.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.545;DB;DP=32;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.05;ReadPosRankSum=-0.665;SOR=0.693","A","C","Patients with the AC genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide."
"1448104022","CRP","3","2.75","Efficacy","rosuvastatin","Coronary Disease","159712443","1275.06","AC=2;AF=1.00;AN=2;DB;DP=50;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.65;SOR=0.836","C","T","Patients with the CT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cardiovascular outcomes."
"1448104050","DRD2","3","1.75","Other","olanzapine","Bipolar Disorder;Depression","113412755","2030.06","AC=2;AF=1.00;AN=2;DB;DP=71;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=59.92;QD=30.30;SOR=0.784","A","G","Female patients with the AG genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype, or decreased concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence prolactin concentrations."
"1448104353","VEGFA","3","1.75","Efficacy","capecitabine;oxaliplatin","Colorectal Neoplasms","43770613","1380.06","AC=2;AF=1.00;AN=2;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.37;SOR=0.784","C","G","Patients with the CG genotype and colorectal cancer may have a poorer response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CC or GG genotype. Other genetic and clinical factors may also influence response to XELOX treatment."
"1448109591","SLC22A2","4","-1","Toxicity","anthracyclines and related substances","Neoplasms","160249250","1311.06","AC=2;AF=1.00;AN=2;DB;DP=35;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.85;SOR=1.885","A","C","Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and increased likelihood as compared to patients with the AA genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
"1448109598","ABCB4","4","-1","Toxicity","anthracyclines and related substances","Neoplasms","87444459","1086.06","AC=2;AF=1.00;AN=2;DB;DP=31;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=26.19;SOR=0.693","G","T","Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype TT and decreased likelihood as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
"1448112052","HTR1B","3","1.75","Toxicity","citalopram","Anxiety Disorders;Depressive Disorder, Major","77462543","380.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.483;DB;DP=30;ExcessHet=3.0103;FS=5.792;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.69;ReadPosRankSum=-0.395;SOR=0.364","C","G","Patients with the CG genotype and anxiety disorder or major depression may have decreased risk of becoming agitated when taking citalopram compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram."
"1448112493","GALNT18","3","1.75","Efficacy","tocilizumab","Arthritis, Rheumatoid","11458319","136.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.297;DB;DP=35;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=59.84;MQRankSum=0.531;QD=3.90;ReadPosRankSum=-0.044;SOR=0.610","C","T","Patients with the CT genotype and rheumatoid arthritis may have decreased response to tocilizumab compared to patients with the CC genotype. Other genetic and clinical factors may affect response to tocilizumab."
"1448123001","ABCB1","3","1.75","Efficacy","losartan","Hypertension","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan."
"1448124216","PTGS1","3","2.25","Efficacy","clopidogrel","major adverse cardiac events (mace)","122369409","590.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.357;DB;DP=45;ExcessHet=3.0103;FS=8.832;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.74;ReadPosRankSum=1.022;SOR=1.160","C","T","Patients with the CT genotype may have increased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel."
"1448256091","GNMT","3","5.5","Toxicity","mercaptopurine","Precursor Cell Lymphoblastic Leukemia-Lymphoma","42960723","3577.06","AC=2;AF=1.00;AN=2;DB;DP=114;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.82;SOR=0.787","C","T","Patients with the CT genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC."
"1448256098","PACSIN2","3","4.5","Toxicity","mercaptopurine","Precursor Cell Lymphoblastic Leukemia-Lymphoma","43001030","632.06","AC=2;AF=1.00;AN=2;DB;DP=24;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.73;SOR=1.085","C","T","Patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma and the rs2413739 CT genotype may have decreased risk of adverse events when treated with mercaptopurine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with mercaptopurine."
"1448256864","ERCC2","3","3.5","Toxicity","Platinum compounds","Carcinoma, Non-Small-Cell Lung","45359191","516.06","AC=2;AF=1.00;AN=2;DB;DP=12;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.21;SOR=1.022","A","G","Patients with the AG genotype and non-small cell lung cancer may have decreased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies."
"1448256872","IL16","3","2.5","Toxicity","Platinum compounds","Carcinoma, Non-Small-Cell Lung","81290798","568.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.844;DB;DP=51;ExcessHet=3.0103;FS=2.622;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.36;ReadPosRankSum=0.022;SOR=0.330","G","T","Patients with the GT genotype and non-small cell lung cancer may have increased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies."
"1448256881","ABCB1","3","6","Toxicity","Platinum compounds","Carcinoma, Non-Small-Cell Lung","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies."
"1448256890","IL1B","3","0","Toxicity","Platinum compounds","Carcinoma, Non-Small-Cell Lung","112840678","381.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.301;DB;DP=33;ExcessHet=3.0103;FS=3.133;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.56;ReadPosRankSum=2.472;SOR=1.314","C","T","Patients with the CT genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies."
"1448256898","IL1B","3","0","Toxicity","Platinum compounds","Carcinoma, Non-Small-Cell Lung","112838252","785.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.560;DB;DP=43;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=19.64;ReadPosRankSum=-0.910;SOR=0.879","C","G","Patients with the CG genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CC genotype. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies."
"1448258734","SLCO1B1","3","3","Toxicity","sorafenib","Diarrhea","21176804","361.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.460;DB;DP=33;ExcessHet=3.0103;FS=3.093;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.30;ReadPosRankSum=-1.572;SOR=1.314","A","G","Patients with the AG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib."
"1448259317","UGT1A8","3","1.75","Efficacy","raloxifene","Menopause;Schizophrenia","233618225","499.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.384;DB;DP=31;ExcessHet=3.0103;FS=8.272;MLEAC=1;MLEAF=0.500;MQ=54.64;MQRankSum=-3.786;QD=16.12;ReadPosRankSum=0.257;SOR=0.346","C","G","Post menopausal women with the CG genotype and schizophrenia may have decreased response to raloxifene compared to patients with the CC genotype. Other genetic and clinical factors may affect response to raloxifene."
"1448265280","TNFAIP3","4","-1.25","Efficacy","ustekinumab","Psoriasis","137878280","1265.06","AC=2;AF=1.00;AN=2;BaseQRankSum=-1.364;DB;DP=40;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;MQRankSum=0.000;QD=32.44;ReadPosRankSum=-0.712;SOR=0.317","G","T","Patients with the GT genotype and psoriasis do not seem to have different response to ustekinumab compared to patients with the TT genotype. Other clinical and genetic factors may affect response to ustekinumab."
"1448265598","AGBL4","3","0","Toxicity","rifampin","Tuberculosis","48647950","623.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.501;DB;DP=41;ExcessHet=3.0103;FS=1.236;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.21;ReadPosRankSum=-1.249;SOR=0.420","A","G","Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin."
"1448265605","AGBL4","3","0","Toxicity","rifampin","Tuberculosis","48643073","877.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.822;DB;DP=64;ExcessHet=3.0103;FS=2.292;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.88;ReadPosRankSum=-0.443;SOR=1.121","A","G","Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin."
"1448266599","KLRD1","3","2.75","Efficacy","adalimumab;certolizumab pegol;etanercept;glucocorticoids;infliximab;methotrexate","Arthritis, Rheumatoid","10307944","977.06","AC=2;AF=1.00;AN=2;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.90;SOR=1.863","A","T","Patients with the AT genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response."
"1448266986","SLC22A2","3","5","Toxicity","Platinum compounds","Carcinoma, Non-Small-Cell Lung","160249250","1311.06","AC=2;AF=1.00;AN=2;DB;DP=35;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.85;SOR=1.885","A","C","Patients with the AC genotype and non-small cell lung cancer may have increased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicity."
"1448267389","CYP1A1","3","2.25","Dosage","warfarin","heart valve replacement","74726549","1288.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.874;DB;DP=100;ExcessHet=3.0103;FS=6.665;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.56;ReadPosRankSum=0.104;SOR=1.378","A","C","Patients with the AC genotype and heart valve replacement may require decreased dose of warfarin compared to patients with the CC genotype. Other clinical and genetic factors affect warfarin dose."
"1448422839","TGFB1","3","2.5","Toxicity","irinotecan","Colorectal Neoplasms","41354391","928.06","AC=2;AF=1.00;AN=2;DB;DP=34;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.00;SOR=1.112","A","G","Patients with the AG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan."
"1448422846","TGFBR2","3","2.5","Toxicity","irinotecan","Colorectal Neoplasms","30605668","530.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.047;DB;DP=37;ExcessHet=3.0103;FS=12.992;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.34;ReadPosRankSum=0.061;SOR=1.308","A","G","Patients with the AG genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan."
"1448427005","ABCB1","3","3","Toxicity","gefitinib","Carcinoma, Non-Small-Cell Lung","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib."
"1448427398","EDN1","3","3","Efficacy","bevacizumab","Breast Neoplasms","12296022","1742.06","AC=2;AF=1.00;AN=2;BaseQRankSum=-1.376;DB;DP=63;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;MQRankSum=0.000;QD=30.04;ReadPosRankSum=0.807;SOR=0.301","G","T","Patients with the GT genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab."
"1448427833","ABCB1","3","0.5","Efficacy","granisetron","Neoplasms","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and cancer may have a lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron."
"1448427972","NTRK2","3","2.75","Toxicity","antidepressants","Depressive Disorder, Major","84673278","474.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.252;DB;DP=46;ExcessHet=3.0103;FS=4.351;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.32;ReadPosRankSum=1.938;SOR=0.662","G","T","Patients with the GT genotype and depression may have increased risk of suicidal thoughts when taking antidepressants compared to patients with the TT genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants."
"1448428030","SLCO1B1","4","-1.25","Toxicity","irinotecan","Neoplasms","21176804","361.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.460;DB;DP=33;ExcessHet=3.0103;FS=3.093;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.30;ReadPosRankSum=-1.572;SOR=1.314","A","G","Patients with the AG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy."
"1448428108","GRIK3","3","3","Toxicity","antipsychotics","Psychotic Disorders","36930738","2033.06","AC=2;AF=1.00;AN=2;DB;DP=57;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.03;SOR=0.841","C","T","Patients with the CT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms."
"1448428117","SLC18A2","3","3","Toxicity","antipsychotics","Psychotic Disorders","117250954","729.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.073;DB;DP=70;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.42;ReadPosRankSum=0.232;SOR=0.602","C","T","Patients with the CT genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms."
"1448522748","PGLYRP4","3","2","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors","Psoriasis","153348279","857.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.163;DB;DP=68;ExcessHet=3.0103;FS=3.312;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.80;ReadPosRankSum=0.740;SOR=0.594","C","T","Patients with the CT genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs."
"1448522754","CTNNA2","3","3","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors","Psoriasis","79673969","1610.06","AC=2;AF=1.00;AN=2;DB;DP=52;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.96;SOR=0.853","A","G","Patients with the AG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs."
"1448522766","IL12B","3","3","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors","Psoriasis","159332892","561.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.443;DB;DP=62;ExcessHet=3.0103;FS=3.511;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.36;ReadPosRankSum=1.435;SOR=1.064","A","G","Patients with the AG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs."
"1448525452","DRD3","3","5","Toxicity","levodopa","gastrointestinal toxicity;Hallucinations;Parkinson Disease","114171968","372.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.437;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.31;ReadPosRankSum=0.000;SOR=0.693","C","T","Patients with the CT genotype and Parkinson's Disease may have a decreased risk of adverse events when treated with levodopa as compared to patients with the TT genotype but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with levodopa."
"1448526098","IL6R","3","2.75","Efficacy","tocilizumab","Arthritis, Rheumatoid","154457616","633.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.841;DB;DP=65;ExcessHet=3.0103;FS=5.128;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.22;ReadPosRankSum=-0.014;SOR=0.293","C","T","Patients with the CT genotype and rheumatoid arthritis may have a poorer response when treated with tocilizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tocilizumab response."
"1448530595","FOXP3","3","2.5","Toxicity","tacrolimus","Kidney Transplantation","49261784","784.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.298;DB;DP=57;ExcessHet=3.0103;FS=2.268;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.27;ReadPosRankSum=1.038;SOR=0.800","G","T","Patients with the GT genotype and kidney transplantation may have increased risk of acute renal toxicity when taking tacrolimus compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy."
"1448532313","IFNL3;IFNL4","3","3.5","Efficacy","ledipasvir;sofosbuvir","Hepatitis C, Chronic;Recurrence","39248147","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.448;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=58.43;MQRankSum=-1.834;QD=13.47;ReadPosRankSum=-0.076;SOR=0.693","C","T","Patients with genotype CT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to ledipasvir/sofosbuvir therapy."
"1448567797","POR","3","1.5","Metabolism/PK","sirolimus","Kidney Transplantation","75985688","1716.06","AC=2;AF=1.00;AN=2;DB;DP=52;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.00;SOR=1.358","C","T","Patients with the CT genotype who underwent kidney transplantation may have decreased trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations."
"1448573615","ABCB1","3","1","Efficacy","tacrolimus","Colitis, Ulcerative","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response."
"1448601910","SLC6A2","3","2.75","Efficacy","venlafaxine","Depressive Disorder, Major","55656513","1042.06","AC=2;AF=1.00;AN=2;DB;DP=36;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.56;SOR=0.957","C","T","Patients with the CT genotype and major depressive disorder may have an decreased response to venlafaxine compared to patients with the CC genotype. Other clinical and genetic factors affect response to venlafaxine."
"1448602689","DPYS","3","3","Toxicity","atenolol","Hyperglycemia;Hypertension","104451462","1891.06","AC=2;AF=1.00;AN=2;DB;DP=61;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.60;SOR=0.836","A","G","Patients with the AG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA genotype. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension."
"1448602877","CES1P1","3","2.5","Toxicity","capecitabine","Drug Toxicity","55759367","360.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.589;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=7.67;ReadPosRankSum=0.933;SOR=0.634","A","G","Patients with the AG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine."
"1448602934","CYP2R1","3","3","Efficacy","peginterferon alfa-2b;ribavirin","Hepatitis C, Chronic","14893332","568.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.274;DB;DP=53;ExcessHet=3.0103;FS=2.375;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.73;ReadPosRankSum=-0.898;SOR=1.179","A","G","Patients with the AG genotype may have increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin."
"1448604251","ABCB1","3","0","Metabolism/PK","methadone","Opioid-Related Disorders","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the rs2032582 AC genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance."
"1448604316","C3","3","0","Toxicity","clozapine","Metabolic Syndrome","6679500","2636.06","AC=2;AF=1.00;AN=2;DB;DP=76;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.91;SOR=2.093","C","T","Patients with the CT genotype and schizophrenia may have increased fasting triglyceride levels, that may confer susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the TT genotype, and decreased fasting triglyceride levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome."
"1448613243","CTLA4","3","4","Metabolism/PK","tacrolimus","Kidney Transplantation","203866282","853.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.535;DB;DP=66;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.55;ReadPosRankSum=0.738;SOR=0.648","A","G","People with the AG genotype undergoing a kidney transplantation may have decreased exposure to tacrolimus, as measured by concentration/distribution, compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to tacrolimus."
"1448615137","ABCB1","3","2","Toxicity","anastrozole","Arthralgia;Breast Neoplasms","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Postmenopausal women with HR+ breast cancer and the AG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole."
"1448615147","ABCB1","3","1.5","Metabolism/PK","anastrozole","Breast Neoplasms","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Postmenopausal women with HR+ breast cancer and the AC genotype may have decreased plasma concentrations of anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer."
"1448615319","ABCB1","3","1","Toxicity","clopidogrel","Coronary Disease;Hemorrhage","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with coronary disease and the AG genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel."
"1448615575","ABCB1","4","-8.75","Efficacy","clopidogrel","platelet reactivity","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have a decreased response to clopidogrel (increased platelet reactivity) as compared to patients with the GG genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel."
"1448615614","CACNA1C","3","1.5","Toxicity","ritodrine","adverse events;Premature Birth","2681966","2500.06","AC=2;AF=1.00;AN=2;DB;DP=58;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.68;SOR=1.382","A","G","Women with premature births and the AG genotype who are treated with ritodrine may have a decreased likelihood of adverse events as compared to women with premature birth and the GG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine."
"1448616678","FOXP3","3","2.5","Efficacy","methotrexate","Psoriasis","49261784","784.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.298;DB;DP=57;ExcessHet=3.0103;FS=2.268;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.27;ReadPosRankSum=1.038;SOR=0.800","G","T","Patients with the GT genotype and psoriasis may experience a decreased response to methotrexate as compared to patients with the TT genotypes and and an increased response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis."
"1448616845","CDA","3","0.5","Toxicity","capecitabine","Neoplasms","20589208","559.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.531;DB;DP=56;ExcessHet=3.0103;FS=5.726;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.18;ReadPosRankSum=-0.198;SOR=0.557","A","C","Patients with cancer and the AC genotype who are treated with capecitabine may have a decreased (but not absent) incidence of adverse events, including hand-foot syndrome, as compared to patients with the AA genotype, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine."
"1448616855","CDA","3","2.75","Toxicity","capecitabine","Hyperbilirubinemia;Neoplasms","20618562","819.06","AC=2;AF=1.00;AN=2;DB;DP=25;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.13;SOR=1.270","C","T","Patients with cancer and the CT genotype who are treated with capecitabine may have increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine."
"1448616865","DPYD","3","2.75","Toxicity","capecitabine","Hyperbilirubinemia;Neoplasms","97696806","81.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.259;DB;DP=16;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=5.10;ReadPosRankSum=0.730;SOR=0.446","A","G","Patients with cancer and the AG genotype may have an increased risk of hyperbilirubinemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine."
"1448616890","SLC22A7","3","2.75","Toxicity","capecitabine","Drug Toxicity;Neoplasms","43302413","1142.06","AC=2;AF=1.00;AN=2;DB;DP=32;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.90;SOR=1.681","C","T","Patients with the CT genotype and colorectal cancer who are treated with capecitabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine."
"1448616900","SLC22A7","3","2.75","Toxicity","capecitabine","Diarrhea;Neoplasms","43304450","788.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.488;DB;DP=41;ExcessHet=3.0103;FS=1.366;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=20.22;ReadPosRankSum=-2.360;SOR=1.101","A","G","Patients with the AG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine"
"1448616922","TYMS","3","5.5","Toxicity","capecitabine","Asthenia;Nausea;Neoplasms;Vomiting","673016","2976.06","AC=2;AF=1.00;AN=2;DB;DP=86;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.75;SOR=1.347","C","T","Patients with the CT genotype and cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of nausea and vomiting as compared to patients with the TT genotype and a decreased likelihood of asthenia as compared to the CC genotype. Other clinical and genetic factors may also influence nausea and vomiting in patients with cancer who are treated with Capecitabine."
"1448617146","ABCB1","3","2.5","Toxicity","atazanavir","HIV Infections","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir."
"1448624874","N6AMT1","3","0","Efficacy","clopidogrel","major adverse cardiac events (mace)","28883961","2693.06","AC=2;AF=1.00;AN=2;DB;DP=83;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.84;SOR=0.793","A","G","Patients with the AG genotype may have increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype AA. Other genetic and clinical factors may also influence the response to clopidogrel."
"1448635585","CYP2B6","4","-2.75","Toxicity","nevirapine","drug reaction with eosinophilia and systemic symptoms;HIV Infections;Stevens-Johnson Syndrome;Toxic liver disease","41006936","384.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.804;DB;DP=34;ExcessHet=3.0103;FS=1.394;MLEAC=1;MLEAF=0.500;MQ=59.51;MQRankSum=1.002;QD=11.31;ReadPosRankSum=1.503;SOR=0.374","G","T","Individuals with HIV and the GT genotype may have a decreased risk of SJS/TEN and DRESS Syndrome when treated with nevirapine as compared to patients with the TT genotype and an increased risk as compared to patients with the GG genotype, but may not be associated with hepatotoxicity. Please note: in two studies, it was the combination of rs28399499 and rs3745274 that was significantly associated with toxicity. Other clinical and genetic factors may also influence risk of SJS/TEN or DRESS Syndrome in patients with HIV who are administered nevirapine."
"1448636111","EGFR","3","3","Efficacy","peginterferon alfa-2a;peginterferon alfa-2b;ribavirin","Hepatitis C, Chronic","55152484","796.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.756;DB;DP=75;ExcessHet=3.0103;FS=3.305;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.38;ReadPosRankSum=0.973;SOR=0.743","A","G","Patients with the AG genotype may have decreased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to peginterferon alfa-2/RBV."
"1448636814","RPTOR","3","5","Efficacy;Toxicity","everolimus","pneumonitis;progression-free survival","80691605","427.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.423;DB;DP=54;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.22;ReadPosRankSum=1.120;SOR=0.693","C","T","Patients with the CT genotype and breast cancer who are treated with everolimus may have increased likelihood of progression-free survival and decreased likelihood of pneumonitis as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus."
"1448636842","ABCB1","3","2.25","Toxicity","everolimus","Breast Neoplasms;Lymphopenia","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype and breast cancer who are treated with everolimus may have increased likelihood of Lymphopenia as compared to patients with the CC genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus."
"1448636848","ABCB1","3","2.25","Toxicity","everolimus","Breast Neoplasms;mucositis","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and breast cancer who are treated with everolimus may have increased likelihood of mucositis as compared to patients with the GG genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus."
"1448640301","DPYD","4","-3.5","Efficacy","fluorouracil","Neoplasms","97450058","503.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.590;DB;DP=30;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.79;ReadPosRankSum=2.793;SOR=1.085","C","T","The current evidence base suggests that there is no association between the rs3918290 CT genotype and response to fluorouracil. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil."
"1448820584","C6","3","1","Metabolism/PK","tacrolimus","liver transplantation","41142504","778.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.404;DB;DP=70;ExcessHet=3.0103;FS=4.767;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.12;ReadPosRankSum=-1.994;SOR=1.329","C","T","Patients undergoing liver transplantation with the CT genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus."
"1449003966","MAFK","3","0.75","Toxicity","isoniazid","drug-induced liver injury;Toxic liver disease","1534767","1309.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.727;DB;DP=67;ExcessHet=3.0103;FS=4.912;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=19.84;ReadPosRankSum=0.628;SOR=0.915","A","G","Patients with the AG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid."
"1449004229","SCN1A","4","-4","Efficacy","carbamazepine;clobazam;ethosuximide;lamotrigine;levetiracetam;oxcarbazepine;valproic acid","Epilepsy","166036278","77.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.612;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=1.94;ReadPosRankSum=-0.553;SOR=0.984","C","T","Patients with epilepsy and the CT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the TT genotypes and a worse response as compared to patients with the CC genotype, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs."
"1449004567","ABCB1","3","4","Efficacy;Metabolism/PK","oxcarbazepine","Epilepsy","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with epilepsy and the AG genotype may have decreased concentrations of oxcarbazepine and worse response as compared to patients with the GG genotypes but improved response as compared to the AA genotype. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy."
"1449005047","CYP3A4","3","1.75","Efficacy;Metabolism/PK","lumefantrine","Malaria","99784473","2096.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.27;SOR=0.859","C","T","Pregnant patients with malaria and the CT genotype may have increased concentrations and an improved response to lumefantrine as compared to patients with the TT genotypes and lower concentrations and worse response to lumefantrine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations and response to lumefantrine."
"1449005066","CYP3A;CYP3A4","3","3.25","Toxicity","cyclosporine;tacrolimus","Kidney Transplantation;transplant rejection","99784473","2096.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.27;SOR=0.859","C","T","Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the rs2740574 CT genotype (CYP3A4 *1A/*1B) may have a decreased likelihood of transplant rejection as compared to kidneys from donors with the rs2740574 TT genotype (CYP3A4 *1A/*1A). Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys."
"1449005382","RABEP1","3","2.25","Other","amisulpride;aripiprazole;clozapine;lithium;mirtazapine;olanzapine;paliperidone;quetiapine;risperidone;valproic acid","Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder","5379957","1331.06","AC=2;AF=1.00;AN=2;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.25;SOR=0.784","A","G","Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AG genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of fasting glucose concentrations as compared to patients with the AA genotype. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications."
"1449005393","ABCB1","3","4","Efficacy;Toxicity","remifentanil;sevoflurane","tonsillectomy","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Pediatric patients undergoing surgery with the AG genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil."
"1449140063","NR1I2","3","3.5","Toxicity;Metabolism/PK","sirolimus;temsirolimus","adverse events;gastrointestinal toxicity;Myelosuppression;Urinary Bladder Neoplasms","119781188","257.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.434;DB;DP=45;ExcessHet=3.0103;FS=1.223;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=5.99;ReadPosRankSum=-0.536;SOR=0.709","C","T","Patients with the CT genotype and bladder cancer may have increased metabolism of temsirolimus as compared to patients with the TT genotype. Patients with the CT genotype who are administered temsirolimus may also have a decreased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CC genotypes and a increased likelihood as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer."
"1449140085","ABCB1","3","1","Metabolism/PK","sirolimus;temsirolimus","hematopoietic stem cell transplantation;Kidney Transplantation;Urinary Bladder Neoplasms","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus."
"1449140229","ABCB1","3","1.5","Metabolism/PK","sirolimus;temsirolimus","Urinary Bladder Neoplasms","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer."
"1449144340","FAM178B","3","0","Efficacy","lithium","Bipolar Disorder","96941334","294.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.522;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.52;ReadPosRankSum=1.022;SOR=0.495","A","G","Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
"1449144376","ADCY1","3","0","Efficacy","lithium","Bipolar Disorder","45607253","942.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.294;DB;DP=66;ExcessHet=3.0103;FS=0.951;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.50;ReadPosRankSum=-0.278;SOR=0.556","A","G","Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
"1449146840","SLC29A1","3","3.25","Efficacy","tipiracil hydrochloride;trifluridine","Colorectal Neoplasms","44233216","489.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.707;DB;DP=47;ExcessHet=3.0103;FS=1.119;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.42;ReadPosRankSum=-0.723;SOR=0.507","A","G","Patients with colorectal cancer and the AG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer."
"1449147022","IFNL3;IFNL4","3","2.5","Efficacy","sofosbuvir;velpatasvir;voxilaprevir","Hepatitis C, Chronic","39248147","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.448;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=58.43;MQRankSum=-1.834;QD=13.47;ReadPosRankSum=-0.076;SOR=0.693","C","T","Patients with genotypes CT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC."
"1449147609","CYP3A4","3","1","Efficacy","buprenorphine","Pain","99784473","2096.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.27;SOR=0.859","C","T","Patients with the rs2740574 CT genotype who are taking buprenorphine for pain may have a decreased analgesic response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence analgesic response to buprenorphine."
"1449155302","POR","3","3","Efficacy","sunitinib","Gastrointestinal Stromal Tumors","75985688","1716.06","AC=2;AF=1.00;AN=2;DB;DP=52;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.00;SOR=1.358","C","T","Patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have shorter progression-free survival time when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sunitinib response."
"1449155637","IL1B","3","3.75","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors;ustekinumab","Psoriasis","112838252","785.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.560;DB;DP=43;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=19.64;ReadPosRankSum=-0.910;SOR=0.879","C","G","Patients with the CG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response."
"1449156809","DBH","3","3","Toxicity","opioids","Opioid-Related Disorders","133657065","1156.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.626;DB;DP=92;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.61;ReadPosRankSum=-1.158;SOR=0.737","A","G","Patients with the AG genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
"1449156815","TH","3","1","Toxicity","opioids","Opioid-Related Disorders","2165105","825.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.220;DB;DP=60;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.24;ReadPosRankSum=0.023;SOR=0.813","A","G","Patients with the AG genotype may have an increased risk of developing opioid dependence as compared to patients with the AA genotype. However, another study failed to find an association. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
"1449157278","OPRD1","3","5.75","Efficacy","buprenorphine","Opioid-Related Disorders","28818676","693.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.835;DB;DP=51;ExcessHet=3.0103;FS=2.539;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.87;ReadPosRankSum=-0.146;SOR=1.223","C","T","Patients with the rs678849 CT genotype may have an increased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to buprenorphine."
"1449157284","OPRD1","3","0.25","Efficacy","methadone","Opioid-Related Disorders","28818676","693.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.835;DB;DP=51;ExcessHet=3.0103;FS=2.539;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.87;ReadPosRankSum=-0.146;SOR=1.223","C","T","African-American patients with the CT genotype may have a decreased response to methadone when being treated for opioid dependence, as compared to patients with the CC genotype. This association was not seen in European-American patients. Response to methadone treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to methadone."
"1449164443","IFNL3;IFNL4","3","2.75","Efficacy","peginterferon alfa-2a;peginterferon alfa-2b","Myeloproliferative Disorders","39248147","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.448;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=58.43;MQRankSum=-1.834;QD=13.47;ReadPosRankSum=-0.076;SOR=0.693","C","T","Patients with the CT genotype may have decreased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to interferon-alpha."
"1449164746","SLC22A5","3","3","Toxicity","imatinib","Gastrointestinal Stromal Tumors","132385482","1027.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.957;DB;DP=80;ExcessHet=3.0103;FS=0.906;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.52;ReadPosRankSum=0.546;SOR=0.560","A","G","Patients with the AG genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for periorbital edema."
"1449164763","EGFR","3","3","Toxicity","imatinib","Gastrointestinal Stromal Tumors","55170394","609.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.836;DB;DP=59;ExcessHet=3.0103;FS=3.860;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.29;ReadPosRankSum=-0.392;SOR=0.604","C","T","Patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage."
"1449165158","ABCB1","4","-0.25","Toxicity","methotrexate","Arthritis, Rheumatoid","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","The current evidence base suggests that there is no significant association between the rs1128503 AG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
"1449165479","FCGR2A","3","6.75","Efficacy","cetuximab","Colorectal Neoplasms;Head and Neck Neoplasms","161509955","2796.06","AC=2;AF=1.00;AN=2;DB;DP=103;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=27.96;SOR=1.007","A","G","Patients with the AG genotype and cancer may have decreased survival times when treated with cetuximab as compared to patients with the GG genotype. However, a meta-analysis found no association between this variant and response to cetuximab while a large clinical study found that patients with the AG genotype had decreased survival times compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival times in patients taking cetuximab."
"1449166396","ABCB1","3","4","Efficacy;Metabolism/PK","omeprazole","Gastroesophageal Reflux","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and gastroesophageal reflux who are treated with omeprazole may have Increased absorption of omeprazole, but decreased response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence absorption rate and response to omeprazole in patients gastroesophageal reflux."
"1449167093","LKAAEAR1;OPRL1","3","0.5","Toxicity","opioids","Opioid-Related Disorders","64086577","845.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.859;DB;DP=83;ExcessHet=3.0103;FS=0.855;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.44;ReadPosRankSum=-0.738;SOR=0.580","C","T","Caucasian patients with the CT genotype may have an increased risk of developing opioid dependence as compared to Caucasian patients with the TT genotype. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
"1449167278","ELP5","3","0","Efficacy","methylphenidate","Attention Deficit Disorder with Hyperactivity","7260420","691.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.816;DB;DP=57;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.81;ReadPosRankSum=-0.528;SOR=0.540","A","G","Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate."
"1449167420","ETFDH","3","0","Efficacy","methylphenidate","Attention Deficit Disorder with Hyperactivity","158680524","1429.06","AC=2;AF=1.00;AN=2;DB;DP=50;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.58;SOR=0.859","C","T","Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate."
"1449167480","ESYT2","3","0","Efficacy","methylphenidate","Attention Deficit Disorder with Hyperactivity","158733764","261.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.362;DB;DP=42;ExcessHet=3.0103;FS=1.468;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=6.23;ReadPosRankSum=0.186;SOR=0.395","G","T","Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate."
"1449168079","ZNF385D","3","0","Efficacy","duloxetine","Depressive Disorder, Major","21753431","441.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.413;DB;DP=67;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=6.69;ReadPosRankSum=-0.489;SOR=0.653","C","T","Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine."
"1449168086","ZNF385D","3","0","Efficacy","duloxetine","Depressive Disorder, Major","21754288","564.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.108;DB;DP=41;ExcessHet=3.0103;FS=1.216;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.77;ReadPosRankSum=-0.828;SOR=0.611","C","T","Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine."
"1449168330","ZNF385D","3","0","Efficacy","duloxetine","Depressive Disorder, Major","21756084","1156.06","AC=2;AF=1.00;AN=2;DB;DP=26;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=35.65;SOR=0.846","C","T","Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine."
"1449168343","ZNF385D","3","0","Efficacy","duloxetine","Depressive Disorder, Major","21756949","827.06","AC=2;AF=1.00;AN=2;DB;DP=29;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.52;SOR=0.906","A","G","Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine."
"1449168371","ZNF385D","3","0","Efficacy","duloxetine","Depressive Disorder, Major","21757835","629.06","AC=2;AF=1.00;AN=2;DB;DP=23;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.96;SOR=1.230","G","T","Patients with the GT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine."
"1449168496","TEX10","3","0","Efficacy","duloxetine","Depressive Disorder, Major","100309102","855.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.354;DB;DP=54;ExcessHet=3.0103;FS=1.090;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.78;ReadPosRankSum=-0.860;SOR=0.525","A","T","Patients with the AT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine."
"1449168510","TEX10","3","0","Efficacy","duloxetine","Depressive Disorder, Major","100349683","697.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.361;DB;DP=56;ExcessHet=3.0103;FS=1.054;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.16;ReadPosRankSum=0.214;SOR=0.941","C","T","Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine."
"1449168524","FCN2","3","0","Efficacy","duloxetine","Depressive Disorder, Major","134883293","932.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.525;DB;DP=68;ExcessHet=3.0103;FS=3.413;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.35;ReadPosRankSum=0.613;SOR=0.459","A","G","Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine."
"1449168698","MIEF2","3","0","Efficacy","duloxetine","Depressive Disorder, Major","18264083","851.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.246;DB;DP=81;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.78;ReadPosRankSum=-1.609;SOR=0.610","G","T","Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine."
"1449171009","CYP3A4","3","2.25","Dosage","buprenorphine","Opioid-Related Disorders","99784473","2096.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.27;SOR=0.859","C","T","Patients with opioid-related disorders and the rs2740574 CT genotype (CYP3A4*1/*1B) may require an increased dose of buprenorphine to prevent withdrawal symptoms as compared to patients with the rs2740574 TT genotype (CYP3A4 *1/*1). Other genetic and clinical factors may also influence dosage of buprenorphine in patients with opioid-related disorders."
"1449171162","SOD2","3","0.5","Toxicity","heroin","Heroin Dependence","159682052","451.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.247;DB;DP=50;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.82;ReadPosRankSum=-1.755;SOR=0.719","C","T","It is currently unclear how the CT genotype affects a patient's risk of developing heroin dependence."
"1449171168","SOD2","3","3","Toxicity","heroin","Heroin Dependence","159691552","310.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.689;DB;DP=32;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.02;ReadPosRankSum=-0.318;SOR=0.558","A","C","Patients with the AC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence."
"1449190104","ABCB1","3","1.75","Toxicity","antineoplastic agents","Neoplasms","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and receiving chemotherapy treatment may have increased severity of nausea as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment."
"1449266588","ABCB1","3","5.625","Metabolism/PK","methadone","Opioid-Related Disorders","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the rs1045642 AG genotype who are receiving methadone maintenance therapy may have decreased clearance of methadone, leading to increased plasma concentration of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs1045642 and methadone and does not include evidence about clinical outcomes."
"1449269278","CYP4F2","4","-3","Other","warfarin","over-anticoagulation","15879621","853.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.514;DB;DP=70;ExcessHet=3.0103;FS=0.907;MLEAC=1;MLEAF=0.500;MQ=59.96;MQRankSum=1.059;QD=12.55;ReadPosRankSum=0.362;SOR=0.576","C","T","Patients with the CT genotype who are treated with warfarin may have a decreased risk of over-anticoagulation as compared to patients with the TT genotype, although not all studies support this. Other clinical factors such as target INR, and dosage (which is also associated with this particular variant) and genetic factors may also influence risk of over-anticoagulation in patients administered warfarin."
"1449270486","KLB","3","0","Dosage","ethanol","Alcoholism","39413373","1342.06","AC=2;AF=1.00;AN=2;DB;DP=41;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.55;SOR=0.693","A","G","Patients with the AG genotype may have reduced alcohol consumption as compared to patients with the GG genotype, but an increased level of alcohol consumption compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's level of alcohol consumption."
"1449270967","TP53","3","0","Toxicity","cyclophosphamide;epirubicin;fluorouracil","Breast Neoplasms;Neutropenia","7669124","931.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.507;DB;DP=60;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.06;ReadPosRankSum=0.221;SOR=0.765","C","T","Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
"1449565066","SLC29A3","4","-0.25","Efficacy","gemcitabine","Carcinoma, Non-Small-Cell Lung","71351651","2034.06","AC=2;AF=1.00;AN=2;DB;DP=67;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.29;SOR=0.854","C","T","Patients with the CT genotype and non-small cell lung cancer who are treated with gemcitabine may have longer overall survival as compared to patients with the CC genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine."
"1449566673","SLC31A1","3","5.75","Efficacy;Toxicity","Platinum compounds","overall survival;Thrombocytopenia","113219836","1468.06","AC=2;AF=1.00;AN=2;DB;DP=47;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.24;SOR=1.022","A","C","Patients with the AC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of thrombocytopenia, and decresed likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer."
"1449566679","SLC31A1","3","2.5","Toxicity","Platinum compounds","Thrombocytopenia","113220123","657.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.144;DB;DP=61;ExcessHet=3.0103;FS=0.995;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.15;ReadPosRankSum=1.079;SOR=0.544","A","G","Patients with the AG genotype and non-small cell lung cancer who are treated with platinum compounds may have a increased severity of thrombocytopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds."
"1449566697","SLC31A1","3","2.75","Efficacy","Platinum compounds","overall survival;Thrombocytopenia","113262744","1751.06","AC=2;AF=1.00;AN=2;DB;DP=53;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.33;SOR=0.732","A","C","Patients with the AC genotype and non-small cell lung cancer may have decreased likelihood of overall survival in as compared to patients with the AA genotype. Other clinical and genetic factors may also influence overall survival in patients who are treated with platinum compounds."
"1449715596","UGT2B7","3","2.25","Efficacy","fentanyl","Pain, Postoperative","69105219","820.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.559;DB;DP=64;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.82;ReadPosRankSum=0.704;SOR=0.665","A","C","Patients with the AC genotype may have an increased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl."
"1449715840","OPRM1","3","2","Toxicity","fentanyl","Vomiting","154093311","1772.06","AC=2;AF=1.00;AN=2;DB;DP=57;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.22;SOR=1.061","A","T","Patients with the rs540825 AT genotype may have a decreased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the TT genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl."
"1449715913","ABCB1","3","2","Toxicity","fentanyl","Pain, Postoperative;Respiratory Insufficiency","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl."
"1449715919","ABCB1","3","0","Toxicity","fentanyl","Pain, Postoperative;Respiratory Insufficiency","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl."
"1449715928","ABCB1","3","0","Toxicity","fentanyl","Pain, Postoperative;Respiratory Insufficiency","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl."
"1449716392","ABCB1","3","0","Toxicity","fentanyl","Neoplasms;Pain","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl."
"1449716764","ABCB1","3","3","Dosage;Efficacy","fentanyl","Pain;Pain, Postoperative","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements."
"1449718317","ERCC1","3","3.25","Toxicity","cyclophosphamide;doxorubicin;fluorouracil","Breast Neoplasms","45420395","1040.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.802;DB;DP=78;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.69;ReadPosRankSum=0.427;SOR=0.595","A","G","Patients with AG genotype and breast cancer may have an increased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy."
"1449718323","CBR1","3","3.25","Toxicity","cyclophosphamide;doxorubicin;fluorouracil","Breast Neoplasms","36072675","761.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.157;DB;DP=58;ExcessHet=3.0103;FS=2.244;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.60;ReadPosRankSum=2.077;SOR=0.439","C","T","Patients with CT genotype and breast cancer may have a decreased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy."
"1449718343","ABCB1","3","2.75","Toxicity","cyclophosphamide;doxorubicin;fluorouracil","Breast Neoplasms","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy."
"1449732040","ABCB1","4","-1.125","Metabolism/PK","risperidone","Bipolar Disorder;Depression;Psychotic Disorders;Schizophrenia;Substance-Related Disorders","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone."
"1449748187","KIF6","3","1","Efficacy","simvastatin","Hypercholesterolemia","39357302","533.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.343;DB;DP=62;ExcessHet=3.0103;FS=5.194;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.75;ReadPosRankSum=-0.499;SOR=0.773","A","G","Patients with the AG genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin."
"1449748202","KIF6","3","1.5","Efficacy","rosuvastatin","Hypercholesterolemia","39357302","533.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.343;DB;DP=62;ExcessHet=3.0103;FS=5.194;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.75;ReadPosRankSum=-0.499;SOR=0.773","A","G","Patients with the AG genotype may have an increased lipid-lowering response to rosuvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to rosuvastatin. Other genetic and clinical factors may also affect a patient's response to rosuvastatin."
"1449748502","ABCB1","3","2.25","Efficacy","tacrolimus","Nephrotic Syndrome","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome."
"1449748511","ABCB1","3","2.25","Efficacy","tacrolimus","Nephrotic Syndrome","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome."
"1449750832","ZNF385D","3","3","Efficacy","duloxetine","Depressive Disorder, Major","21753382","456.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.996;DB;DP=54;ExcessHet=3.0103;FS=2.769;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.78;ReadPosRankSum=0.433;SOR=1.355","C","T","Patients with the CT genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence duloxetine response."
"1450112801","ABCG2","3","2","Metabolism/PK","methotrexate","Osteosarcoma","88141361","512.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.373;DB;DP=52;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.25;ReadPosRankSum=0.787;SOR=0.727","G","T","Patients with osteosarcoma and the GT genotype may have increased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients."
"1450371713","FCGR2A","3","2.25","Efficacy","rituximab","Arthritis, Rheumatoid","161509955","2796.06","AC=2;AF=1.00;AN=2;DB;DP=103;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=27.96;SOR=1.007","A","G","Patients with rheumatoid arthritis and the AG genotype may have a decreased response to rituximab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to rituximab."
"1450373489","OPRM1","3","0","Efficacy","methadone","Heroin Dependence","152994560","831.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.766;DB;DP=78;ExcessHet=3.0103;FS=1.902;MLEAC=1;MLEAF=0.500;MQ=53.82;MQRankSum=-3.195;QD=10.94;ReadPosRankSum=2.208;SOR=0.446","C","T","Patients with the CT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence."
"1450373616","NQO1","3","2","Efficacy","imatinib","Gastrointestinal Stromal Tumors","69709857","2334.06","AC=2;AF=1.00;AN=2;DB;DP=73;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.97;SOR=0.898","A","G","Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival times in patients receiving imatinib."
"1450373854","KCNJ6","3","5","Efficacy","morphine","Pain","37917643","1299.06","AC=2;AF=1.00;AN=2;DB;DP=42;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.48;SOR=1.292","C","T","Patients with the CT genotype may have an increased analgesic response to morphine as compared to patients with the TT genotype, but a decreased response as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to morphine."
"1450374881","ABCB1","3","2","Toxicity","methylphenidate","Attention Deficit Disorder with Hyperactivity","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the AC genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have lower adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate."
"1450374895","TH","3","3.5","Efficacy","methylphenidate","Attention Deficit Disorder with Hyperactivity","2165105","825.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.220;DB;DP=60;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.24;ReadPosRankSum=0.023;SOR=0.813","A","G","Patients with the AG genotype and attention deficit hyperactivity disorder (ADHD) may have a increased treatment response (based on the Improvement subscale of the Clinical Global Impression scale (CGI-I)) when treated with methylphenidate as compared to patients with the GG genotype who started from a lower Clinical Global Impressions-Severity scale (CGI-S) score. Other genetic and clinical factors may also influence response to methylphenidate."
"1450375024","ABCB1","3","2.5","Toxicity","bleomycin;cisplatin;etoposide","Testicular Neoplasms;Vomiting","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with testicular cancer and the AG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide."
"1450375035","CYP3A;CYP3A4","3","2.5","Toxicity","bleomycin;cisplatin;etoposide","Alopecia;Testicular Neoplasms","99784473","2096.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.27;SOR=0.859","C","T","Patients with testicular cancer and the CT genotype may have an increased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide."
"1450375059","ERCC2","3","2.5","Toxicity","bleomycin;cisplatin;etoposide","Anemia;Testicular Neoplasms","45364001","527.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.383;DB;DP=30;ExcessHet=3.0103;FS=4.499;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=17.59;ReadPosRankSum=-1.027;SOR=0.170","C","T","Patients with testicular cancer and the CT genotype may have a decreased risk of developing anemia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of anemia as a result of treatment with bleomycin, cisplatin and etoposide."
"1450375080","ERCC1","3","2.5","Toxicity","bleomycin;cisplatin;etoposide","febrile neutropenia;Testicular Neoplasms","45420395","1040.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.802;DB;DP=78;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.69;ReadPosRankSum=0.427;SOR=0.595","A","G","Patients with testicular cancer and the AG genotype may have a decreased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide."
"1450377181","NAT2","3","2.25","Toxicity","isoniazid;phenytoin","Drug interaction with drug;Drug Toxicity","18400285","735.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.877;DB;DP=56;ExcessHet=3.0103;FS=8.058;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.62;ReadPosRankSum=-0.470;SOR=1.907","C","T","Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin."
"1450377193","NAT2","3","2.25","Toxicity","isoniazid;phenytoin","Drug interaction with drug;Drug Toxicity","18400484","650.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.345;DB;DP=53;ExcessHet=3.0103;FS=4.006;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.28;ReadPosRankSum=-0.099;SOR=0.283","C","T","Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin."
"1450377339","TCF7L2","3","2","Toxicity","tacrolimus","liver transplantation","113149972","618.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.451;DB;DP=63;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.98;ReadPosRankSum=-0.499;SOR=0.598","C","T","Patients who are undergoing liver transplantation and receive a donor liver with the CT genotype may have an increased risk for new-onset diabetes mellitus (NODM) when treated with tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors may also influence risk for NODM."
"1450810228","OPRM1","3","3.25","Toxicity","ethanol","Alcoholism","154047412","347.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.264;DB;DP=26;ExcessHet=3.0103;FS=6.204;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.48;ReadPosRankSum=0.087;SOR=1.763","C","T","Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism."
"1450810236","OPRM1","3","6.75","Toxicity","heroin;opioids","Heroin Dependence;Opioid-Related Disorders","154047412","347.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.264;DB;DP=26;ExcessHet=3.0103;FS=6.204;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.48;ReadPosRankSum=0.087;SOR=1.763","C","T","Patients with the CT genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
"1450810375","OPRM1","3","1.25","Toxicity","ethanol","Alcoholism","154061407","272.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.001;DB;DP=37;ExcessHet=3.0103;FS=1.409;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=7.57;ReadPosRankSum=-0.643;SOR=0.346","A","G","Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism."
"1450810381","OPRM1","3","3.25","Toxicity","cocaine","Cocaine-Related Disorders","154061407","272.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.001;DB;DP=37;ExcessHet=3.0103;FS=1.409;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=7.57;ReadPosRankSum=-0.643;SOR=0.346","A","G","Patients with the AG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence."
"1450810387","OPRM1","3","6","Toxicity","opioids","Opioid-Related Disorders","154061407","272.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.001;DB;DP=37;ExcessHet=3.0103;FS=1.409;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=7.57;ReadPosRankSum=-0.643;SOR=0.346","A","G","Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence."
"1450811273","CHRNA4","3","0","Toxicity","ethanol","Alcoholism","63350733","1780.06","AC=2;AF=1.00;AN=2;DB;DP=60;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.69;SOR=0.914","A","G","Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism."
"1450811641","ABCB1","4","-2.25","Dosage","methadone","Heroin Dependence;Opioid-Related Disorders","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","The current evidence base suggests that there is no significant association between the rs1128503 AG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
"1450813881","HYKK","3","2.75","Efficacy","varenicline","Tobacco Use Disorder","78510715","2240.06","AC=2;AF=1.00;AN=2;DB;DP=64;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=25.04;SOR=0.822","C","T","Patients with the CT genotype may be more likely to quit smoking by weeks 9-12 of varenicline treatment as compared to patients with the CC genotype. Other genetic or clinical factors may also affect response to varenicline."
"1450814192","OPRM1","3","1.75","Efficacy","highly active antiretroviral therapy (haart)","HIV Infections","154119607","1962.06","AC=2;AF=1.00;AN=2;DB;DP=72;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.44;SOR=0.781","A","G","Hispanic patients with the AG genotype may have a greater decrease in viral load following the initiation of HAART as compared to Hispanic patients with the GG genotype. This association was not seen in European or African American patients. Other genetic or clinical factors may also affect a patient's response to HAART."
"1450814563","GABRA2","3","2","Toxicity","cocaine","Cocaine-Related Disorders","46388848","495.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.924;DB;DP=39;ExcessHet=3.0103;FS=1.342;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.71;ReadPosRankSum=-1.341;SOR=0.368","C","G","Patients with cocaine dependence and the CG genotype may have increased cocaine cue-reactivity as compared to patients with the CC genotype. Other genetic or clinical factor may also affect cocaine cue-reactivity in patients with cocaine dependence."
"1450814647","HTR2A","3","2.25","Efficacy","bupropion","Depressive Disorder, Major","46866425","597.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.836;DB;DP=56;ExcessHet=3.0103;FS=5.456;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.87;ReadPosRankSum=-0.523;SOR=0.833","C","T","Patients with the CT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion."
"1450814659","SLC18A2","3","2.75","Efficacy","bupropion","Depressive Disorder, Major","117264991","1129.06","AC=2;AF=1.00;AN=2;DB;DP=37;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.26;SOR=1.148","C","T","Patients with the CT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion."
"1450814923","PPARG","3","1.25","Efficacy","pioglitazone","Diabetes Mellitus, Type 2","12351626","589.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.073;DB;DP=45;ExcessHet=3.0103;FS=1.184;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.40;ReadPosRankSum=-0.965;SOR=1.061","C","G","Patients with Type II diabetes and the CG genotype may have an increased response to pioglitazone as compared to patients with the CC genotype. However, another study found no association between this variant and response to pioglitazone. Other genetic and clinical factors may also affect a patient's response to pioglitazone."
"1450814929","PTPRD","3","2.25","Efficacy","pioglitazone","Diabetes Mellitus, Type 2","8879118","251.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.768;DB;DP=42;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=6.80;ReadPosRankSum=-0.787;SOR=0.507","C","T","Patients with Type II diabetes and the CT genotype may have a decreased response to pioglitazone as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to pioglitazone."
"1450815114","ATP1A2","3","0","Efficacy","olanzapine","Schizophrenia","160108064","484.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.572;DB;DP=54;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.97;ReadPosRankSum=-0.764;SOR=0.668","C","T","Patients with schizophrenia and the CT genotype may have a decreased response to olanzapine as compared to patients with the CC genotype but an increased response as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to olanzapine."
"1450815172","PPA2","3","0","Efficacy","risperidone","Schizophrenia","105432212","904.06","AC=2;AF=1.00;AN=2;DB;DP=27;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.48;SOR=0.765","A","C","Patients with schizophrenia and the AC genotype may have an increased response to risperidone as compared to patients with the AA genotype but a decreased response as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to risperidone."
"1450820863","DRD2","3","1.75","Efficacy","prochlorperazine","Nausea","113425564","512.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.291;DB;DP=37;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.24;ReadPosRankSum=0.777;SOR=0.874","C","T","Patients with the CT genotype may have an increased incidence of nausea following treatment with prochlorperazine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine."
"1450822470","OPRD1","3","3","Toxicity","heroin","Heroin Dependence","28839325","408.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.118;DB;DP=41;ExcessHet=3.0103;FS=2.895;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.97;ReadPosRankSum=1.531;SOR=1.206","C","G","Patients with the CG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence."
"1450822690","OPRD1","3","3.5","Toxicity","cocaine","Cocaine-Related Disorders","28818676","693.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.835;DB;DP=51;ExcessHet=3.0103;FS=2.539;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.87;ReadPosRankSum=-0.146;SOR=1.223","C","T","Patients with the CT genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the CC genotype. This association was only seen in African American participants. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence."
"1450822829","HINT1","3","1.25","Other","nicotine","cessation;Tobacco Use Disorder","131160322","683.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.275;DB;DP=48;ExcessHet=3.0103;FS=4.196;MLEAC=1;MLEAF=0.500;MQ=59.88;MQRankSum=-1.023;QD=14.55;ReadPosRankSum=1.217;SOR=1.292","C","T","Patients with the CT genotype may be less likely to successfully quit smoking for at least one year as compared to patients with the CC genotype. Other genetic or clinical factors may also affect the likelihood of a patient successfully quitting smoking."
"1450822836","HINT1","3","2.75","Efficacy","nicotine","Tobacco Use Disorder","131160322","683.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.275;DB;DP=48;ExcessHet=3.0103;FS=4.196;MLEAC=1;MLEAF=0.500;MQ=59.88;MQRankSum=-1.023;QD=14.55;ReadPosRankSum=1.217;SOR=1.292","C","T","Patients with the CT genotype may have a decreased response to nicotine replacement therapy (NRT) and be abstinent from smoking 6 months after therapy as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to nicotine replacement therapy."
"1450823123","OPRM1","3","3.5","Toxicity","heroin","Heroin Dependence","154093438","2605.06","AC=2;AF=1.00;AN=2;DB;DP=61;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=25.19;SOR=0.865","C","T","Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence."
"1450928486","HTT;MSANTD1","3","0","Efficacy","risperidone","Schizophrenia","3241491","1067.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.047;DB;DP=76;ExcessHet=3.0103;FS=1.936;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.63;ReadPosRankSum=3.539;SOR=0.652","C","T","Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
"1450928522","DRD3","3","0","Efficacy","risperidone","Schizophrenia","114171968","372.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.437;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.31;ReadPosRankSum=0.000;SOR=0.693","C","T","Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the TT genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
"1450928528","COMT","4","-1.5","Efficacy","risperidone","Schizophrenia","19962712","616.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.046;DB;DP=49;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.85;ReadPosRankSum=0.320;SOR=0.693","C","T","Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance in one study following correction for multiple testing, while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone."
"1450929222","ABCB1","3","5.75","Dosage","fentanyl","Pain;Pain, Postoperative","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the rs1045642 AG genotype may have decreased fentanyl dose requirements as compared to patients with the GG genotype, but increased fentanyl dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements."
"1450929786","ABCB1","4","-1.25","Efficacy","fentanyl","Pain","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have an increased response to fentanyl as compared to patients with the AA genotype. However, another study did not find an association between this variant and response to fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl."
"1450929792","ABCB1","3","3","Dosage","methadone","Pain","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the rs1045642 AG genotype and who are receiving methadone for analgesia may required a decreased dose as compared to patients with the GG genotype, but an increased dose as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone dose requirements for analgesia."
"1450929798","ABCB1","4","-3.5","Dosage","methadone","Heroin Dependence;Opioid-Related Disorders","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","The current evidence base suggests that there is no significant association between rs1045642 AG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
"1450929804","ABCB1","4","-1.25","Dosage","morphine","Pain;Pain, Postoperative","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have decreased morphine dose requirements as compared to patients with the GG genotype, but increased dose requirements as compared to patients with the AA genotype. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements."
"1450929810","ABCB1","3","2","Dosage","oxycodone","Pain","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the AG genotype may have decreased oxycodone dose requirements as compared to patients with the GG genotype, but increased oxycodone dose requirements as compared to patients with the AA genotype. However, another study did not find an association between this variant and oxycodone dosing. Other genetic and clinical factors may also affect a patient's oxycodone dose requirements."
"1450929816","ABCB1","3","1","Efficacy","tramadol","Fractures, Bone;Pain;Pain, Postoperative","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the rs1045642 AG genotype may have an increased analgesic response to tramadol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol."
"1450930440","OPRD1","3","2.25","Other","heroin","Heroin Dependence","28855013","479.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.188;DB;DP=55;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.59;ReadPosRankSum=-2.005;SOR=0.693","A","G","Patients with the AG genotype may begin using heroin at a later age as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's age at first use of heroin."
"1450930548","TXNDC11","3","2.75","Efficacy","hydrochlorothiazide","Hypertension","11680345","488.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.849;DB;DP=41;ExcessHet=3.0103;FS=2.694;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.92;ReadPosRankSum=-0.326;SOR=0.869","G","T","Patients with hypertension and the GT genotype may have a decreased systolic blood pressure response to hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
"1450930839","CHRNB4","3","3","Toxicity","nicotine","Tobacco Use Disorder","78625057","1639.06","AC=2;AF=1.00;AN=2;DB;DP=61;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.35;SOR=0.767","A","G","Patients with the AG genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nicotine dependence."
"1450931583","HTR2A","3","1.75","Toxicity","citalopram","Depressive Disorder, Major;Nausea;Vomiting","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","Patients with major depressive disorder and the CT genotype may be less likely to experience nausea, vomiting, or sexual dysfunction when treated with citalopram as compared to patients with the CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's likelihood of experiencing citalopram-induced side effects."
"1450931960","GNB3;P3H3","3","2.75","Efficacy","sertraline","Depressive Disorder, Major","6839862","825.06","AC=2;AF=1.00;AN=2;DB;DP=30;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.45;SOR=1.942","A","G","Patients with major depressive disorder and the AG genotype may be less likely to respond to sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sertraline."
"1450932697","OPRD1","3","2.75","Toxicity","buprenorphine;fentanyl;tramadol","Opioid-Related Disorders;Sexual Dysfunctions, Psychological","28863085","1217.06","AC=2;AF=1.00;AN=2;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.81;SOR=1.061","C","T","Patients with the CT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may less likely to experience sexual dysfunction or reproductive system disorders as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence."
"1450932703","ARRB2","3","2.25","Toxicity","buprenorphine;fentanyl;tramadol","adverse events;Opioid-Related Disorders","4719343","402.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.451;DB;DP=32;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.58;ReadPosRankSum=-0.170;SOR=0.892","C","T","Patients with the CT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may less likely to experience adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence."
"1450932989","CYP27B1","3","2.5","Efficacy","deferasirox","beta-Thalassemia","57768302","334.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.940;DB;DP=48;ExcessHet=3.0103;FS=2.755;MLEAC=1;MLEAF=0.500;MQ=59.88;MQRankSum=0.720;QD=7.44;ReadPosRankSum=-0.945;SOR=0.853","G","T","Patients with beta-thalassemia and the GT genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox."
"1450933052","TNFAIP3","3","2","Efficacy","Tumor necrosis factor alpha (TNF-alpha) inhibitors","Arthritis, Psoriatic;Psoriasis","137878280","1265.06","AC=2;AF=1.00;AN=2;BaseQRankSum=-1.364;DB;DP=40;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;MQRankSum=0.000;QD=32.44;ReadPosRankSum=-0.712;SOR=0.317","G","T","Patients with the GT genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs."
"1450933116","ADGRL3","3","1.75","Toxicity","nicotine","Tobacco Use Disorder","61380610","532.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.941;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.10;ReadPosRankSum=-0.932;SOR=0.772","A","T","Patients with ADHD and the AT genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence."
"1450935200","CYP3A4","3","0","Metabolism/PK","cyclosporine","Kidney Transplantation","99784473","2096.06","AC=2;AF=1.00;AN=2;DB;DP=68;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.27;SOR=0.859","C","T","Patients with the rs2740574 CT genotype and who are treated with cyclosporine following kidney transplantation may have increased blood concentrations of cyclosporine as compared to patients with the rs2740574 CC genotype. This annotation only covers the pharmacokinetic relationship between rs2740574 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect blood concentrations of cyclosporine."
"1450935917","XPO1","3","2.25","Toxicity","Drugs For Treatment Of Tuberculosis","Drug Toxicity;Tuberculosis","61476721","1050.06","AC=2;AF=1.00;AN=2;DB;DP=34;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.88;SOR=0.941","A","G","Patients with the AG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis (anti-TB) drugs as compared to patients with the AA genotype. Note that this association was only observed in a subgroup analysis of patients with probable hepatotoxicity. Other genetic and clinical factors may also affect a patient's risk of developing anti-TB drug-induced hepatotoxicity."
"1450944540","ABCB1","3","0.25","Toxicity","cyclosporine","hematopoietic stem cell transplantation;Neurotoxicity Syndromes","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the AG genotype may be at a decreased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the GG genotype. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment."
"1450963020","ERCC2","3","2","Toxicity","Platinum compounds","Carcinoma, Non-Small-Cell Lung;pneumonitis","45364001","527.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.383;DB;DP=30;ExcessHet=3.0103;FS=4.499;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=17.59;ReadPosRankSum=-1.027;SOR=0.170","C","T","Patients with the CT genotype and non-small-cell lung cancer may have an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for pneumonitis when treated with platinum-based chemotherapy."
"1450963060","ERCC2","3","2.5","Toxicity","Platinum compounds","adverse events;Carcinoma, Non-Small-Cell Lung","45364001","527.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.383;DB;DP=30;ExcessHet=3.0103;FS=4.499;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=17.59;ReadPosRankSum=-1.027;SOR=0.170","C","T","Patients with the CT genotype and non-small-cell lung cancer may have an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events following treatment with platinum-based chemotherapy."
"1451105080","CALCA","3","2","Efficacy","botulinum toxin type a","Migraine NOS","14972978","1193.06","AC=2;AF=1.00;AN=2;DB;DP=40;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.59;SOR=0.743","A","G","Patients with the AG genotype and chronic migraine may have a decreased response to botulinum toxin A as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A."
"1451106460","SYT1","3","3.5","Toxicity","cocaine","Cocaine-Related Disorders","79430071","856.06","AC=2;AF=1.00;AN=2;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.71;SOR=1.302","A","G","Patients with the AG genotype may have an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence."
"1451110320","SLC19A1","3","0","Toxicity","methotrexate","adverse events;Arthritis, Rheumatoid","45525110","1425.06","AC=2;AF=1.00;AN=2;DB;DP=47;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.67;SOR=0.737","A","G","Patients with rheumatoid arthritis and the AG genotype may have an increased risk of experiencing adverse events as compared to patients with the GG genotype. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events."
"1451118277","PDE3A","3","3","Efficacy","hydrochlorothiazide","Hypertension","20020830","658.06","AC=2;AF=1.00;AN=2;DB;DP=25;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.91;SOR=0.874","C","G","Patients with hypertension and the CG genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
"1451118326","STN1","3","3","Efficacy","atenolol","Hypertension","103918139","1148.06","AC=2;AF=1.00;AN=2;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.03;SOR=0.859","A","C","Patients with hypertension and the AC genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol."
"1451118332","TBX2","3","3","Efficacy","atenolol","Hypertension","61406405","420.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.978;DB;DP=36;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.37;ReadPosRankSum=1.125;SOR=0.693","C","T","Patients with hypertension and the CT genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol."
"1451118338","PLCE1","3","3","Efficacy","hydrochlorothiazide","Hypertension","94136183","367.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.256;DB;DP=36;ExcessHet=3.0103;FS=1.402;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.50;ReadPosRankSum=3.084;SOR=0.385","A","G","Patients with hypertension and the AG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
"1451118340","ADO","3","3","Efficacy","hydrochlorothiazide","Hypertension","62805174","1483.06","AC=2;AF=1.00;AN=2;DB;DP=52;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=30.90;SOR=0.866","C","G","Patients with hypertension and the CG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
"1451121880","ERCC1","3","3.25","Toxicity","cisplatin","Drug Toxicity","45420395","1040.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.802;DB;DP=78;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.69;ReadPosRankSum=0.427;SOR=0.595","A","G","Patients with the AG genotype may have an increased risk for toxicity when treated with cisplatin chemotherapy regimens as compared to patients with the GG genotype. However, some studies find no association with drug toxicity or one study reported reduced risk in heterozygotes. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy."
"1451121940","ERCC1","3","3.75","Efficacy","cisplatin","Esophageal Neoplasms;Ovarian Neoplasms;Stomach Neoplasms","45420395","1040.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.802;DB;DP=78;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.69;ReadPosRankSum=0.427;SOR=0.595","A","G","Patients with the rs11615 AG genotype may have a decreased response to cisplatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin."
"1451123020","PDYN","3","0.75","Toxicity","opioids","Opioid-Related Disorders","1979580","634.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.803;DB;DP=70;ExcessHet=3.0103;FS=6.698;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.76;ReadPosRankSum=0.717;SOR=0.824","A","G","Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the GG genotype. Note that this association was only found in a subset of patients analyzed. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
"1451124852","GALNT14","3","1.75","Efficacy","cisplatin;fluorouracil","Liver Neoplasms","31024648","515.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.143;DB;DP=54;ExcessHet=3.0103;FS=1.079;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.73;ReadPosRankSum=-0.199;SOR=1.007","G","T","Patients with liver cancer and the GT genotype may have decreased overall survival when treated with cisplatin and fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy."
"1451124880","GALNT14","3","1.5","Efficacy","sorafenib","Hepatitis C;Liver Neoplasms","31024648","515.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.143;DB;DP=54;ExcessHet=3.0103;FS=1.079;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.73;ReadPosRankSum=-0.199;SOR=1.007","G","T","Patients with liver cancer, anti-HCV antibodies and the GT genotype may have a decreased overall survival when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sorafenib."
"1451125672","XYLT2","3","2.5","Toxicity","carboplatin;gemcitabine","Carcinoma, Non-Small-Cell Lung;Thrombocytopenia","50360095","652.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.415;DB;DP=47;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.89;ReadPosRankSum=-0.298;SOR=0.776","C","G","Patients with non-small cell lung cancer and the CG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia."
"1451126020","SLC28A2","3","2.75","Toxicity","tenofovir disoproxil fumarate","HIV Infections;nephrotoxicity","45253280","738.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.750;DB;DP=85;ExcessHet=3.0103;FS=4.394;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=8.79;ReadPosRankSum=-0.232;SOR=1.242","C","T","Patients with HIV and the CT genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity."
"1451126064","CYP27B1","3","3.25","Toxicity","tenofovir disoproxil fumarate","HIV Infections;nephrotoxicity","57764205","668.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.275;DB;DP=44;ExcessHet=3.0103;FS=1.227;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.92;ReadPosRankSum=-0.958;SOR=1.075","A","G","Patients with HIV and the AG genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity."
"1451126312","MOBP","3","2","Efficacy","creatine","Amyotrophic Lateral Sclerosis","39492990","1172.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.609;DB;DP=72;ExcessHet=3.0103;FS=2.056;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.29;ReadPosRankSum=-0.185;SOR=0.473","A","G","Patients with ALS and the AG genotype may have an increased response to treatment with creatine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to creatine."
"1451129800","CACNA1C","3","2.5","Toxicity","ethanol","Alcoholism;Bipolar Disorder","2551994","1741.06","AC=2;AF=1.00;AN=2;DB;DP=54;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.24;SOR=0.846","C","T","Patients with bipolar disorder and the CT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence."
"1451130640","RORA","3","2.25","Efficacy","interferon beta-1a","Multiple Sclerosis","61174799","597.64","AC=1;AF=0.500;AN=2;BaseQRankSum=2.181;DB;DP=45;ExcessHet=3.0103;FS=1.130;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.58;ReadPosRankSum=-0.531;SOR=0.892","C","T","Patients with multiple sclerosis and the CT genotype may have a decreased response to interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to interferon-beta."
"1451131846","NFKBIB;SIRT2","3","2","Toxicity","gefitinib","Toxic liver disease","38900291","899.64","AC=1;AF=0.500;AN=2;BaseQRankSum=4.483;DB;DP=54;ExcessHet=3.0103;FS=1.332;MLEAC=1;MLEAF=0.500;MQ=59.89;MQRankSum=0.000;QD=17.64;ReadPosRankSum=0.983;SOR=1.097","C","G","Patients with non-small cell lung cancer and the CG genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity."
"1451131858","TAB2","3","2","Toxicity","gefitinib","Diarrhea","149325172","1550.06","AC=2;AF=1.00;AN=2;DB;DP=57;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.70;SOR=1.329","C","T","Patients with non-small cell lung cancer and the CT genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea."
"1451133765","ABCB1","3","2.5","Efficacy","morphine;nortriptyline","Pain","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with neuropathic pain and the rs1045642 AG genotype may have a decreased response to combined therapy with morphine and nortriptyline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to morphine and nortriptyline."
"1451134300","COMT","3","2","Toxicity","opioids","Dizziness","19962712","616.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.046;DB;DP=49;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.85;ReadPosRankSum=0.320;SOR=0.693","C","T","Patients with the CT genotype and treated with long-term opioids may be more likely to develop dizziness as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing dizziness when treated with opioids."
"1451134540","COMT","3","2","Toxicity","opioids","Sexual Dysfunctions, Psychological","19962712","616.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.046;DB;DP=49;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.85;ReadPosRankSum=0.320;SOR=0.693","C","T","Female patients with the CT genotype may be less likely to experience a loss of libido when treated with long-term opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of losing libido when treated with opioids."
"1451135380","ABCB1","3","0.75","Dosage","sufentanil","Pain, Postoperative","87531302","756.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.168;DB;DP=38;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=22.25;ReadPosRankSum=-0.337;SOR=0.830","A","C","Patients with the rs2032582 AC genotype may have increased dose requirements of sufentanil as compared to patients with the CC genotype but decreased dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect dose requirements of sufentanil."
"1451137828","OPRM1","3","3.25","Toxicity","opioids","Opioid-Related Disorders","154072003","734.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.136;DB;DP=54;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.69;ReadPosRankSum=-0.223;SOR=0.682","C","T","Patients with the CT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
"1451138140","GAD1","3","3","Dosage","methadone","Heroin Dependence","170815885","1352.06","AC=2;AF=1.00;AN=2;DB;DP=47;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=29.39;SOR=0.976","C","G","Patients with heroin dependence and the rs3762555 CG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect methadone dose requirements in MMT."
"1451138166","GAD1","3","3","Dosage","methadone","Heroin Dependence","170815568","320.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.069;DB;DP=33;ExcessHet=3.0103;FS=3.192;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.02;ReadPosRankSum=0.604;SOR=1.134","C","G","Patients with heroin dependence and the CG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT."
"1451139960","CRYBG2","3","0","Toxicity","opioids","Nausea;Vomiting","26343953","701.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.743;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.62;ReadPosRankSum=0.031;SOR=0.821","G","T","Patients with the GT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to people with the GG genotype. Other genetic and clinical factors may also affect the severity of nausea and vomiting in patients treated with opioids."
"1451141140","CLCC1","3","0","Toxicity","opioids","Nausea;Vomiting","108937356","630.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.769;DB;DP=49;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.14;ReadPosRankSum=0.528;SOR=0.693","G","T","Patients with the GT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting."
"1451141146","POM121L2","3","0","Toxicity","opioids","Nausea;Vomiting","27309272","405.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.347;DB;DP=37;ExcessHet=3.0103;FS=1.311;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.59;ReadPosRankSum=-0.363;SOR=0.835","C","T","Patients with the CT genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting."
"1451146140","TH","3","3","Toxicity","opioids","Opioid-Related Disorders","2172610","714.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.285;DB;DP=37;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=19.31;ReadPosRankSum=0.871;SOR=0.793","A","G","Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
"1451146160","TH","3","3","Toxicity","opioids","Opioid-Related Disorders","2172367","722.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.320;DB;DP=66;ExcessHet=3.0103;FS=2.186;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.29;ReadPosRankSum=-0.269;SOR=0.389","C","T","Patients with the CT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
"1451149000","SLC6A4","3","2.5","Dosage","morphine","Pain","30197993","2417.06","AC=2;AF=1.00;AN=2;DB;DP=74;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.66;SOR=0.693","A","C","Patients with cancer pain and the AC genotype may have increased morphine dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's morphine dose requirements."
"1451150040","THSD7B","3","1.5","Toxicity","ethanol","Alcoholism","137506661","402.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-3.108;DB;DP=44;ExcessHet=3.0103;FS=1.230;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.82;ReadPosRankSum=-0.225;SOR=0.948","A","G","Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism."
"1451150060","CADM2","3","1.5","Toxicity","ethanol","Alcoholism","85464643","167.02","AC=2;AF=1.00;AN=2;DB;DP=7;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=23.86;SOR=0.941","A","G","Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism."
"1451151460","DPP6","3","1.5","Toxicity","ethanol","Alcoholism","153791989","2572.06","AC=2;AF=1.00;AN=2;DB;DP=61;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=40.86;QD=29.33;SOR=0.986","C","G","Patients with the CG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism."
"1451217440","IFNL3;IFNL4","3","1","Efficacy","peginterferon alfa-2a","Hepatitis B, Chronic","39248147","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.448;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=58.43;MQRankSum=-1.834;QD=13.47;ReadPosRankSum=-0.076;SOR=0.693","C","T","Patients with hepatitis B and the CT genotype may have a decreased response to treatment with peginterferon-alpha 2a and/or 2b as compared to patients with the TT genotype. However, one study found this association in the opposite direction, while another failed to find an association. Other genetic and clinical factors may also affect a patient's response to treatment peginterferon-alpha 2a and/or 2b"
"1451217520","IFNL3;IFNL4","3","2.5","Efficacy","sofosbuvir","Hepatitis C, Chronic","39248147","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.448;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=58.43;MQRankSum=-1.834;QD=13.47;ReadPosRankSum=-0.076;SOR=0.693","C","T","Patients with the CT genotype may have a decreased response to treatment with sofosbuvir and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with sofosbuvir and ribavirin."
"1451217540","IFNL3;IFNL4","3","1","Efficacy","interferons","Hepatitis C","39248147","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.448;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=58.43;MQRankSum=-1.834;QD=13.47;ReadPosRankSum=-0.076;SOR=0.693","C","T","Patients with a HCV genotype I infection and the rs12979860 CT genotype may have a decreased response to treatment with interferons as compared to patients with the CC genotype. However, this association was not found in patients with HCV genotype II infections. Other genetic and clinical factors may also affect response to treatment with interferons."
"1451217560","IFNL3;IFNL4","3","2","Efficacy","interferons","Hepatitis C","39248147","565.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.448;DB;DP=44;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=58.43;MQRankSum=-1.834;QD=13.47;ReadPosRankSum=-0.076;SOR=0.693","C","T","Patients with the CT genotype may have a decreased response to treatment with interferons and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with interferons and ribavirin."
"1451223540","CYP2B6","3","1.5","Toxicity","methadone","Neonatal Abstinence Syndrome","41009358","170.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.434;DB;DP=43;ExcessHet=3.0103;FS=3.968;MLEAC=1;MLEAF=0.500;MQ=48.66;MQRankSum=-4.633;QD=4.27;ReadPosRankSum=-3.157;SOR=1.819","A","G","Infants who have been been exposed to methadone in utero and who have the AG genotype may been less likely to require treatment for neonatal abstinence syndrome as compared to infants with the AA genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
"1451223580","PNOC","3","0","Toxicity","buprenorphine","Neonatal Abstinence Syndrome","28333789","1063.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.174;DB;DP=67;ExcessHet=3.0103;FS=0.952;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.62;ReadPosRankSum=0.000;SOR=0.549","A","C","Infants who have been exposed to buprenorphine in utero and are born to women with the AC genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the CC genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
"1451223586","PNOC","3","0","Toxicity","methadone","Neonatal Abstinence Syndrome","28333789","1063.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.174;DB;DP=67;ExcessHet=3.0103;FS=0.952;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.62;ReadPosRankSum=0.000;SOR=0.549","A","C","Infants who have been exposed to methadone in utero and are born to women with the AC genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the CC genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
"1451223592","CYP2A7P1;CYP2B6","3","1.5","Toxicity","methadone","Neonatal Abstinence Syndrome","41006936","384.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.804;DB;DP=34;ExcessHet=3.0103;FS=1.394;MLEAC=1;MLEAF=0.500;MQ=59.51;MQRankSum=1.002;QD=11.31;ReadPosRankSum=1.503;SOR=0.374","G","T","Infants who have been exposed to methadone in utero and who have the GT genotype may be less likely to require treatment for neonatal abstinence syndrome as compared to infants with the GG genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
"1451238365","OPRM1","3","3.5","Toxicity","heroin","Heroin Dependence","154061407","272.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.001;DB;DP=37;ExcessHet=3.0103;FS=1.409;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=7.57;ReadPosRankSum=-0.643;SOR=0.346","A","G","Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence."
"1451240740","TMEM43;XPC","3","2.75","Toxicity","cisplatin","Neutropenia;Urinary Bladder Neoplasms","14145949","581.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.699;DB;DP=50;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.38;ReadPosRankSum=-1.033;SOR=0.784","G","T","Patients with bladder cancer and the GT genotype may be at an increased risk of developing neutropenia when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia when treated with cisplatin."
"1451240746","TMEM43;XPC","3","2.75","Toxicity","cisplatin","Drug Toxicity;Urinary Bladder Neoplasms","14145949","581.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.699;DB;DP=50;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.38;ReadPosRankSum=-1.033;SOR=0.784","G","T","Patients with bladder cancer and the GT genotype may be at an increased risk of experiencing drug toxicity when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when treated with cisplatin."
"1451257000","POR","3","0.5","Metabolism/PK","tacrolimus","Transplantation","75985688","1716.06","AC=2;AF=1.00;AN=2;DB;DP=52;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.00;SOR=1.358","C","T","Patients with the CT (POR *1/*28) genotype and transplantation who are treated with tacrolimus in combination with the CYP3A5 expressors genotype *1/*1 or *1/*3 (rs776746) may have increased metabolism of tacrolimus as compared to patients with the CC (*1/*1) genotype, however this has been contradicted in a number of studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1057868 and tacrolimus and does not include evidence about clinical outcomes."
"1451257700","MTRR","3","4.75","Efficacy","methotrexate","Arthritis, Juvenile Rheumatoid;Arthritis, Rheumatoid","7870860","1568.06","AC=2;AF=1.00;AN=2;DB;DP=49;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.09;SOR=0.693","A","G","Patients with the AG genotype and Rheumatoid Arthritis or Juvenile Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate response."
"1451266065","DPYD","1A","104","Toxicity","tegafur","Neoplasms","97450058","503.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.590;DB;DP=30;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.79;ReadPosRankSum=2.793;SOR=1.085","C","T","Patients with the rs3918290 CT genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the CC genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
"1451274984","DPYD","1A","222.25","Toxicity","capecitabine","Neoplasms","97450058","503.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-1.590;DB;DP=30;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=16.79;ReadPosRankSum=2.793;SOR=1.085","C","T","The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
"1451277440","HTR2C","3","6.875","Toxicity","risperidone","Metabolic Syndrome","114903581","882.06","AC=2;AF=1.00;AN=2;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=31.50;SOR=0.836","C","G","Patients with two X-chromosomes and the CG genotype who are treated with risperidone may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele."
"1451282140","CYP19A1","3","5","Efficacy","tamoxifen","Breast Neoplasms","51210647","646.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.339;DB;DP=43;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.04;ReadPosRankSum=0.768;SOR=0.754","A","C","Pre-menopausal women with the AC genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to tamoxifen."
"1451287240","DPYD","1A","93.25","Toxicity","capecitabine","Neoplasms","97883329","451.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.571;DB;DP=50;ExcessHet=3.0103;FS=4.029;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=9.22;ReadPosRankSum=0.462;SOR=1.292","A","G","Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
"1451337885","NAT2","3","3","Toxicity","isoniazid;pyrazinamide;rifampin","Toxic liver disease;Tuberculosis","18400285","735.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.877;DB;DP=56;ExcessHet=3.0103;FS=8.058;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.62;ReadPosRankSum=-0.470;SOR=1.907","C","T","Patients with the rs1041983 CT genotype and tuberculosis may have an increased risk of developing toxic liver disease when treated with isoniazid, pyrazinamide and rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxic liver disease when treated with isoniazid, pyrazinamide and rifampin."
"1451352140","KCNJ6","3","2.5","Dosage","opioids","Low Back Pain","37917643","1299.06","AC=2;AF=1.00;AN=2;DB;DP=42;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.48;SOR=1.292","C","T","Patients with the rs6517442 CT genotype may have decreased opioid dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect opioid dose requirements."
"1451352146","ABCB1","3","2.5","Toxicity","opioids","Low Back Pain","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the rs1045642 AG genotype may be more likely to experience nausea when treated with opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of experiencing nausea when treated with opioids."
"1451356840","NFKBIA","3","1.75","Dosage","sufentanil","Pain, Postoperative","35401887","648.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.565;DB;DP=54;ExcessHet=3.0103;FS=1.059;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.01;ReadPosRankSum=1.384;SOR=0.625","C","T","Patients with the rs696 CT genotype may require decreased doses of sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sufentanil dosage requirements."
"1451398106","FKBP5","3","1.75","Efficacy","fluoxetine","Mood Disorders","35702206","808.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.400;DB;DP=68;ExcessHet=3.0103;FS=4.729;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.25;ReadPosRankSum=-1.791;SOR=1.044","A","G","Patients with mood disorders and the rs4713916 AG genotype may have an increased response to fluoxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluoxetine."
"1451398120","FKBP5","3","1.75","Efficacy","mirtazapine","Mood Disorders","35702206","808.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.400;DB;DP=68;ExcessHet=3.0103;FS=4.729;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.25;ReadPosRankSum=-1.791;SOR=1.044","A","G","Patients with mood disorders and the rs4713916 AG genotype may have an increased response to mirtazapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to mirtazapine."
"1451403600","CYP2A7P1;CYP2B6","3","2","Toxicity","opioids","Opioid-Related Disorders","41006936","384.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-0.804;DB;DP=34;ExcessHet=3.0103;FS=1.394;MLEAC=1;MLEAF=0.500;MQ=59.51;MQRankSum=1.002;QD=11.31;ReadPosRankSum=1.503;SOR=0.374","G","T","Patients with the rs3745274 GT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence."
"1451403608","DRD3","3","2.5","Toxicity","opioids","Opioid-Related Disorders","114171968","372.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.437;DB;DP=28;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.31;ReadPosRankSum=0.000;SOR=0.693","C","T","Patients with the rs6280 CT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence."
"1451407348","HTR2A","4","-1.25","Toxicity","sertraline","Depressive Disorder, Major;Sexual Dysfunctions, Psychological","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","Patients with the rs6311 CT genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with sertraline."
"1451416400","HTR2A","4","-3","Efficacy","antidepressants","Bipolar Disorder;Depression;Depressive Disorder, Major","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","The current evidence base suggests that there is no significant association between the rs6311 CT genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants."
"1451416408","HTR2A","3","1.125","Toxicity","antidepressants","adverse events;Bipolar Disorder;Depression;Depressive Disorder, Major","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","Patients with the rs6311 CT genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants."
"1451416946","CDA","3","2.25","Toxicity","gemcitabine;paclitaxel","Nausea;Pancreatic Neoplasms","20589208","559.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.531;DB;DP=56;ExcessHet=3.0103;FS=5.726;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=10.18;ReadPosRankSum=-0.198;SOR=0.557","A","C","Patients with pancreatic cancer and the rs2072671 AC genotype may have a decreased risk of experiencing nausea when treated with FOLFIRINOX as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing nausea when treated with FOLFIRINOX."
"1451417123","ABCB1","3","1.25","Metabolism/PK","temozolomide","Glioma","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with glioma and the rs1128503 AG genotype may have decreased concentrations of temozolomide as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs1128503 and temozolomide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence temozolomide concentrations."
"1451447440","PACSIN2","3","2.25","Efficacy","azathioprine","Irritable Bowel Syndrome","43001030","632.06","AC=2;AF=1.00;AN=2;DB;DP=24;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=28.73;SOR=1.085","C","T","Patients with irritable bowel disorders and the rs2413739 CT genotype may have a decreased response to azathioprine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to azathioprine."
"1451476360","ERCC1","3","2","Toxicity","cisplatin;doxorubicin","mucositis;Osteosarcoma","45420395","1040.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.802;DB;DP=78;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.69;ReadPosRankSum=0.427;SOR=0.595","A","G","There is currently no available evidence regarding the association between the rs11615 AG genotype and risk of developing mucositis when treated with cisplatin and doxorubicin. However, patients with osteosarcoma and the rs11615 AA genotype may have a decreased risk of developing mucositis when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing mucositis when treated with cisplatin and doxorubicin."
"1451476520","CYBA","3","2.5","Toxicity","cisplatin;doxorubicin","Anemia;mucositis;Osteosarcoma","88646828","597.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.735;DB;DP=50;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=12.72;ReadPosRankSum=0.878;SOR=0.859","A","G","Patients with osteosarcoma and the rs4673 AG genotype may be at a decreased risk of experiencing side effects when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with cisplating and doxorubicin."
"1451511240","FPGS","3","0.25","Metabolism/PK","methotrexate","Precursor Cell Lymphoblastic Leukemia-Lymphoma","127800446","256.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.539;DB;DP=23;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.16;ReadPosRankSum=0.443;SOR=0.627","C","T","Patients with acute lymphoblastic leukemia and the rs1544105 CT genotype may have increased concentrations of methotrexate as compared to patients with the CC genotype but decreased concentrations as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1544105 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations."
"1451511344","SLC19A1","3","1.5","Metabolism/PK","methotrexate","Precursor Cell Lymphoblastic Leukemia-Lymphoma","45514947","2472.06","AC=2;AF=1.00;AN=2;DB;DP=77;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=33.41;SOR=0.747","A","C","Patients with acute lymphoblastic leukemia and the rs1051296 AC genotype may have decreased concentrations of methotrexate as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs1051296 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations."
"1451547422","FPGS","3","2.25","Efficacy","methotrexate","Precursor Cell Lymphoblastic Leukemia-Lymphoma","127800446","256.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.539;DB;DP=23;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=11.16;ReadPosRankSum=0.443;SOR=0.627","C","T","Patients with acute lymphblastic leukemia (ALL) and the rs1544105 CT genotype may have a decreased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to methotrexate."
"1451551426","ERCC1","3","1.75","Efficacy","cisplatin;gemcitabine","Carcinoma, Non-Small-Cell Lung","45420395","1040.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.802;DB;DP=78;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.69;ReadPosRankSum=0.427;SOR=0.595","A","G","Patients with the rs11615 AG genotype may have a decreased response to treatment with cisplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin and gemcitabine"
"1451551460","ERCC1","3","0","Efficacy","cisplatin","Pancreatic Neoplasms","45420395","1040.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.802;DB;DP=78;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.69;ReadPosRankSum=0.427;SOR=0.595","A","G","Patients with the rs11615 AG genotype may have a decreased response to treatment with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to chemotherapy."
"1451553580","ABCB1","3","0","Metabolism/PK","methotrexate","Burkitt Lymphoma;Lymphoma, T-Cell;Precursor Cell Lymphoblastic Leukemia-Lymphoma","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the rs1045642 AG genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations."
"1451553595","ABCB1","4","-1.25","Efficacy","methotrexate","Precursor Cell Lymphoblastic Leukemia-Lymphoma","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
"1451608148","AKR1C3","3","1.5","Other","doxorubicin","Breast Neoplasms","5099115","1414.06","AC=2;AF=1.00;AN=2;DB;DP=45;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.89;SOR=0.739","C","G","Patients with breast cancer and the rs1937840 CG genotype may have increased absolute leucocyte and neutrophil counts when treated with doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence absolute leucocyte and neutrophil counts when treated with doxorubicin."
"1451621726","ABCB1","3","2.5","Toxicity","methotrexate","Lymphoma;mucositis;Osteosarcoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the rs1128503 AG genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate."
"1451621742","ABCB1","4","-0.375","Efficacy","methotrexate","Arthritis, Juvenile Rheumatoid;Arthritis, Rheumatoid","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
"1451635167","FASTKD3;MTRR","4","-1.25","Toxicity","methotrexate","Arthritis, Juvenile Rheumatoid;Arthritis, Rheumatoid","7870860","1568.06","AC=2;AF=1.00;AN=2;DB;DP=49;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.09;SOR=0.693","A","G","The current evidence base suggests that there is no significant association between the rs1801394 AG genotype and risk of methotrexate-induced toxicity in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
"1451635460","OPRD1","3","2.25","Efficacy","disulfiram","Cocaine-Related Disorders","28818676","693.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.835;DB;DP=51;ExcessHet=3.0103;FS=2.539;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.87;ReadPosRankSum=-0.146;SOR=1.223","C","T","Patients with cocaine dependence and the rs678849 CT genotype may have a decreased response to disulfiram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to disulfiram."
"1451638961","ABCB1","3","2.25","Toxicity","paclitaxel","Breast Neoplasms;Peripheral Nervous System Diseases","87550285","1452.64","AC=1;AF=0.500;AN=2;BaseQRankSum=3.193;DB;DP=104;ExcessHet=3.0103;FS=0.000;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=15.62;ReadPosRankSum=1.858;SOR=0.656","A","G","Patients with the rs1128503 AG genotype may have decreased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel."
"1451721028","ARID5B","3","0","Toxicity","Glucarpidase","nephrotoxicity","61963818","1517.06","AC=2;AF=1.00;AN=2;DB;DP=46;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=32.98;SOR=0.874","C","T","Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10821936 CT genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
"1451726525","ABCB1","4","-1.25","Efficacy","docetaxel","Breast Neoplasms;Neoplasms","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel."
"1451760600","HTR2A","3","1","Toxicity","Selective serotonin reuptake inhibitors","ability to concentrate;Depressive Disorder, Major;Diarrhea;Dizziness;Tremor","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","Patients with the rs6311 CT genotype may have an increased risk of experiencing adverse events when treated with selective serotonin reuptake inhibitors (SSRIs) as compared to patients with the CC or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with SSRIs."
"1451761248","ABCC4","3","2","Toxicity","tenofovir disoproxil fumarate","HIV Infections;nephrotoxicity","95021537","1770.64","AC=1;AF=0.500;AN=2;BaseQRankSum=0.842;DB;DP=95;ExcessHet=3.0103;FS=0.838;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=19.04;ReadPosRankSum=-0.231;SOR=0.892","A","C","Patients with HIV and the rs3742106 AC genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate."
"1451834440","ABCB1","3","3","Toxicity","tramadol","Opioid-Related Disorders","87509329","1584.06","AC=2;AF=1.00;AN=2;DB;DP=48;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.44;SOR=1.203","A","G","Patients with the rs1045642 AG genotype may have an increased risk of developing opioid dependence when treated with tramadol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence."
"1451952740","VEGFB","3","1.5","Toxicity","sorafenib","Drug Toxicity","64237220","655.64","AC=1;AF=0.500;AN=2;BaseQRankSum=-2.126;DB;DP=52;ExcessHet=3.0103;FS=2.620;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=13.11;ReadPosRankSum=-0.447;SOR=1.236","C","T","Patients with the rs12366035 CT genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib."
"1451980660","FASTKD3;MTRR","3","2","Efficacy","sevoflurane","sedation","7870860","1568.06","AC=2;AF=1.00;AN=2;DB;DP=49;ExcessHet=3.0103;FS=0.000;MLEAC=2;MLEAF=1.00;MQ=60.00;QD=34.09;SOR=0.693","A","G","Patients with the rs1801394 AG genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration."
"1452043786","HTR2A","4","-6.25","Efficacy","venlafaxine","Depressive Disorder, Major","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","The current evidence base suggests that there is no association between the rs6311 CT genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine."
"1452043985","HTR2A","4","-7","Efficacy","paroxetine","Depressive Disorder, Major;Obsessive-Compulsive Disorder","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","The current evidence base suggests that there is no association between the rs6311 CT genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine."
"1452044040","HTR2A","4","-5.75","Efficacy","escitalopram","Depressive Disorder, Major","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","The current evidence base suggests that there is no association between the rs6311 CT genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram."
"1452044060","HTR2A","4","-11.25","Efficacy","citalopram","Depressive Disorder, Major","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","The current evidence base suggests that there is no association between the rs6311 CT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram."
"1452050260","HTR2A","4","-2","Efficacy","fluvoxamine","Depressive Disorder, Major","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","Patients with the CT genotype may have a decreased response to fluvoxamine as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine."
"1452050340","HTR2A","4","-2.75","Toxicity","fluoxetine","Depressive Disorder, Major","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","Patients with the CT genotype who are treated with fluoxetine may have decreased, but not absent, risk of sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to fluoxetine."
"1452050380","HTR2A","3","1.5","Toxicity","paroxetine","Depression;Depressive Disorder, Major","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","Patients with the CT genotype who are treated with paroxetine may have decreased, but not absent, risk of nausea or sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to paroxetine."
"1452050405","HTR2A","4","-6.5","Efficacy","sertraline","Depressive Disorder, Major","46897343","996.64","AC=1;AF=0.500;AN=2;BaseQRankSum=1.022;DB;DP=70;ExcessHet=3.0103;FS=2.025;MLEAC=1;MLEAF=0.500;MQ=60.00;MQRankSum=0.000;QD=14.66;ReadPosRankSum=0.449;SOR=0.840","C","T","The current evidence base suggests that there is no association between the rs6311 CT genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline."
